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Extracts from early case studies featuring the use and
limitations of the NO donors, amyl nitrite and glyceryl
trinitrate, in the treatment of angina pectoris
'Few things are more distressing to a physician than to stand beside a suffering
patient who is anxiously looking to him for that relieffrom pain which he feels himself
utterly unable to afford...
'Perhaps there is no class ofcases in which such occurrences as this take place
so frequently as in some kinds of cardiac diseases, in which angina pectoris forms at
once the most prominent and the mostpainful and distressing symptom...
'Brandy, ether, chloroform, ammonia, and other stimulants have hitherto been
chiefly relied upon for the relief of angina pectoris; but the alleviation which they
produce is but slight...
'On pouring ten drops ofthe [amyl] nitrite on a cloth and giving it to a patient
to inhale...the pain completely disappeared, and generally did not reappear till its
wonted time next night.'
Dr T.L. Brunton, The Lancet, 1867.
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'About three minutes after the dose [ofglyceryl trinitrate] had been placed on
his tongue he noticed a sensation offulness in both sides of the neck, succeeded by
nausea. For a moment or two there was a little mental confusion, accompanied by a
loud rushing noise in the ears, like steam passing out ofa kettle...
'...there was for a few minutes unconsciousness accompanied by convulsive
action of the muscles of the face, and stertorous breathing. After swallowing some
brandy-and-water, she vomited, and the unpleasant symptoms gradually subsided...
'One afternoon whilst seeing outpatients, I remembered that I had the bottle in
my pocket. Wishing to taste it, I applied the moistened cork to my tongue...The
pulsation rapidly increased and soon became so severe that each beat of the heart
seemed to shake my whole body...
'Sometimes it produced curious fits of gaping; she went on yawning and
yawning, and seemed as ifshe would never stop...
'A friend, who for some days took four drops every three or four hours,
informs me that at times it affected his head "most strangely "...
'She became quite insensible, and once remained so for ten minutes. Each
fainting-fit was "followed by cold shivers, " which "shook her violently all over. " Her
husband and friends were greatly alarmed, but she thought on the whole it had done
her good...
'...he called attention to the fact that the administration of the drug [glyceryl
trinitrate] always caused an increased flow of urine. On examination... the urine was
seen spoutingfrom the extremity ofeach ureter in a little jet some three or four inches
high. Ordinarily the urine dribbles away drop by drop and never spouts out. The
patient was much amazed, and said that in the whole course of his life he had never
known it go on in that way. If he took beer or spirits it would increase the flow, but
this, to use his own expression, "licked everything.
Dr W. Murrell, The Lancet, 1879.
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Abstract
Nitric oxide (NO) is a powerful vasodilator that is synthesised by the endothelial cells
that line healthy blood vessels. NO is now recognised to have many roles in the
cardiovascular system, regulating blood vessel tone and the activity of platelets and
inflammatory cells. Reduced bioavailability of endothelium-derived NO is a feature of
many cardiovascular diseases and the delivery of exogenous NO is an attractive
therapeutic option. Conventional NO donors such as the organic nitrates have been
used for many years, but they have limitations that restrict their clinical use. S-
Nitrosothiols are NO donor drugs that are emerging as potential therapeutic alternatives
to conventional NO donors, although their mechanism of action is poorly understood.
Recently, two novel S-nitrosothiols, N-(S-nitroso-iV-acetylpenicillamine)-2-amino-2-
deoxy-l,3,4,6,tetra-C-acetyl-B-D-glucopyranose (RIG200) and S-nitroso-TV-
valerylpenicillamine (SNVP), have been described to have selectivity for endothelium-
denuded blood vessels. Therefore, they are particularly appealing in the treatment of
conditions where the vascular endothelium is damaged. This thesis describes
experiments which further elucidate the mechanism of action and therapeutic potential
of these novel S-nitrosothiols, by comparison to conventional NO donors.
NO donors were administered specifically to the lumen of isolated rat femoral
arteries in an in vitro perfusion system. Pretreatment with inhibitors of the NO:soluble
guanylate cyclase (sGC) pathway were used clarify the mechanism of action of NO
donors. The induction of tolerance was investigated by continuous perfusion of NO
donors for 20 h. The therapeutic potential of SNVP was investigated in an in vivo
rabbit model of balloon angioplasty, by measuring the adhesion of radiolabeled
platelets to vessels following endothelial damage
The key findings were that S-nitrosothiol-mediated vasodilator activity is a
complex process that is dependent on intracellular antioxidant molecules, particularly
glutathione. The site ofNO release influenced both its susceptibility to inactivation by
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reactive oxygen species and the extent of sGC involvement. Evidence is also presented
to show that the novel S-nitrosothiols do not induce self-tolerance with prolonged
administration and remain fully active in nitrate-tolerant vessels.
Experiments then focused on the sustained actions of lipophilic S-nitrosothiols
in models of endothelial damage. Firstly, glyco-SNAP, an analogue of RIG200 with
poor lipophilicity, failed to produce a sustained vasodilatation in endothelium-denuded
rat femoral arteries. This result lends weight to the hypothesis that lipophilic S-
nitrosothiols exert a sustained vasodilatation in arteries with damaged endothelium
through retention in lipid-rich sub-endothelial layers. In the model of balloon
angioplasty, the conventional NO donor, glyceryl trinitrate, had no significant effect on
platelet adhesion to damaged carotid arteries and also caused a substantial and
potentially undesirable fall in blood pressure. In contrast, SNVP caused a >60%
reduction in platelet adhesion at a concentration that had minimal effects on blood
pressure.
S-nitrosothiols represent an attractive alternative to conventional NO donor
drugs. In particular, lipophilic S-nitrosothiols such as RIG200 and SNVP have
advantages over nitrates, as they do not engender vascular tolerance and are selective
for vessels with a damaged endothelium. SNVP prevents platelet adhesion to vessels
that have undergone angioplasty and subsequently may reduce restenosis in the long-
term. The results suggest that these novel compounds may have applications in the
treatment of a range of cardiovascular conditions, including atherosclerosis,
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The vascular endothelium is a monolayer of cells lining the inside of blood vessels.
For many years, it was believed that the endothelium merely acted as a structural
barrier, controlling the access of molecules to underlying smooth muscle cells.
However, in the last 30 years it has been shown that the endothelium plays a crucial
role in the regulation of vascular haemostasis, through the synthesis and release of
vasoactive substances, including prostacyclin, thromboxanes, endothelins and growth
factors to name but a few. One sustance in particular has attracted a great deal of
attention. A powerful vasodilating substance named endothelium-derived relaxing
factor (EDRF) was released from endothelial cells on stimulation. In was only in the
1980s that EDRF was identified as the free radical nitric oxide (NO). Subsequently,
this 'simple' molecule has been shown to have a staggering array of actions, not just in
the cardiovascular system, but in almost every region of the body.
As our understanding of NO developed, it became apparent that NO-related
endothelium-dependent relaxations are attenuated in a number of cardiovascular disease
states, notably hypertension and atherosclerosis. Therefore, the delivery of exogenous
NO to areas of diminished NO activity is an attractive therapeutic option in the
management of these common conditions. However, the clinical use of NO donors is
limited. Only the organic nitrates and sodium nitroprusside have a clinical use in the
management of specific cardiovascular conditions and both have limitations,
preventing a wider application. However, an extensive range of NO donors has now
been described, each with their own mechanism of NO release to potentially fulfil a
range of therapeutic applications. The subject of this thesis is a class of NO donors
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called the S-nitrosothiols. In particular, it focuses on several novel S-nitrosothiols
which have been shown to have selective actions in endothelial-denuded arteries. If
NO can be targeted specifically to sites of endothelial injury, then these compounds
will have unique benefits over other NO donors, minimising side effects through
targeted delivery ofNO to where it is most needed.
1.2 STRUCTURE AND FUNCTION OF BLOOD
VESSELS
1.2.1 Structure of the vessel wall
The vessel wall is divided into three layers; the intima, the media and the adventitia
(Rhodin, 1980; Fig 1.1).
1.2.1.1 Tunica intima
The intima is the innermost layer of the vessel wall surrounding the vessel lumen. A
single layer of endothelial cells covers the inner surface forming the vascular
endothelium. These are highly specialised cells that carry out a number of functions.
Firstly, they act as a barrier preventing blood components from coming into contact
with cells deeper in the vascular wall. In addition, they form a non-reactive surface,
preventing the activation and adhesion of certain blood cells such as platelets and
immune cells. These cells also act as a means of signal transduction through the
synthesis and release a number of regulatory factors, such as prostaglandins,
thromboxanes, endothelins, growth factors and nitric oxide (NO). These substances
play a role in the contractile state of the underlying smooth muscle cells, regulation of
cell proliferation and migration, activation of blood cells and thrombogenicity; which



















The subendothelial layer, between the endothelial cells and the internal elastic lamina,
is composed of connective tissue. The size and composition of this region varies with
the type ofblood vessel, but generally contains bundles of collagen, elastic fibrils and,
occasionally, smooth muscle cells and fibroblasts. The internal elastic lamina plays a
part in determining the distensability of the vessel wall.
1.2.1.2 Tunica media
The middle layer of blood vessels is composed of layers of vascular smooth muscle
cells (VSMCs) between sheets of collagen and elastin fibres. The predominance of
VSMCs over elastic layers is determined by the type ofblood vessel (i.e. elastic versus
muscular arteries). The contractile state of VSMCs is crucial in determining blood
distribution and, consequently, is tightly regulated by neural control and an array of
humoural factors.
1.2.1.3 Tunica adventitia
The outermost layer forms a sheath over the external elastic lamina that covers the
media. The thickness and composition of this layer varies considerably, depending on
the vessel type and location. Essentially it consists of fibroelastic connective tissue to
provide additional strength and to anchor the vessel in the surrounding tissue. The
adventitia of larger arteries houses nerves and minute blood vessels (vasa vasorum)
which provide oxygen and nutrients to vessels with thick medial layers.
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1.3 THE DISCOVERY OF THE IDENTITY OF EDRF
In 1980, Furchgott & Zawadzki demonstrated that the presence of an intact vascular
endothelium was required for acetylcholine (ACh)-mediated vasodilatation of rabbit
aortic strips or rings (Furchgott & Zawadzki, 1980). The vasodilator response of
acetylcholine could be prevented by removal of the endothelium by gentling rubbing
the intimal surface. The authors expanded on these findings by demonstrating that an
endothelium-intact strip of aorta stimulated with ACh could induce a vasodilator
response in an adjacent denuded strip, suggesting that a factor released from
endothelial cells passes to VSMC where it causes vasodilatation. This factor was
shown to be distinct from the established endothelial product, prostacyclin (PGI2), and
other arachidonic acid products (see Furchgott, 1984). The factor was named
"endothelium-derived relaxing factor" (EDRF). Other groups confirmed the important
role of EDRF, using an endothelium-intact tissue as a donor and endothelial-denuded
vascular smooth muscle to detect EDRF. The effluent from ACh-perfiised aortic
segments (Griffith et al., 1984), or endothelial cells culture on microcarrier beads
(Cocks et al., 1985; Gryglewski et al., 1986), was shown to relax denuded aortic
arteries. These 'simple' bioassay techniques, proved invaluable in the discovery of the
chemical identity ofEDRF.
In the years following its discovery, the properties of EDRF were rapidly elucidated.
Firstly it was established that vasodilatation in response to EDRF was mediated by
conversion of guanosine triphosphate (GTP) to cyclic guanosine 3',5'-monophosphate
(cGMP) by soluble guanylate cyclase (sGC) in VSMC (Rapoport & Murad, 1983).
Soon after the inhibitory effects of the NO scavenger, haemoglobin (Hb), and the sGC
inhibitor, methylene blue (MB), demonstrated that EDRF was released basally, as well
as by stimulation with agonists such as ACh, bradykinin, adenine nucleotides,
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thrombin, substance P, histamine and calcium ionophores (Furchgott, 1984; Martin et
al., 1985). Basal release of EDRF was confirmed by monitoring the effect of Hb and
MB on vascular tone in unstimulated blood vessels. In addition, release of EDRF
could also be increased by mimicking endogenous stimuli such as a pulsatile flow
(Rubanyi et al., 1986) and changes in oxygen concentration (Furchgott, 1984).
Bioassay cascade systems were used to estimate the half life of EDRF.
Estimates varied considerably, but it was generally concluded that the half life was
only a few seconds, confirming the labile nature ofEDRF (Griffith et al., 1984; Cocks
et al., 1985; Gryglewski et al., 1986) and contributing to the slow progress of its
identification. Further experiments also indicated that the short half life of EDRF could
be extended by factors which offer protection from superoxide radicals in solution.
Superoxide dismutase (SOD), the endogenous enzyme which catalyses the inactivation
of superoxide to hydrogen peroxide, prolonged the biological activity of EDRF
(Rubanyi et al., 1986), as did cytochrome c, which oxidises superoxide to molecular
oxygen. In contrast, superoxide generators, like Fe2+ and pyrogallol, reduced the
activity of EDRF (Gryglewski et al., 1986; Moncada et al., 1986; Furchgott et al.,
1987). Interestingly, it was also shown a few years later that methylene blue inhibits
EDRF-mediated vasodilatation partially through the generation of superoxide, rather
than inhibition of sGC (Marczin et al., 1992).
Between 1986 and 1988 two groups independently suggested that the free radical nitric
oxide (NO) could be EDRF (Ignarro et al., 1986; Furchgott et al., 1987; Ignarro et al.,
1988). Despite the similar biological properties of NO, the suggestion was
controversial, especially since NO was essentially regarded as a poisonous gas and an
environmental pollutant (Denninger & Marietta, 1999). However, conclusive evidence
to support this claim came with a chemiluminescence technique was established that
could measuring low concentrations of NO. Using ozone to generate a
chemiluminescent product (Downes et al., 1976), it was demonstrated that bradykinin-
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stimulated endothelial cells generated sufficient chemiluminescence to account for a
biologically active amount of NO (Palmer et al., 1987). Direct pharmacological
comparison of EDRF and NO demonstrated that both mediate vasodilatation through
the generation of cGMP in VSMCs (Rapoport & Murad, 1983) and were susceptible to
inhibition by haemoglobin and superoxide generators, but protected by SOD (Palmer et
al., 1987; Ignarro et al., 1988).
At present it is generally accepted that EDRF is NO, although some authors have
presented data that suggests that EDRF may not be NO per se. Initially, the wide range
in reported half-lives of EDRF were of some concern, varying between 3 to 50
seconds (Furchgott, 1984; Myers et al., 1990; Moncada et al., 1991), although this
may reflect differences in the oxygenation state of the physiological solution used.
Also, NO is not anionic and, therefore, does not bind to resins during passage through
anion exchange columns. However, EDRF does bind to these columns (Cocks et al.,
1985; Long et al., 1987), although it is not clear if this is an artefact caused by a
chemical reaction during passage through the column (Moncada et al., 1991).
Additionally, NO reacts with haem to produce paramagnetic nitrosyl haem, whereas
EDRF does not (Moncada et al., 1991).
One possible explanation for such anomolous findings is that EDRF is an NO-
containing compound, or more specifically is carried between cells as an NO-adduct.
One suggestion is that NO is carried as an iron-sulphur nitrosyl (Vanin, 1991). These
complexes are found endogenously and are high capacity NO adducts (Vanin et al.,
1997; Ueno & Yoshimura, 2000; Butler & Megson, 2002). The iron content of
endothelial cells is reduced during EDRF synthesis and iron-sulphur nitrosyls can be
detected after endothelial cell stimulation by electron paramagnetic resonance (Mulsch
et al., 1993). However, although the vasodilator effects of these compounds are
similar to EDRF in some bioassay systems, the longer duration of the vasodilatation of
iron-sulphur nitrosyl contradicts the hypothesis that they are EDRF (Feelisch et al.,
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1994). Another alternative is that EDRF is carried as an S-nitrosothiol. Thiols are
sulphydryl-containing compounds (RSHs) that exist in high concentrations
physiologically and their nitrosated form have been identified under physiological
conditions (Gaston, 1999). S-nitrosothiols have biological actions similar to EDRF
and Myers et al. (Myers et al., 1990) suggested that EDRF is the nitrosated form of
cysteine (S-nitrosocysteine; SNOC). Certainly, the stability of EDRF in this particular
study more accurately represented SNOC than NO, however, the non-specific
measurement ofNO and N02" may have biased comparisons (Moncada et al., 1991).
Other pharmacological studies dispute the suggestion that EDRF is SNOC (Feelisch et
al., 1994) and at present it is almost unanimously agreed that EDRF is NO.
1.4 THE NO:sGC PATHWAY
Ever since the discovery ofNO as an important physiological regulator, the pathway of
its biological action has been the focus of much research. Uncertainty surrounds
almost every stage of the pathway , but the generally agreed aspects are summarised in
Fig 1.2. Briefly, in blood vessels, stimuli such as shear stress or pharmacological
agents acting on receptors, stimulate an increase in cytosolic calcium in endothelial
cells. The increase in calcium stimulates the enzyme NO synthase to generate NO, that
diffuses, or is carried, out of endothelial cells and into underlying VSMCs. NO binds
to, and activates, sGC increasing the generation of cGMP. cGMP stimulates protein
kinase G, which ultimately lowers cytosolic calcium in VSMC, leading to the
dephosphorylation of myosin light chains. This inhibits contraction, resulting in
















Figure 1.2 Schematic diagram of the NO:sGC pathway in blood vessels.
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1.4.1 Induction of NO synthesis
Physiologically, the most important regulator ofNO synthesis and release is the shear
stress caused by 'drag' of flowing blood across endothelial cell surface (Rubanyi &
Vanhoutte, 1986). The mechanism by which the endothelium senses shear stress and
translates the signal into NO synthesis has not been fully identified. As stated above,
NO synthesis generally requires an increases in endothelial cell cytosolic calcium
concentrations. However, NO release has been shown to occur at Ca2+ concentrations
as low as 10 nM (Mo et al., 1991), suggesting that shear stress may be able to directly
stimulate NO production in a calcium-independent manner (Ayajiki et al., 1996;
Fisslthaler et al., 2000; Nakano et al., 2000). Ingber (Ingber, 1997) suggest that the
force of shear stress itself modulates the cell cytoskeleton via mechanoreceptors,
although this theory has not yet been applied to endothelial cells specifically.
Additionally, shear stress also influences NO synthesis through slower mechanisms,
such as phosphorylation and increased transcription of the NO synthesising enzyme
(Vallance & Chan, 2001).
Many endogenous factors carried by the blood, such as histamine, adenine
nucleotides, bradykinin, endothelin, serotonin, substance P, thrombin and
noradrenaline, can also trigger NO synthesis (Furchgott, 1984; Lerman et al., 1991).
All these factors bind to receptors on endothelial cells and ultimately increase cytosolic
calcium. A number of exogenous pharmacological agents act in similar ways.
Acetylcholine and other muscarinic receptor agonists, as well as calcium ionophores,
both produce increases in cytosolic calcium in endothelial cells. Once again, there is
evidence of routes of cellular transduction by which agonists can stimulate NO
synthesis in a calcium-independent manner (Butt et al., 2000). Regulation is most
likely occur by phosphorylation of the NO synthesising enzyme (Butt et al., 2000;
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Fisslthaler et al., 2000), or through alteration of enzyme expression and transcription
(Nishida et al., 1992; Weiner et al., 1994).
1.4.2 Synthesis of NO
In the endothelium, NO is synthesised enzymatically by NO synthase (NOS; see Sect
1.4.3), using the amino acid L-arginine (L-arg), but not the stereoisomer, D-Arginine,
as substrate (Palmer et al., 1988). The terminal guanido nitrogen of L-arg undergoes a
five-electron oxidation, followed by cleavage to form free NO and L-citrulline (Stuehr
& Griffith, 1992; Fig 1.3). L-citrulline is recycled back to L-arg through a scries of
enzymatic reactions (Morris & Billiar, 1994), although in the case of endothelial NOS
(eNOS) L-arg concentration (150-250 |iM) is unlikely to be rate limiting due to the low
substrate requirement ofNOS (ifm=5-10 |iM) (Bult et al., 1999; Hobbs et al., 1999).
L-arginine analogues such as asymmetrical NG,NG-dimethyl-L-arginine (ADMA), NG-
monomethyl-L-arginine (L-NMMA), and NG-nitro-L-arginine methyl ester (L-NAME)
act as competitive, reversible inhibitors of NOS (Rees et al., 1990; Vallance et al.,
1992; Fig 1.4). Use of L-arginine analogues in vivo, produces an increase in arterial
tone, indicating that NOS synthesises NO basally in the absence of any
pharmacological agonist in both animals (Aisaka et al., 1989; Rees et al., 1989;
Gardiner et al., 1990; Chu et al., 1991) and humans (Vallance et al., 1989; Haynes et
al., 1993). D-Arginine analogues do not inhibit NOS activity (Palmer et al., 1988).
Oxygen and nicotinamide adenine dinucleotide phosphate (NADPH) are co-
substrates (Palmer & Moncada, 1989; Leone et al., 1991), and the reaction also
requires a number of co-factors, importantly (6R)-5,6,7,8-tetrahydrobiopterin (BH4;
Rodriguez-Crespo et al., 1996) and Ca27calmodulin complex (Busse & Mulsch, 1990;
Mayer et al., 1990). NG-hydroxy-L-guanidine is formed as an intermediate (Stuehr et
al., 1991) and analogues of this intermediate may represent potential NO donor drugs













It has been suggested that NOS actually generates nitroxyl ions (NO ), the reduced
form of NO (Fukuto et al., 1992). NO" is a poor activator of sGC (Feelisch et al.,
1994; Dierks & Burstyn, 1996) and therefore may require prior oxidation to NO by
tissue factors (Nelli et al., 2000). The role of NO" in vasodilatation is controversial




In mammals, there are three NOS isoforms. Each isoform has its gene on a different
chromosome (Nathan & Xie, 1994), although the isoforms share greater than 50%
homology (Forstermann et al., 1994).
The first isoform to be purified and cloned was neuronal NOS (nNOS/NOSI)
located in the rat and porcine cerebellum (Bredt & Snyder, 1990; Mayer et al., 1990).
Since then, nNOS has been found in most areas of the nervous system, as well as in
skeletal muscle (Stuehr, 1999). NO generated from nNOS is thought to act as a
neurotransmitter and has been shown to exert control on the cardiovascular system, via
both the central and peripheral nervous system (Cederqvist et al., 1991; Fluang et al.,
1995). In addition, nNOS activation may have a role in a number of brain functions,
including plasticity and memory (Schuman & Madison, 1991). Endothelial NOS
(eNOS/NOS III) is expressed in the endothelium of arteries and veins and was first
cloned from bovine aortic endothelial cells (Nishida et al., 1992). The structure and
regulation of eNOS are discussed below. Both eNOS and nNOS are found
constitutively and are Ca27calmodulin-dependent. Inducible NOS (iNOS/NOS II) acts
independently of Ca2+/calmodulin and, in general, is synthesised in response to
inflammatory stimuli (Stuehr, 1999). It was first purified and cloned from mouse
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macrophages (Lowenstein et al., 1992; Xie et al., 1992). Expression can be induced in
most cell types in response to cytokines, generating sufficiently high local levels ofNO
that are cytotoxic. Subsequently, the expression of iNOS in immune cells is thought to
act as a defence mechanism, attacking invading pathogens with NO.
1.4.3.2 NOS structure and regulation
All NOS isoforms are composed of two homodimeric subunits, with each monomer
containing an N-terminal-oxygenase domain and a C-terminal reductase domain.
Dimerization of the two subunits is a pre-requisite for activation and is triggered by the
activation of calmodulin with high calcium concentrations. The central region between
the domains contains recognition sequences for activated calmodulin (Stuehr, 1999).
In the case of eNOS and nNOS, NO synthesis is initiated when the Ca27calmodulin
complex binds to this central region. Calmodulin is thought to be permanently bound
to iNOS, resulting in permanent maximal activation (Cho et al., 1992). Calmodulin is
thought to be necessary for electron transfer between the two domains (Bredt et al.,
1991; Abu-Soud et al., 1994; Abu-Soud et al., 1994). The reductase domains bind
flavins which transfer electrons from NADPH. The electrons are then transferred to the
haem iron in the oxygenase domain, via the Ca27calmodulin bridge. Following this the
two substrates, L-arg and oxygen, bind to the oxygenase domain, catalysing the
formation ofNO and L-citrulline. The two subunits are thought to align head-to-head,
with electrons passing from the reductase domain of one subunit to the oxygenase
domain of the other (Fig 1.5).
BH4 and L-Arg allosterically regulate each other's binding (Klatt et al., 1994).
However, a number of other roles have been proposed for BH4. It has been suggested
that BH4 is necessary for the dimerization of the NOS subunits, through regulation of
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redox status may instead be necessary for the efficient transfer of electrons to the
oxygenase domain (Rodriguez-Crespo et al., 1996; Abu-Soud et al., 1997). In favour
of this theory is the finding that in the absence of sufficient BH4, NOS can generate
superoxide rather than NO (Heinzel et al., 1992; Cosentino & Katusic, 1995; Gorren
et al., 1996; Vasquez-Vivar et al., 1998; Xia et al., 1998). This dysfunctional
superoxide-generating form of NOS has been linked to a number of cardiovascular
conditions (see Sect 1.7.1.2)
L-arginine analogues block NOS activity by different methods (Pou et al., 1992; Abu-
Soud et al., 1994). L-NMMA occupies the L-arg binding site, but this coupling does
not allow efficient electron transfer to the haem. In contrast, L-NAME prevents the
reduction of haem group, making it unreactive to oxygen. The ability of different L-
arginine analogues to inhibit NOS varies with the model used and unexpected findings
such as L-NMMA acting as a substrate for NOS, or inhibiting L-NAME-induced
NOS-inactivation have been reported (Hobbs et al., 1999). The structure of the
analogue also affects the relative selectivity for the NOS isoform, albeit somewhat
marginally (Stuehr & Griffith, 1992). Attention has focused on inhibitors of NOS
which are highly isoform specific, particularly to selectively inhibit iNOS in septic
shock or cardiovascular pathophysiology. iNOS-specific inhibitors such as N-(3-
(aminomethyl)benzyl)acetamidine (1400W; Garvey et al., 1997; Miller et al., 2000) are
currently under experimental investigation (Hobbs et al., 1999). NO itself can also
bind to the haem iron, inhibiting NOS activity and acting as a negative feedback (Buga
et al., 1993; Abu-Soud et al., 1995; Hurshman & Marietta, 1995).
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1.4.4 Soluble guanylate cyclase
1.4.4.1 sGC isolation
The primary target for NO is the cytosolic enzyme sGC, which catalyses the
production of the second messenger cGMP. cGMP is the primary mediator of
vasodilatation, inhibition of platelet activation and many other actions of NO.
Particulate guanylate cyclase (pGC) is found in the membranes of cells. It also
catalyses the formation of cGMP, but it is activated by ligands such as atrial and brain
natriuretic peptide and not by EDRF/NO (Denninger & Marietta, 1999).
sGC was first identified in mammalian cells in 1969 (Hardman & Sutherland, 1969;
Ishikawa et al., 1969; Schultz et al., 1969; White & Aurbach, 1969). It has structural
and biochemical similarities to adenylate cyclase (AC). AC catalyses the formation of
cyclic adenosine-3',5'-monophosphate (cAMP), mediating many cellular processes,
including vasodilatation and inhibition of platelet activation (Denninger & Marietta,
1999). sGC has been studied far less extensively than AC, partly due to the difficulty
in isolating and purifying the enzyme (Hobbs, 1997). sGC is highly expressed in the
lung and brain, but its isolation from bovine lung is laborious and yields little active
protein. Initial purification techniques isolated sGC subunits of variable size depending
on species and tissue (Waldman & Murad, 1987). Many early studies using purified
sGC, were carried out on haem-free sGC and subsequently showed unusual activity to
ligands (Gerzer et al., 1981; Gerzer et al., 1981). The contamination of isolated sGC
with detergents, redox compounds and metal chelators during purification could also
be a source of erroneous findings. Subsequently, interpretation of results from early
studies on purified sGC requires care (Waldman & Murad, 1987). The development of
over-expression systems will undoubtedly make the purification of sGC easier
(Denninger & Marietta, 1999).
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1.4.4.2 sGC structure and regulation
sGC exists as a heterodimer consisting of an a and p subunit. Several isoforms of each
subunit have been isolated. Each subunit of sGC can be divided into three sections; the
cGMP-catalytic domain, the dimerisation domain and the haem-binding domain (Fig
1.6).
The catalytic domain catalyses the conversion of guanosine-5'-triphosphate to cGMP.
Catalysis requires divalent ions, particularly Mg2+ and Mn2+. Of these, Mg2* is found
in higher concentrations in the cell cytoplasm and probably plays the greater role in
vivo (Ohlstein et al., 1982). As the name suggests, the dimerisation domain controls
the pairing of subunits and probably mediates which isoforms of both subunits can
combine (Hobbs, 1997).
The haem-binding domain is the region that is believed to bind NO. Each mole of
dimer contains one mole of haem (Wolin et al., 1982), linked to sGC by the four
nitrogens of the porphyrin ring and a distal fifth bond to his 105 of the p subunit
(Wedel et al., 1994; Fig 1.6). NO binds to the iron of haem when it is in the Fe2+ state,
causing almost a 100 fold increase in basal activation. It is now accepted that haem-
deficient sGC is not activated by NO, unless a source of haem is also added (Craven &
De Rubertis, 1978; Craven & DeRubertis, 1978; Craven et al., 1979). Oxidation of
haem iron to a ferric state prevents NO-induced activation of sGC, whereas reducing
agents such as thiols, ascorbate and dithiothreitol, tend to enhance sGC activity
(Braughler et al., 1979; Waldman & Murad, 1987). Carbon monoxide also binds to
the haem iron of sGC, but causes only a weak activation, and subsequently, tends to
act as a competitive inhibitor of sGC (Stone & Marietta, 1995). The exact mechanism
of sGC activation by NO is still unclear. It is assumed that NO binds to the haem,
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drawing iron from the plane of the porphyrin ring. The his 105 bond is broken,
producing a conformation change in the catalytic domain and stimulating the
production of cGMP (Gerzer et al., 1981; Wedel et al., 1994; Lawson et al., 2000).
NO has been shown to be the only nitrogen monoxide capable of activating sGC
(Feelisch et al., 1994; Dierks & Burstyn, 1996). NO has a remarkable affinity for sGC
and subsequently, it is the deactivation of sGC which remains a mystery. NO-sGC has
a half life in the order ofminutes (Palmer et al., 1987), which is unusually short for a
nitrosyl-haem complex. It has been shown that NO dissociates from sGC within 5
seconds (Kharitonov et al., 1997), but whether this rapid dissociation is an intrinsic
factor of sGC following activation, or is mediated by cellular factors, possibly thiols,
has not been established (Kharitonov et al., 1997; Brandish et al., 1998).
NO is also believed to bind to additional areas of sGC, although these have not been
identified. There are two groups of free thiols in sGC, but at present, there is no
evidence that NO reacts with these groups, particularly as NO itself is a poor S-
nitrosating agent (Butler et al., 1995). Interestingly, oxidation of these thiols can lead
to enhanced activation or cause inactivation of sGC, depending on the group which is
oxidised (Braughler, 1983). Thiol alkylating agents (Katsuka et al., 1977; Ignarro &
Gruetter, 1980) or exogenous thiols, which form disulphide bridges with the thiols of
sGC, inhibit basal and stimulated cGMP production (Kimura et al., 1975; Waldman et
al., 1983). These effects can be reversed with dithiothreitol, which restores free thiol
groups (Brandwein et al., 1981). Important thiols are juxtaposed in the catalytic site
(Kamisaki et al., 1986). Stimulation of the enzyme through haem activation appears to
enhance the reactivity of the thiol groups or improve accessibility to thiol modulators,
allowing a synergistic activation or promoting deactivation (Kamisaki et al., 1986).
sGC also contains a copper ion and it has been shown that exogenous Cu(II) ions and
Cu(I) chelators modulate sGC activity (Schrammel et al., 1996). The role of the Cu in
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sGC has not been fully explained, but one suggestion is that Cu catalyses the
breakdown of S-nitrosothiols to NO, which can then activate sGC (Hobbs, 1997).
It is only in the last 10 years that specific sGC antagonists have been identified.
Previously methylene blue had been used as an inhibitor of sGC, but this agent also
inhibits NOS and generates superoxide (Marczin et al., 1992; Luo et al., 1995).
Therefore, it compounds is of little use in determining any sGC-independent actions of
EDRF or NO. Recently, Garthwaite described a novel sGC inhibitor, 1H-
[l,2,4,]oxodiazolo[4,3-a]quinoxalin-l-one (ODQ; Garthwaite et al., 1995) that has
been extremely useful in clarifying the role of sGC. ODQ does not generated
superoxide or inhibit NOS, AC or pGC activity. It is generally assumed that ODQ is an
irreversible inhibitor of sGC through oxidation of the haem of sGC (Schrammel et al.,
1996), although the exact mechanism or nature of inactivation of sGC has yet to be
identified. One limitation is that ODQ cannot be used systemically in vivo, as ODQ
reacts with haemoglobin and binds to myoglobin of the heart (Hobbs, 1997; Wegener
et al., 1999).
1.4.5 Targets for cGMP
cGMP has numerous targets in vascular smooth muscle cells. These are discussed
below in three main categories (Carvajal et al., 2000; Fig 1.7).
1.4.5.1 Protein kinase G
The main mechanism of cGMP-induced vasodilatation is believed to be via activation












One pathway ofCa2+release is the inositol 1,4,5-triphosphate (IP3) pathway. IP3 acts
on receptors on the sarcoplasmic reticulum, releasing calcium from sarcoplasmic
stores. Calcium binds to calmodulin forming a complex that activates myosin light
chain kinase in VSMCs. This kinase phosphorylates myosin light chains, triggering
smooth muscle contraction (Walter, 1989).
Like other protein kinases, PKG phosphorylates proteins, regulating their
activity. For example PKG inhibits IP3 production, as well as the co-product,
diacylglycerol, another activator of myosin light chain kinase, by phosphorylation of
phospholipase C (Rasmussen et al., 1987; Waldmann & Walter, 1989; Lincoln &
Cornwell, 1993). PKG also phosphorylates the IP3 receptor, downregulating its
activity (Komalavilas & Lincoln, 1996). Additionally, PKG activates plasmalemmal
and sacroplasmic reticulum Ca2+-ATPases, which promote cellular efflux of Ca2+ and
the uptake of Ca2+ into intracellular stores, respectively (Furukawa et al., 1988;
Cornwell et al., 1991). PKG also regulates the activity of several plasma membrane
ion channels, preventing the influx of Ca2+ ions from the extracellular space into the
cytosol (Tanaka et al., 1998; Yamakage et al., 1996; Tewari & Simard, 1997). Finally,
in some tissues PKG decreases the sensitivity of VSMC contractile apparatus to Ca2+
(Chen & Rembold, 1992).
Therefore, PKG acts to 1) downregulate the production of factors releasing
Ca2+, 2) downregulate the activity of the receptor for Ca2+-releasing factors, 3) promote
uptake of cytosolic Ca2+ into intracellular stores, 4) promote efflux of Ca2+ out of the
cell, 5) decrease the sensitivity of contractile apparatus to cytosolic Ca2+ (Lohmann et
al., 1997; Carvajal et al., 2000).
1.4.5.2 Regulation of plasma membrane channels
cGMP can regulate ion channels on the plasma membrane independently of PKG,
leading to hyperpolarisation. Hyperpolarisation of the cell membrane reduces the open
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time of voltage-gated Ca2+ channels, resulting in a reduction in cytosolic Ca2 . Some
channels are directly cGMP-gated, although this type of channel has yet to be found in
VSMCs (Zagotta & Siegelbaum, 1996).
1.4.5.3 Phosphodiesterases
Phosphodiesterases (PDEs) are a large class of enzymes which catalyse the hydrolysis
of nucleotides such as cGMP and cAMP. Several isoforms (types II, III & V)
hydrolyse cGMP, but the binding of cGMP also influences the activity of the PDE
(Carvajal et al., 2000; Degerman et al., 1997). In vascular tissue and platelets, cGMP
inhibits activity of PDEs which control the hydrolysis of cAMP, extending the action
of cAMP. Therefore, cGMP and cAMP may act synergistically to induce vasodilatation
and inhibition of platelet activation. At present, PDEs are of great interest due to the
success of the anti-impotence drug, sildenafil (Viagra; Vallance, 1999). Sildenafil
inhibits PDE V, enhancing cGMP-mediated vasodilatation and increasing blood flow
to the corpus cavernosum - a particularly PDE V rich area of the body (Goldstein et al.,
1998; Moreland et al., 1998).
1.4.6 cGMP-independent actions of NO
It has long been known that very high concentrations of NO (e.g. produced by iNOS)
have cGMP-independent actions (see Sect 1.6.3), but it has become clear that much
lower concentrations of NO may also have cGMP-independent effects. NO and NO
donor drugs have been shown to cause vasodilatation (Homer & Wanstall, 2000;
Wanstall et al., 2001) and inhibition ofplatelet aggregation (Gordge et al., 1998; Sogo
et al., 2000) which is only partially mediated by cGMP. The identity of these
mechanisms has yet to be conclusively identified. However, candidates include
voltage-sensitive calcium channels (Travis et al., 2000), calcium dependent potassium
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channels (Mistry & Garland, 1998; Plane et al., 1998; Homer & Wanstall, 2000; Plane
et al., 2001), sarcoplasmic reticulum Ca2+-ATPases and Na7K+-ATPases (Gupta et
al., 1994; Homer & Wanstall, 2000). In addition, modifiers of protein sulphydryl
groups inhibit NO-mediated changes in the activity channels (Bolotina et al., 1994;
Campbell et al., 1996; Gordge et al., 1998). This suggest that NO alters channel
activity through modification, most likely by S-nitrosation, of these thiol groups. The
cGMP-independent actions ofNO are discussed in more detail in Chapter 3.
1.5 NO BIOCHEMISTRY
The common assumption that, because of its small size and lack of charge, NO merely
diffuses across intracellular and extracellular spaces, and the membranes that separate
them (Lancaster, 1994) may be true, yet it overlooks a number of possible reactions.
In comparison to other radicals, NO is relatively unreactive (Beckman & Koppenol,
1996; Denninger & Marietta, 1999). Nevertheless, NO is still a free radical and the
diverse nature and reactivity of the biological environment presents NO with a plethora
ofpossible reactions that can modulate its activity.
1.5.1 Reaction with molecular oxygen
The reaction ofNO with molecular oxygen (02) is slow (k=6.6 xlO6 M'V1) and results
in the formation of inactive nitrite (N02") and nitrate (N03~) (Eqns 1,2; Feelisch, 1991),
although nitrite formation predominates (Ignarro et al., 1993). Because the initial step
is second order with respect to NO (i.e. 2 molecules of NO react with 1 molecule of
02), the reaction is slow physiologically, due to low (nM) concentrations of NO (Ford
et al., 1993; Kharitonov et al., 1995; Keshive et al., 1996). However, the reaction
may be significant in the presence of high concentrations of NO (Beckman &
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Koppenol, 1996), which can occur due to the induction of iNOS or through
pharmacological intervention.
2NO + 02 -> 2N02 (1)
2N02 + H20 -> N02" + NO; + 2H+ (2)
The formation of nitrogen dioxide (N02) is an intermediate step in the inactivation of
NO by 02 (Butler et al., 1995). The species can interact with additional molecules of
NO to produce higher nitrogen dioxides (Eqn 3), which are powerful S-nitrosating
agents (see below), and can be hydrolysed to nitrite (Eqn 4).
NO + N02 -> N203 (3)
N203 + H20 -> 2N02 + 2H+ (4)
1.5.2 Reaction with superoxide
In vivo, the reaction of NO with the oxygen-derived free radical, superoxide (02~), is
arguably more important in the inactivation of NO (Beckman & Koppenol, 1996).
Superoxide is generated as a by-product of cellular respiration and metabolism.
However, the high concentrations of Mn and Zn SOD isozymes, together with the
hydrogen peroxide metabolising enzyme, catalase limit intracellular 02" levels
(Freedman & Crapo, 1982; Fig 1.8).
SOD
_ catalase




Figure 1.8 Pathway of superoxide deactivation by SOD and catalase.
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Antioxidants, such as thiols and glutathione (GSH)-related enzymes, such as GSH
peroxidase also contribute to antioxidant defence (Freedman & Crapo, 1982).
Superoxide generation is enhanced in a number of cardiovascular conditions, due to
enhanced activation of white blood cells, reduced SOD and dysfunctional NOS (see
Sect 1.7). Therefore, superoxide levels may become a problem as SOD becomes
saturated. Oxygen radicals may also be generated by interaction with free or protein-
complexed metal ions such as iron and copper (Freedman & Crapo, 1982; Beckman &
Koppenol, 1996). The reaction between NO and superoxide is first order and occurs at
essentially a diffusion-limited rate (&=7xl09 M'V1), to form peroxynitrite (ONOO)
(Eqn 5; Huie & Padmaja, 1993; Vinten-Johansen, 2000). Peroxynitrite rapidly
isomerises to form inactive nitrate (Eqn 6; Saran et al., 1990), but is also a potent
nitrating species, especially direct nitration of tyrosine residues, and oxidising agent,
through an alternative decomposition to hydroxyl radical (OH) and nitrogen dioxide
(Eqn 7; White et al., 1994; Beckman & Koppenol, 1996; Patel et al., 1999; Vinten-
Johansen, 2000).
no + oto V onoo (5)
onoo" -> no3- (6)
onoo" -> no2 + oh (7)
Reaction with haem
As mentioned above, NO regulates the activity of sGC through binding to the Fe2' of
the haem moiety. This reaction is incredibly rapid, which allows NO to modulate sGC
activity at the low concentrations of NO produced by the endothelium, even after
allowing for loss of NO in transit (Beckman & Koppenol, 1996). Haem groups are
present in a number of other cellular enzymes. NO binds to the haem group of
deoxyhaemoglobin (k= 10"7 M"V; Gladwin et al., 2000), effectively competing with
oxygen. NO also binds to the haem group of NOS, inhibiting NO generation and,
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therefore, forming a negative feedback pathway (Buga et al., 1993). NO has also been
shown to regulate the function of other haem-containing proteins such as the
cytochrome cP450 reductase isozymes (Stamler et al., 1992; Wink et al., 1993),
cytochrome oxidases (Brown, 1995; Giulivi, 1998) and catalase (Wink et al., 1993;
Brown, 1995). NO can also bind to, and regulate the function of, non-haem iron-
containing proteins (Butler et al., 1995; Butler & Megson, 2002).
1.5.4 Reaction with lipoproteins
The plasma membrane is rich in lipids and lipoproteins, which are susceptible to
peroxidation. The oxidation of lipids to form lipid peroxyl radicals, may exacerbate or
even cause, cardiovascular conditions such as atherosclerosis (Ross, 1993; Maxwell &
Lip, 1997). NO itself does not cause lipid peroxidation (Rubbo et al., 1994), but
higher nitrogen oxides, such as N02, can modify lipids. Indeed, it has been suggested
that the reaction ofNO with 02 (to yield higher nitrogen oxides) is greater in the lipid
rich compartments of the plasma membrane (Liu et al., 1998). Alternatively, NO may
limit lipid peroxidation by directly reacting with lipid peroxyl radicals; essentially
acting as an antioxidant (Rubbo et al., 1994; Patel et al., 1999).
1.5.5 Reaction with thiols
A thiol (RSH) is a compound which contains a sulphydryl (SH) group. The group can
be S-nitrosated to produce an S-nitrosothiol. S-nitrosothiols share many of the
properties ofNO and are the focus ofmuch research, including this thesis (RSNOs are
discussed later in Sect 1.8.6). The direct reaction ofNO with thiol groups is negligible
under physiological conditions. However, RSNOs are found physiologically and may
serve to 'stabilise' free NO (Stamler et al., 1992; Butler et al., 1995; Gaston, 1999).
Formation of S-nitrosothiols is due to the presence of several intermediate reactions.
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Firstly, higher nitrogen oxides (nitrogen dioxide, N02; dinitrogen trioxide, N203;
dinitrogen tetroxide, N204), formed from the reaction of NO with 02, can nitrosate
thiols (Eqns 8, 9; Kharitonov et al., 1995; Keshive et al., 1996).
2N02 + RSH -> RSNO+ NO; + H+ (8)
N203 + RSH -> RSNO+ NO; + H+ (9)
Additionally, peroxynitrite can also react with thiols to form RSNOs, although it is a
relatively weak nitrosating agent and is more likely to oxidise thiols to their disuphide
(Wink et al., 1994; Mayer et al., 1998). Other redox forms of NO (NO", NO+) will
also be able to react with thiols to form RSNOs (Butler et al., 1995; Dierks & Burstyn,
1996). Nitrosonium ions (NO+) cannot exist in aqueous solution at physiological pH
for a significant period of time and therefore NO+ donors must directly interact with
thiol groups to induce nitrosation. The physiological role of nitroxyl ions (NO"),
especially its generation by NOS, is hotly debated.
1.6 NO IN PHYSIOLOGY
Although, this thesis focuses on the role of NO in the cardiovascular system, NO is
synthesised in many organs of the body, where it regulates a wide range of essential
functions.
1.6.1 Bloodvessels
As mentioned previously, NO is synthesised continuously from the endothelium of
blood vessels and this basal release contributes to the vascular tone of underlying
smooth muscle cells (Palmer et al., 1987; Palmer et al., 1988; Palmer & Moncada,
1989). Subsequently, NO production is now recognised to be a major factor in the
control ofblood pressure and local blood flow in animals (Aisaka et al., 1989; Rees et
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al., 1989; Gardiner et al., 1990; Chu et al., 1991) and man (Vallance et al., 1989;
Haynes et al., 1993).
1.6.2 Platelets
The endothelium acts as an anti-thrombogenic lining to blood vessels, both physically
and through the production ofNO. NO donor drugs were first shown to inhibit platelet
aggregation in response to ADP, before EDRF was identified as NO (Mellion et al.,
1981). Prostacyclin (PGI2), another endothelium-derived vasodilator, also inhibits
platelet aggregation, acting synergistically with NO (Radomski et al., 1987).
However, PGI2 only has weak effects on platelet adhesion (Higgs et al., 1978). NO
inhibits the activation ofplatelets, preventing both aggregation and adhesion to reactive
components of the vessel wall (Radomski et al., 1987; May et al., 1991). The
mechanism of NO-mediated platelet inactivity is complicated and multifactorial, with
both cGMP-dependent and independent mechanisms involved (Gordge et al., 1996;
Gordge et al., 1998; Sogo et al., 2000). Platelets themselves synthesise NO via eNOS
(Radomski et al., 1990; Radomski et al., 1990) and have been shown to store NO in
vesicles as S-nitrosothiols (Hirayama et al., 1999). Synthesis and release of NO (or
NO-adducts) occurs when platelets are activated (due to increased intracellular calcium
(Ware et al., 1986) and likely acts as a negative feedback to limit the extent of the
thrombotic response and provide a means ofbreakdown of aggregates that has already
formed.
1.6.3 Immune cells
NO also inhibits the activity of white blood cells, preventing their activation and
adhesion to the vessel wall (May et al., 1991). White cells can synthesise NO
following activation by lipopolysaccharide or inflammatory cytokines such as tumour
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necrosis factor, interleukins and interferon-y (Hibbs et al., 1987; Vallance & Moncada,
1994). Activation leads to the expression of iNOS, generating high concentrations of
NO (Nussler & Billiar, 1993), that are cytotoxic through inhibition of a number of
essential cellular mechanisms, including mitochondrial respiration (Granger &
Lehninger, 1982), the citric acid cycle (Hibbs et al., 1988) and DNA replication
(Krahenbuhl, 1980). Superoxide may also be generated by white cells, which will
subsequently lead to peroxynitrite production (Beckman & Koppenol, 1996). The
toxic cocktail of NO, superoxide and peroxynitrite has been suggested to act as a
cellular defence mechanism, by killing invading pathogens. Indeed, inhibitors of NOS
have been shown to inhibit the cytotoxicity of activated macrophages (Hibbs et al.,
1987).
1.6.4 Heart
NO will clearly influence the function of the heart through vasodilatation of blood
vessels, reducing pre- and after-load and through dilatation of coronary blood vessels.
A number of studies have shown that the endocardium, myocardium and papillary
muscles of the heart synthesise NO via eNOS (Schulz et al., 1991; Henderson et al.,
1992; De Belder et al., 1993). The stretch of the walls of the heart as it fills with blood
releases NO from the endocardium and the endothelium of coronary blood vessels
(Smith et al., 1991; Pinsky et al., 1997). The physiological significance of
endocardium-derived NO is far from clear (Paulus & Shah, 1999); NO has been
suggested to have a positive (Klabunde et al., 1991) or negative (Mohan et al., 1996)
inotropic effect, depending on its concentration. NO also alters the contractile state of
the myocardium in both systole and diastole (Paulus & Shah, 1999). Additionally, NO
regulates the sympathetic nerves that control the heart (Balligand et al., 1993; Bartunek
et al., 1997). Conflicting findings of the direct role of NO in the heart may be due to
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the high intracellular concentrations of myoglobin (~200 pM) that will presumably
scavenge low concentrations ofNO in a similar fashion to Hb (Wegener et al., 1999).
1.6.5 Peripheral nerves
The function ofNO-releasing nerves was studied before EDRF was identified as NO.
Non-adrenergic, non-cholinergic (NANC) nerves synthesise and release an EDRF-like
substance, presumably NO or an NO-adduct (Gillespie et al., 1989; Gillespie &
Sheng, 1990). Therefore, NO fulfills some of the criteria of a neurotransmitter. NANC
nerves regulate the tone of specific blood vessels, including cerebral arteries (Toda &
Okamura, 1990) and arteries in the corpus cavemosum that mediate penile erection
(Rajfer et al., 1992). They also regulate non-vascular smooth muscle, contributing to
bronchodilatation (Barnes, 1993), stomach distension and relaxation of the sphincters
of the gut (Burleigh, 1992).
1.6.6 Central nervous system
NOS-containing nerves are widespread throughout the brain. Activation of the neural
glutamate receptors, lead to the release ofNO (Garthwaite et al., 1988) which may act
as a retrograde messenger, sending signals back to pre-synaptic neurons (Vallance &
Moncada, 1994). Indeed, S-nitrosation of the glutamate receptor inhibits activity,
operating as a negative feedback mechanism (Lipton et al., 1993). NO has also been
suggested to be involved in a number of central processes, including arousal (Bagetta
et al., 1993), pain perception (Meller & Gerbhart, 1993), memory (O'Dell et al., 1991)
and neural degeneration (Rothman & Olney, 1987).
Recently, it has been shown that haemodynamic effects of S-nitrosothiols are
altered in the presence of anaesthesia (Travis et al., 1997). Further work showed that
direct injection of S-nitroso-L-cysteine into the brain of conscious animals produce a
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greater peripheral haemodynamic effect than its stereoisomer S-nitroso-D-cysteine
(Davisson et al., 1997). The authors suggest that the central nervous system may
contain specific S-nitrosothiol receptors, through which these compounds can exert an
influence without prior decomposition to NO.
1.6.7 Kidney
The kidney is a highly important organ, filtering blood and controlling the excretion of
metabolites, water and salts. Functional impairment of the kidney has been suggested
to be the underlying cause of essential hypertension and will exacerbate a number of
other cardiovascular diseases (Guyton et al., 1990; Lifton, 1996). Unsurprisingly, NO
from the endothelium of renal blood vessels, regulates blood flow through the kidney
and, subsequently, influences sodium homeostasis (Zou & Cowley, 1997; Plato &
Garvin, 1999). In addition, NO regulates the release of renin from the kidney (Vidal et
al., 1988) and protects against ischaemia-reperfusion injury (Pararajasingam et al.,
2000). Many of the effects of NO in the kidney are initiated through activation of the
endothelin system, producing a further level of complexity between autocrine and
paracrine systems (Plato & Garvin, 1999; Kotelevtsev & Webb, 2001).
1.6.8 Others
NO also exerts a profound effect on the respiratory system. Generation of NO in
pulmonary blood vessels modulates basal tone (Greenberg et al., 1987) and, in
combination with NANC nerve-derived NO, influences the tone of bronchial smooth
muscle. The close interaction between blood vessels and the lung provides a subtle
control of oxygen delivery to the blood and inhaled NO has dramatic effects on vessel
tone and blood oxygen content (Barnes, 1993). Additionally, NO from immune cells
in the lungs will provide an early defence against inhaled pathogens (Barnes, 1993).
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As mentioned above, NANC nerves also play a role in gut motility in the
gastrointestinal tract. In addition, bacteria in the saliva are involved in the reduction of
nitrate, present in many foods, to nitrite. Nitrite is acidified to NO in the stomach and
has been suggested to act as a defence mechanism against ingested pathogens
(Benjamin et al., 1994). NO may also have a cytoprotective role in the gastrointestinal
system through enhanced mucosal blood flow, stimulation of mucus secretion and
inhibition ofproinflammatory cells (Del Soldato et al., 1999; Bandarage et al., 2000).
Oestrogens regulate eNOS expression and activity and may contribute to the
many physiological changes experienced throughout pregnancy (Conrad et al., 1993).
NO also contributes to uterine relaxation and vasodilatation during labour: a process
which is sometimes compared to an 'inflammatory event'. Indeed, there is marked
expression of Ca2+-independent NOS before labour, that diminishes after birth
(Natuzzi et al., 1993).
1.7 NO IN PATHOPHYSIOLOGY
1.7.1 Overproduction of NO
Most cardiovascular conditions focus on a depletion of endogenous NO. However,
sometimes an overproduction ofNO, due to iNOS expression can be detrimental.
1.7.1.1 Immune response
As mentioned previously (Hibbs et al., 1987; Vallance & Moncada, 1994), activated
white blood cells produce NO as a defence against invading pathogens. However, the
production ofNO contributes to the inflammatory response, enhancing vasodilatation,
vascular leakage and tissue damage (Vallance & Moncada, 1994). NO is generated
from iNOS expression in infected tissue cells as well as invading immune cells (Quinn
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et ah, 1995). iNOS has been detected in the arthritic joints (Farrell et al., 1992),
infected kidney nephrons glomeruli (Jansen et ah, 1994), psoriatic lesions (Bruch
Gerharz et ah, 1996), gut ulcers (Middleton et ah, 1993) and the liver cells infected
with malarial schizonts (Nussler & Billiar, 1993; Morris & Billiar, 1994). In serious
infections such as septic shock, there is a massive overactivity of the immune system.
Enough NO is generated to have systemic effects, causing potentially fatal
hypotension, myocardial depression and non-specific tissue damage (Rees et ah,
1990). NOS-inhibitors can reverse this hypotension, but also inhibit constitutive NO
generation (Kilbourn et ah, 1990; Nava et ah, 1991). The development of iNOS-
specific inhibitors is likely to be therapeutically advantageous in such conditions
(Quinn et ah, 1995; Hobbs et ah, 1999). However, Bhagat et al. recently showed that
iNOS expression may not be responsible for the dilatation of human hand veins in
response to cytokines (Bhagat et ah, 1999). Instead, the authors propose that there is
increased expression of enzymes controlling BH4 synthesis. Subsequently, enhanced
eNOS activation may be the cause of excessive NO generation in sepsis, rather than
expression of iNOS.
1.7.1.2 iNOS in cardiovascular disease
In general, there is a decreased bioavailability of NO in cardiovascular diseases (see
below). However, iNOS expression is often seen in diseased tissue. In patients with
heart disease, iNOS is found in areas surrounding infarcted myocardium (De Belder et
al., 1993; Fukuchi et ah, 1998; Vejlstrup et ah, 1998). iNOS is also found in skeletal
muscle ofpatients with chronic heart failure (CHF; Adams et ah, 1997) and in blood
vessels of a rat model of CHF (Miller et ah, 2000). iNOS is also upregulated in
atherosclerotic vessels (Bult et ah, 1999; Li & Forstermann, 2000) or normal vessels
after vascular injury (Kibbe et ah, 1999). iNOS expression may be a counter-
mechanism to supplement NO production in areas where constitutive NOS activity is
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diminished. Alternatively, it may be acting to counteract an upregulation of
vasoconstrictive factors or to negate the effect of NO inactivation by oxygen free
radicals. Although, NO may 'scavenge' reactive oxygen species, the formation of
peroxynitrite may further accentuate tissue damage and inflammation (White et al.,
1994; Beckman & Koppenol, 1996; Vinten-Johansen, 2000). Recently, expression of
a dysfunctional NOS isoform, that generates superoxide rather than NO, has been
demonstrated in a number of cardiovascular conditions, such as hyperlipidemia
(Pritchard et al., 1995), coronary artery disease (Cosentino & Katusic, 1995), nitrate
tolerance (Kaesemeyer et al., 2000; Munzel et al., 2000) and heart failure (Miller et al.,
2000). This failed counter-regulatory mechanism will further accelerate disease
progression.
1.7.2 Endothelial dysfunction in cardiovascular disease
Endothelial dysfunction is characterised as a reduction in the bioavailability of NO and
is prevalent in most cardiovascular disorders including hypertension (Linder et al.,
1990; Calver et al., 1992; Panza et al., 1993), hypercholesterolemia (Drexler et al.,
1991; Creager et al., 1992), atherosclerosis (Ludmer et al., 1986; Forstermann et al.,
1988), heart failure (Kubo et al., 1991; Katz et al., 1992), thrombosis (Loscalzo,
2001) and diabetes (Calver et al., 1992). Originally, endothelial dysfunction was
characterised by a reduced response to endothelial-dependent dilators such as
acetylcholine or NOS inhibitors like L-NMMA, but not endothelium-independent
mediators such as the NO donors sodium nitroprusside or glyceryl trinitrate (Drexler et
al., 1991; Calver et al., 1992). Such results were interpreted to be indicative of a
reduced production of NO from the endothelium. However, although this
interpretation is still likely to be correct, as our understanding of cardiovascular disease
grows, it has become clear that endothelial dysfunction is multifactorial (Harrison,
1997; Vallance & Chan, 2001). NO generation by eNOS may be lost due to loss of
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endothelial cells, lack ofNOS substrate or co-factor availability, or downregulation of
eNOS expression (Cohen et al., 1988; Shimokawa & Vanhoutte, 1989; Drexler et al.,
1991). An upregulation in the levels of the endogenous NOS inhibitor ADMA has also
been found in hypertensive patients with renal failure (Vallance et al., 1992),
hypercholesterolaemic rabbits (Yu et al., 1994) and endothelial cells that have
regenerated following denudation by balloon angioplasty (Azuma et al., 1995).
Increases in oxidized lipoproteins may also enhance eNOS dysfunction and NO
diffusion (Galle et al., 1991; Tanner et al., 1991; Pritchard et al., 1995). Available NO
can be further diminished by reactive oxygen species-mediated scavenging under
conditions of oxidative stress brought on by increased oxygen radical production or
reduced anti-oxidant protection (Gryglewski et al., 1986; Nakazono et al., 1991).
Finally, it should be highlighted that vascular smooth muscle itself may become less
sensitive to NO cardiovascular diseases (Robinson et al., 1982; Calver et al., 1992),
although the exact cause(s) have not been fully elucidated.
In more severe cardiovascular disease, vascular remodelling and ventricular
hypertrophy increases the number of cells and distance NO must diffuse to cause
relaxation of the outermost VSMCs and myocytes (Egan et al., 1987; Folkow, 1990).
Additionally, disruption to laminar blood flow can reduce eNOS activity and reduce the
proximity ofNO-scavenging red blood cells to the endothelium (Wei Liu et al., 1989;
Butler et al., 1998).
1.7.3 Vascular disease and vessel occlusion
Vascular disease, or atherosclerosis, is a common condition seen in aging blood
vessels, particularly in patients who have a number of risk factors including diabetes,
smoking, high cholesterol levels and hypertension (Vogel, 1997). At present it is
unclear if endothelial dysfunction is a cause or result of early stages of atherosclerosis,
although the loss of the protective effects of NO clearly worsens the situation
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(Celermayer et al., 1992). The initial marker of vascular disease is the deposition of
lipids, forming a 'fatty streak'. As the disease progresses, a distinct lesion begins to
form, composed of many cells including proliferating smooth muscle cells, white-
blood cell derived foam cells and fat and calcium deposition (Ross, 1993; Davies,
2000). The disease can progress further until a distinctly structured atherosclerotic
lesion forms and begins to protrude into the the vessel lumen, obstructing flow. Areas
of the lesion may become weakened, exposing reactive components, leading to
thrombus formation which further occludes the lumen. Sudden plaque rupture will lead
to a massive area of thrombosis and inflammation at the exposed lipid core, that may
totally occlude the vessel lumen. Even 'stable plaques' are vunerable to endothelial
erosion that leads to chronic thrombosis at these sites (Davies, 2000). Aggregates may
break free from the plaque surface, forming circulating microemboli that may lodge in
small vessels elsewhere in the circulation. In the case of the coronary circulation, when
blood flow through arteries is diminished to such an extent that the heart no longer
receives adequate blood to maintain function, ischaemia will occur and the area of the
heart become infarcted (Opie, 1990). Infarction of the heart worsens the efficiency of
the heart, exacerbating the situation, until the heart fails. It has been estimated that
acute myocardial infarction due to vascular occlusion accounts for 250,000 deaths each
year in the UK (Gershlick, 2001).
1.7.4 Non-pharmacological intervention
A number of surgical and cardiological techniques have been developed to restore flow




Coronary artery bypass grafting (CABG) is an invasive surgical technique used when
there is extensive multiple vessel disease in the coronary circulation (Kaiser, 1985).
Essentially a blood vessel is surgically grafted or rerouted to improve blood flow to
ischaemic regions. A blood vessel, such as a saphenous vein or radial artery, is
isolated and then grafted from a patent artery to an artery in the ischaemic region,
'bypassing' the obstruction. Alternatively, the internal mammary artery may be
redirected to the ischaemic region, without directly transplanting a blood vessel from
elsewhere in the body. Open heart surgery clearly carries a great deal of risk, but the
technique has been shown to improve heart function and reduce cardiovascular events
compared to medicinal therapy alone (Berger et al., 2001; Hueb et al., 2001).
However, long-term success is limited by spasm, accelerated atherosclosis and
thrombolytic occlusion of the graft, and high dose thrombolytic therapy has
complications preventing long-term use (Janero & Ewing, 2000).
1.7.4.2 Angioplasty
The prevalence of vascular diseases encouraged researchers to develop a less invasive
technique to recanalise occluded coronary arteries. In the 1970s Gruntzig et al.
modified balloon catheters, previously used to restored blood flow through peripheral
arteries, to allow them to be used in the coronary circulation (Gruntzig et al., 1979).
Essentially a catheter with a deflated balloon at its tip is introduced into the femoral
artery under local anaesthetic. The catheter is manipulated into the coronary circulation
via shaped guidewires. The balloon is placed at the site of the obstruction and then
inflated. Inflation stretches the artery, 'cracks' the lesion and, subsequently, restores
blood flow (Janero & Ewing, 2000; Fig 1.9). Increasing expertise and catheter design
improved the success rate, in terms of improved blood flow, of percutaneous





















was as efficient as CABG in practically all subgroups of patients with vascular disease
(Berger et al., 2001; Gershlick, 2001).
The main limitation of CABG and PTCA is the reocclusion of treated arteries
due to acute thrombosis and vasospasm (Mabin et al., 1985). In PTCA, in particular,
these processes lead to chronic reocclusion due to restenosis. Restenosis is
multifactorial and involves elastic recoil, adhesion of blood cells to artery, proliferation
and migration of intimal smooth muscle cells and vascular remodelling (Wei Liu et al.,
1989; Bult, 2000; Janero & Ewing, 2000). Damage to the endothelium of treated
arteries is unavoidable and will contribute to most of the above processes. Despite
advances in pharmacological agents (Swanson et al., 2001) and drug delivery systems
(Lincoff et al., 1994; Wolinsky, 1994), restenosis still remains a problem. In fact,
>30% of patients require additional intervention within 6 months after angioplasty
(King et al., 1994), inflicting a huge burden on the healthcare budget (Wei Liu et al.,
1989; Lincoff et al., 1994; Janero & Ewing, 2000). Angioplasty will be discussed
further in Chapter 7.
1.7.4.3 Stenting
A further recent adaptation to angioplasty has been the deployment of stents (see
Ruygrok & Serruys, 1996, for history), which are now in routine use (Topol &
Serruys, 1998; Fleisch & Meier, 1999). Stents are small metal devices, formed of a
mesh of struts that fit over the deflated angioplasty balloon. When the balloon is
inflated, the stent expands, forming a tubular structure that holds the vessel wall open.
The rigid structure of the stent prevents elastic recoil and vasospasm, maintaining
patency and restricting the extent of vascular remodelling. However, the metallic nature
of stents themselves promotes causing smooth muscle cells of the intima to proliferate
extensively (Hoffmann et al., 1996) and neointimal size is often greater than that
associated with angioplasty alone. Consequently, restenosis still remains a problem in
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over 20% of cases (Fischman et al., 1994; Serruys et al., 1994; Bauters et al., 1998).
Antiplatelet agents, such as aspirin, clopidogrel and gycoprotein (GP) Ilb/IIIa
inhibitors and the coating of stents with non-reactive, or drug eluting, surfaces has had
a reasonable degree of success in reducing neointima formation (Swanson et al.,
2001). For example, stents eluting the anti-mitotic compound sirolimus (rapamycin)
have been particularly effective at inhibiting neointimal hyperplasia (Sousa et al.,
2001). However, these compounds do not have anti-platelet actions and the long-term
effectiveness of such stents (> 1 yr) has yet to be established. At present, restenosis
still remains a significant problem (Bult, 2000; Swanson et al., 2001).
1.8 NO DONORS
Due to the prevalence of endothelial dysfunction in cardiovascular disease and
unavoidable damage following interventional cardiology, the delivery of exogenous
NO to areas of diminished NO activity is an attractive therapeutic option in the
management of these conditions. There is now an extensive number of classes of NO
donors, yet only the organic nitrates and sodium nitroprusside (SNP) are used
clinically and both have limitations. With the development of novel NO donors, NO
supplementation is likely to become more prevalent for a wider range of disorders
(Megson, 2000).
1.8.1 Organic nitrates
1.8.1.1 Mechanism of action
Organic nitrates, particularly glyceryl trinitrate (GTN; Fig 1.10), have been used
medicinally since the 19th century. They are still the most commonly used NO donors
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today, mainly to relieve the symptoms of angina. Nitrates are recognized to be
venoselective (MacAllister et al., 1995) and their symptomatic effect is primarily due to
decreased venous return to the heart, reducing cardiac workload. The dilatation of large
coronary and collateral arteries will also enhance their effectiveness (Parker, 1987;










Figure 1.10 Chemical structure of two organic nitrates, GTN and ISDN.
GTN is particularly stable in comparison to other NO donors and it does not generate
NO spontaneously in solution. Instead GTN must be biotransformed to active NO. In
VSMCs, 1 mole ofNO is generated per molecule of GTN (Bennett et al., 1989). The
factor that biotransforms GTN in vivo remains elusive. Initially, studies focused on
reducing agents, such as thiols. Thiols were proposed to reduce the nitrate groups to
nitrite and then further react with nitrite to generate free NO or unstable S-nitrosothiols
(Ignarro et al., 1981). There is an overwhelming body of contradictory work in this
area (Fung et al., 1989), but the consensus is that thiols are unlikely to be sufficiently
powerful reducing agents to facilitate all the reduction steps needed to metabolise GTN
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to NO (Megson, 2000; Schroder, 1985), even at the high physiological concentrations
of intracellular GSH in blood vessels (0.5-10 mM; Boesgaard et al., 1993; Kurz et al.,
1993; Haj-yehia & Benet, 1996).
The observation that the stereoisomers of the nitrate isosorbide dinitrate (ISDN;
Fig 1.10) have a 10-fold difference in potency in blood vessels (Bennett et al., 1988)
suggests that biological enzymes mediate biotransformation to NO. Initially,
glutathione-S-transferases (GSTs) were suggested to cleavage of nitrate groups, via a
glutathione-dependent mechanism. Results were once again conflicting (Yeates et al.,
1989; Sakanashi et al., 1991; Chung et al., 1992; Kurz et al., 1993; Seth & Fung,
1993). GSTs can indeed mediate partial denitrification of nitrates such as GTN,
although these enzymes selectively remove the central nitrate, producing 1,3-GDN as a
by-product (Jakoby et al., 1976). However, convincing evidence suggests that it is the
denitration of one of the terminal nitrates (co-producing of 1,2-GDN) that is linked to
the biological activity ofGTN (Brien et al., 1986; Bennett et al., 1989).
A better, but far from definite, proposal is that the cytochrome P450 pathway
mediates biotransformation (Servent et al., 1989; Schroder & Schror, 1990; Yeates,
1992; Minamiyama et al., 2001). A 200 kD microsomal protein in the membrane of
smooth muscle cells has also been identified as the endogenous nitrate bioactivator
(Chung & Fung, 1990; Chung & Fung, 1992; Seth & Fung, 1993), but it has yet to be
fully isolated and characterised (for review of potential enzymes see Bennett et al.,
1994; Bauer et al., 1995).
1.8.1.2 Therapeutic applications
In 1867 amyl nitrite was used to treat angina in Edinburgh (Brunton, 1867), followed
12 years late by the use of the organic nitrate, GTN (Murrell, 1879); a compound that
is still in clinical use today. Occasionally, it is also used in the treatment severe
myocardial ischaemia and infarction. GTN can be administered as sprays, ointment,
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sublingual tablets and slow release GTN patches. Transdermal patches allow the
duration of action to be extended up to 8 h to treat patients with chronic angina. Oral
ISDN and isosorbide mononitrate are alternatives that have a slower onset, but a longer
duration of action (Parker, 1987).
Experimentally, GTN has been investigated in many models of other
cardiovascular diseases. Transdermal patches reduce platelet activation (Herbert et al.,
1997), despite GTN being a weak inhibitor ofplatelet aggregation in vitro (Sogo et al.,
2000). This may be because platelets themselves lack the mechanism to biotransform
GTN (Weber et al., 1996), with sufficient biotransformation in vascular tissue in vivo
to influence platelet activity (Megson & Webb, 2000). This antiplatelet activity
contributes to the anti-anginal effects ofGTN, by preventing cyclic flow reductions in
the coronary circulation (Folts et al., 1991). GTN has also been demonstrated to
reduce platelet adhesion in a model of angioplasty (Lam et al., 1988). However, high
concentrations are required for sufficient benefit, leading to systemic side-effects such
as hypotension. Additionally, GTN was only effective in animals with extensive
arterial injury, which occurs infrequently with modem day angioplasty catheters and
clinical expertise.
Despite improving heart function, at present it is unclear whether nitrates
significantly reduce mortality in patients with myocardial ischaemia/infarction (Yusuf et
al., 1988; ESPRIM group, 1994; Munzel, 2001). Other side-effects of organic nitrates
are severe headaches, postural hypotension, and the development of tolerance (Parker,
1987).
1.8.1.3 Nitrate tolerance
The major limitation of organic nitrates is the induction of tolerance. Tolerance is
defined as the loss of therapeutic effect with continuous administration; GTN is almost
completely ineffective within 24 hours). Although activity can be restored by a 4-12
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hour drug free period, intermittent dosing can be a problem for patients with chronic
angina (Abrams et al., 1998).
Due to the lack of understanding of the mechanism of organic nitrate
bioactivation, it is unsurprising that the underlying cause of tolerance also remains a
mystery. Many theories have been proposed, including plasma volume expansion
(Parker et al., 1991), upregulation of neurohormonal vasoconstrictor pathways
(Packer et al., 1987; Parker et al., 1991; Munzel et al., 1995) and desensitization of
sGC (Axelsson & Andersson, 1983; Waldman et al., 1986; Mulsch et al., 2001). Most
attention has focused on the hypothesis that tolerance is caused by impaired activation
ofGTN (Brien et al., 1986; Slack et al., 1989; Feelisch & Kelm, 1991), particularly as
levels of 1,2-GDN formation are reduced in tolerant tissues (Bennett et al., 1989). It
had previously been shown that alkylation of free thiols inhibited the vasodilatory
effect of GTN (Needleman et al., 1973; Needleman & Johnson, 1973) and that nitrate
tolerance could be prevented, or partially reversed, by administering exogenous thiols
(Packer et al., 1987). For many years it was assumed that depletion of thiols necessary
for the biotransformation ofnitrates was the underlying cause of tolerance. There is an
overwhelming body of literature investigating the role of thiols in tolerance induction
(Gruetter & Lemke, 1985; Fung et al., 1989; Munzel et al., 1989; Boesgaard et al.,
1993; Haj-yehia & Benet, 1996), although presence of numerous contradictory
reports suggest that thiol depletion is not the underlying cause of tolerance, but may be
observed as a consequence.
More recently, two novel theories have received much attention (Parker &
Gori, 2001). Munzel et al. showed that tolerance was accompanied by an increase in
superoxide generation leading to scavenging of GTN-derived NO (Munzel et al.,
1995). The authors elaborated further, showing that GTN produced superoxide
through stimulation of endothelial NAD(P)H-dependent oxidases (Munzel et al.,
1996), decreased levels of SOD (Munzel et al., 1999) and induction of a dysfunctional
form of eNOS (Kaesemeyer et al., 2000; Munzel et al., 2000). Upregulation of
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oxidant stress can explain the beneficial effects of thiols in tolerance; acting as
antioxidants in a similar way to vitamins C (Bassenge et al., 1998; Watanabe et al.,
1998) and E (Watanabe et al., 1997). Attention has also returned to cGMP-dependent
phosphodiesterases, as there is an upregulation of phosphodiesterase expression and
activity in nitrate-tolerant vessels (Axelsson & Andersson, 1983; Kim et al., 2001).
However, both novel theories do not sufficiently explain all the contradictory findings
(see Chapter 5) and it is likely that we will only understand organic nitrate tolerance
when we more fully understand the mechanism of nitrate action.
1.8.2 Sodium nitroprusside (SNP)
1.8.2.1 Mechanisms of action







Figure 1.11 Chemical structure of SNP.
The mechanism of SNP biotransformation is, once again, poorly understood. It is
often assumed that SNP decomposes to NO spontaneously in solution (Ignarro et al.,
1981; Feelisch & Noack, 1987; Schroder & Schror, 1990). However, SNP is stable in
solution at physiological pH (Butler & Glidewell, 1987),unless exposed to light,
reducing agents including thiols, or biological factors (Ignarro & Gruetter, 1980;
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Leeuwenkamp et al., 1986; Bates et al., 1991; Kowaluk et al., 1992; Marks et al.,
1995). Similarly to GTN, cytochrome P450 reductase enzymes have also been
implicated in the biotransformation of SNP to NO (Rao et al., 1991), although the
physiological importance of this has yet to be determined (Smith & Kruszyna, 1974).
Additionally, a smaller membrane-bound protein, distinct from the protein that
metabolises GTN, has been identified that releases NO from SNP (Kowaluk et al.,
1992). Membrane-mediated biotransformation to NO is a possibilty, as nitroprusside is
a divalent ion and therefore would be unlikely to cross the plasma membrane
(Kowaluk et al., 1992). However, SNP has been shown to cross biological
membranes, albeit slowly (Rodkey & Collison, 1977; Butler et al., 1988). Also, the
lack of inhibitory effect of membrane-impermanent haemoproteins on SNP-induced
vasodilatation, suggests an intracellular breakdown (Gruetter et al., 1979). Unlike
organic nitrates, SNP is a potent inhibitor of platelet aggregation in vitro (Sogo et al.,
2000), suggesting that platelets contain factors that can activate SNP. Additionally,
SNP is equipotent in arteries and veins (Armstrong et al., 1975) and does not induce
self-tolerance or show cross-tolerance to GTN (Kieth et al., 1982; Kowaluk et al.,
1987; Hinz & Schroder, 1998; Sage et al., 2000; Minamiyama et al., 2001).
1.8.2.2 Therapeutic applications and limitations
SNP was first used as a vasodilator in 1929. Nowadays, the compound is only
occasionally used to control severe hypertension and induce hypotension during
anaesthesia (Butler & Glidewell, 1987). SNP needs to be given as an intravenous
infusion, limiting its clinical use. Also, it is considered difficult to titrate due to its
potent and rapid hypotensive effect and the necessity to be shielded from light during
preparation and infusion (Megson, 2000). More worrying is the presence of the five
cyanide groups in the molecule, which can be released through interaction with red
blood cells (Smith & Kruszyna, 1974). It has been suggested that prior release of
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cyanide groups may even be necessary to release NO (Bates et al., 1991), although
this is controversial (Butler et al., 1988). Normally, the body can cope with low
concentrations (0.5 mg/kg/hr) of cyanide by converting it to thiocyanate via the
thiosulphate-dependent rhodanase system, but that said, in isolated instances cyanide
poisoning has been seen with prolonged use of SNP (Michenfelder & Tinker, 1977).
Nowadays, the use of SNP is mostly restricted to clinical studies, where it is regularly
used as an endothelium-independent vasodilator.
1.8.3 Molsidomine derivatives (SIN-1)
1.8.3.1 Mechanisms of action
Molsidomine is converted to the NO donor 3-morpholinosydnonomine (SIN-1 or
linsidomine) in the liver in vivo (Bohn & Schonafinger, 1989). SIN-1 must undergo
several further reactions before NO is finally released and these occur spontaneously in
the blood (Feelisch et al., 1989). Firstly, SIN-1 is converted to SIN-1A via
hydroxylation. Secondly, molecular oxygen converts SIN-1A to SIN-1 C, producing
NO as a by-product (Bohn & Schonafinger, 1989; Fig 1.12). Like other NO donors,
SIN-1 was orignally believed to act through the stimulation of sGC (Noack &
Feelisch, 1989), although Rinaldi et al. (Rinaldi & Cingolani, 1983) demonstrated a
poor association between the time course of cGMP generation and haemodynamic
effect, suggesting that other cellular mechanism are involved. Unlike organic nitrates,
SIN-1 has anti-platelet actions (Gerzer et al., 1989) and does not induce self-tolerance
or exhibit cross-tolerance with nitrates (Sutsch et al., 1989; Rudolph & Dirschinger,
1991; Hinz & Schroder, 1998).
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1.8.3.2 Therapeutic applications and limitations
Molsidomine derivatives were first used in the treatment of angina in the late 1970s
(Majid et al., 1980) and have subsequently been used clinically to treat coronary
vasospasm (Danchin et al., 1991), heart failure (Unger et al., 1994) and angina
(Messin et al., 1995). Molsidomine, but not its derivatives, can be administered orally.
Experimentally, molsidomine and SIN-1 have been shown to reduce platelet
adhesion to vessels following balloon angioplasty. A reduction in the extent and
prevalence of thrombotic occlusion was shown (Groves et al., 1993; Provost et al.,
1997), but there was variability in the effectiveness of the compounds to prevent
restenosis (Groves et al., 1995; Rikitake et al., 1998; Kalinowski et al., 2001). That
said, the ACCORD study, a large clinical trial, also showed improved luminal diameter
6 months after coronary angioplasty (Lablanche et al., 1997). Results from other
experimental models show that SIN-1 has other anti-atherogenic effects, by inhibiting
the oxidation of lipoproteins (Rikitake et al., 1998) and the proliferation of smooth
muscle cells (Groves et al., 1995).
However, the therapeutic potential of SIN-1 is limited by findings that it co-
generates superoxide (Feelisch et al., 1989; Holm et al., 1998). Superoxide itself will
have a detrimental effect, but localised and simultaneous generation of NO and
superoxide will undoubtedly produce cytotoxic peroxynitrite. Indeed, SIN-1 is often
used as a peroxynitrite generator in scientific studies (Lipton et al., 1993;
Amirmansour et al., 1999; Mathy-Hartert et al., 2000). Peroxynitrite generation may
explain the lack of beneficial effects of these compounds in preventing neointimal
growth (De Meyer et al., 1995) and in reducing mortality in patients with chronic heart




1.8.4.1 Mechanisms of action
Diazeniumdiolates (NONOates) constitute a novel class of NO donor drugs. Although
these compounds have been recognised for many years, they became the focus of
attention as NO donor drugs in 1991 (Maragos et al., 1991). They are composed of a
diolate group ([N(0")N=0]) bound to nucleophile adduct (a secondary or primary
amine or polyamine) via a nitrogen atom (Maragos et al., 1991). NONOates
decompose spontaneously at physiological pH and temperature, to generate up to 2
molar equivalents of NO. The rate of decomposition is dependent on the structure of
the nucleophile adduct (Hrabie et al., 1993). A range of NONOates have now been
described with half-lives varying from seconds to hours (Morley & Keefer, 1993; Fig
1.13). It has been proposed that the modification of the structure of the nucleophile
adduct may also engender selectivity for vascular beds and cellular absorption (Brilli et
al., 1997).
An attractive feature of this class of compounds is that decomposition is not
catalysed by thiols or biological tissue and can be predicted following first-order
kinetics (Morley et al., 1993; Mooradian et al., 1995). Subsequently, biological
activity such as vasodilatation (Maragos et al., 1991; Morley et al., 1993), inhibition of
platelet aggregation (Diodati et al., 1993; Sogo et al., 2000) and inhibition of VSMC
proliferation (Mooradian et al., 1995) closely correlate with the amount of NO
generated in vitro. Unsurprisingly, NONOates are not susceptible to tolerance,






































At present NONOates have not been used clinically and have been tested in
surprisingly few animal models of cardiovascular diseases. That said, results from
animal models of neointima formation look promising. SPER/NO applied peri-
vascularly reduced neointima formation induced by peri-arterial collars (Yin &
Dusting, 1997), balloon angioplasty (Kaul et al., 2000) and also in bypass veins
(Chaux et al., 1998). MAHMA/NO-eluting stents also reduce platelet adhesion to
artificial grafts (Hanson et al., 1995) and local infusion devices releasing PROLI/NO
reduced cell proliferation following endarterectomy-induced injury (Chen et al., 1997).
Additionally, DEA/NO prevents and reverses vasospasm in a primate model of
subarachnoid hemorrhage, without affecting systemic blood pressure (Pluta et al.,
1997). Three NONOates have been shown to lower vascular resistance in models of
pulmonary hypertension (Vanderford et al., 1994; Brilli et al., 1997). The use of
NONOates orally has yet to be frilly clarified, although transdermal preparations have
already been developed (Shabani et al., 2001).
NONOates will undoubted be investigated in clinical trials once long-term
safety has been established. The toxicity of by-products needs to be confirmed,
especially whether subsequent reactions between decompostion products leads to the
formation of carcinogenic nitrosamines (Maragos et al., 1991). The known rate of NO
generation and wide range ofhalf lives are a distinct advantage that could be exploited
for medical gain.
1.8.5 Hybrid NO donor drugs
Hybrid NO donors represent a novel approach to the design of NO releasing
compounds. This class covers a range of established drugs that have been structurally
modified to incorporate NO-containing moieties. The aim of this strategy is to
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synthesise drugs that release NO, but still retain the pharmacological activity of the
parent compound. Importantly, the release of NO must be balanced to provide
sufficient activity within the concentration range of the parent compound (Bandarage et
al., 2000).
1.8.5.1 S-Nitrosated adducts
Initially, a hybrid approach was applied to inhibitors of angiotensin converting enzyme
(ACE). ACE is the endogenous enzyme which converts angiotensin I to angiotensin II;
a potent vasoconstrictor and anti-natriuretic agent. Captopril is an example of an ACE
inhibitor that contains a SH group, which can be nitrosated, forming S-nitrosocaptopril
(SNO-Cap; Loscalzo et al., 1989; Fig 1.14). SNO-Cap has sGC-mediated vasodilator
and anti-platelet action, yet retains the ability to inhibit ACE (Cooke et al., 1989;
Loscalzo et al., 1989). Additionally, SNO-Cap appears to preferentially dilate coronary
arteries (Cooke et al., 1989). Intravenous SNO-Cap produces a long-lasting
hypotensive effect in vivo (Shaffer et al., 1991) and, similarly to other S-nitrosothiols,
is less susceptible to tolerance (Shaffer et al., 1991; Zhang et al., 1994; Matsumoto et
al., 1995). Part of the NO-mediated actions of SNO-Cap may be due to ACE
inhibition, as ACE also inactivates bradykinin, an endogenous stimulator of EDRF




Figure 1.14 Chemical structure of the hybrid NO donor/ACE-inhibitor, SNO-Cap.
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Tissue-type plasminogen activator (t-PA) is an endogenous enzyme synthesised by the
endothelium. Fibrin, a constituent of thrombus, binds to t-PA stimulating the
conversion of plasminogen to plasmin; a powerful fibrinolytic agent. t-PA contains a
single SH group which can be S-nitrosated, allowing t-PA to directly inhibit platelets,
as well exerting a slightly greater fibrinolytic activity than native t-PA (Stamler et al.,
1992). More recently, the combined anti-thrombotic and anti-inflammatory action of
SNO-t-PA has been shown to reduce cardiac necrosis following ischaemia-reperfusion
injury in vivo (Delyani et al., 1996).
Von Willebrand factor (vWF) is synthesised and released by damaged blood
vessels. The binding of vWF to platelet glycoprotein receptors induces platelet
activation, causing adhesion to the damaged region. Recombinant fragments of vWF,
such as AR545C, bind to platelet receptors, competing with the binding of endogenous
vWF to platelet receptors and therefore prevent the initiation of thrombosis. Inbal et al
have shown that S-nitrosated AR545C causes a greater inhibition of platelet adhesion
and aggregation than recombinant vWF that is not S-nitrosated (Inbal et al., 1999).
1.8.5.2 NO adducts of non-steroidal anti-inflammatory drugs
A particularly attractive concept is the addition of NO to non-steroidal anti¬
inflammatory drugs (NSAIDs). NSAIDs inhibit the generation of thromboxanes by
inhibition of cyclo-oxygenase, which induce platelet activation. The simultaneous
release of NO should act synergistically with the NSAID-adduct, to provide greater
anti-platelet activity. The major limitation of NSAIDs are their gastric toxicity due to
the inhibition of prostacyclin in the gut.Therefore, another potential benefit of NO-
releasing NSAIDS is that NO may alleviate NSAID-induced gastrointestinal irritation
by enhancing mucosal blood flow, stimulating mucus secretion and inhibiting
gastrointestinal inflammatory cells (Wallace & Cirino, 1994; Del Soldato et al., 1999;
Bandarage et al., 2000).
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Nitrate groups have been successfully incorporated into the most commonly
used NSAID, aspirin (NCX4016, NCX4215; Fig 1.15a). Additionally, an S-
nitrosothiol ester can be linked to another frequently used NSAID, diclofenac
(Bandarage et al., 2000; Fig 1.15b).
a R =—H aspirin
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Figure 1.15 Chemical structure of three NO-NSAID hybrids, (a) R = structural changes allowing
addition of a nitrate group to aspirin, (b) Area highlighted in bold represents the structural changes
facilitating addition of a S-nitrosothiol group to diclofenac.
Several studies show that these compounds have comparable or greater anti-platelet
effects than the parent NSAID, without causing excessive vasodilatation or
hypotension (Lechi et al., 1996; Del Soldato et al., 1999; Wallace et al., 1999; Momi et
al., 2000). NCX-4016 has also been demonstrated to have a greater inhibitory effect
on restenosis than aspirin, following PTCA in a transgenic model of
hypercholesterolaemia (Napoli et al., 2001). Importantly, these drugs still retain the
analgesic and peripheral anti-inflammatory effects of the parent compound, when given
orally (Ukawa et al., 1998; Del Soldato et al., 1999; Bandarage et al., 2000). The NO-
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adduct also provides effective protection against ulceration of the gut mucosa and may
allow these compounds to be better tolerated long-term (Ukawa et al., 1998; Del
Soldato et al., 1999; Wallace et al., 1999; Bandarage et al., 2000; Tashima et al.,
2000). In particular, S-nitrosated diclofenac analogues should avoid the strict
metabolism requirements of the nitrate-NSAIDs and, therefore, might not be expected
to induce nitrate tolerance (Bandarage et al., 2000). Further work is now required to
establish to what extent NO generation and/or inhibition of eicosanoid synthesis
contributes to the therapeutic benefits of these compounds (Lechi et al., 1996; Wallace
et al., 1999).
1.8.5.3 Compounds containing a furoxanyl moiety
The dihydropyridine class of calcium antagonists can be linked to the NO-donating
furoxans (Di Stilo et al., 1998; Fig 1.16). These compounds cause vasodilatation
through sGC stimulation as well as inhibition of voltage-dependent Ca2+ ion channels
on VSMCs. The same group have also linked furoxans to a,- (Fruttero et al., 1995)
and p,-antagonists (Boschi et al., 1997). Both produce vasodilatation of isolated aortic
strips through a combination of adrenoreceptor antagonism and NO release. Furoxans
have also been attached to a histamine H2 receptor antagonist, and provide a greater
protection against gastric ulcers than anti-histamine drugs alone (Coruzzi et al., 2000).
These effectiveness of these compounds in pathophysiological models in vivo still




Figure 1.16 Chemical structure of an example of a furoxan-Ca2+ channel antagonist hybrid. Area
highlighted in bold represents the structural changes allowing addition of a furoxan group to the
dihydropyridine group.
1.8.5.4 Nipradilol
It was hypothesised that the combining of a nitrovasodilator and adrenoreceptor
antagonist would provide additional beneficial cardiovascular actions by counteracting
the undesirable side-effects of the individual drugs. Nipradilol (K-351; Fig 1.17) is an
orally active compound that was first described in the early 1980s as a non-specific (3-
receptor antagonist containing a nitroxy ester group (Uchida et al., 1983). Addition of
this group instils the drug with vasodilator actions similar to GTN, as well as
enhancing the (3-antagonistic potency and providing antagonism for a-receptors
(Uchida et al., 1983). There is conflicting evidence as to whether nipradilol shows
selectivity for large (Uchida et al., 1983) or small (Lamping & Bloom, 1995) arteries.
Recently, Thakur et al demonstrated that nipradilol inhibits the development of
atherosclerotic lesions in a rabbit model ofhypercholesterolaemia and eNOS inhibition,
although the efficacy of the parent compound was not tested (Thakur et al., 2002).
Interestingly, the beneficial actions ofnipradilol appear to be partially due to increased
eNOS expression (Jayachandran et al., 2001; Thakur et al., 2002).
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Figure 1.17 Chemical structure of nipradilol.
The binding of nipradilol to (3,-receptors is required for both nipradilol-derived NO
release and eNOS potentiation (Jayachandran et al., 2001). The beneficial effects of
nipradilol in cardiovascular conditions have been well studied in both animal models
and small clinical studies (Hayashi & Iguchi, 1998), although no large-scale clinical
trials have been carried out. It appears that nipradilol administered twice daily retains
its antihypertensive potency over 24 h (Haneda et al., 1995). However, from a
mechanistic point of view, it has yet to be fully established whether continuous use
leads to loss of the nitrate-related actions due to the development of tolerance, without




S-Nitrosothiols (general formula R-S-N=0) are nitrosated derivatives of the ubiquitous
biological molecules, thiols. S-nitrosothiols are found endogenously and include S-
62
Ch.1 - Introduction
nitrosoalbumin (SNO-Alb), the S-nitrosated form of the most abundant thiol in blood
plasma (Stamler et al., 1992; Marley et al., 2001), S-nitrosoglutathione (GSNO; Fig
1.18a), the S-nitrosated form of the most common intracellular thiol (Gaston et al.,
1993), SNOC (Fig 1.18b), an S-nitrosated low molecule weight thiol perhaps released
from endothelial cells (Myers et al., 1990) and S-nitrosohomocysteine, which
generates less reactive oxygen species than its parent thiol, homocysteine (Stamler et
al., 1993). S-Nitrosothiol complexes stabilise NO and probably represent an








Figure 1.18 Chemical structure of two endogenous S-nitrosothiols; (a) GSNO, (b) SNOC.
As well as binding to the haem group of red blood cell Hb, the thiol groups of Hb can
be S-nitrosated, forming S-nitrosohaemoglobin (Jia et al., 1996). This is a particularly
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controversial area ofNO biology and there is increasing evidence that both oxygen and
NO are carried by haemoglobin in red blood cells, allosterically regulating the affinity
for each other to provide a dynamic control of oxygen delivery and blood vessel tone
(Jia et al., 1996; Wolzt et al., 1999; Gladwin et al., 2000).
1.8.6.2 Mechanisms of action
Classically, the bioactivity of S-nitrosothiols requires decomposition to free NO. At
one time, the in vitro stability of S-nitrosothiols was unpredictable. This was due to the
presence of trace metal ions in experimental solutions. The use of specific copper (I)
chelators demonstrated that Cu(I) ions catalyse the decomposition of S-nitrosothiols
(Dicks et al., 1996; Al-Sa'doni et al., 1997; Butler et al., 1998) producing NO and the
corresponding disulphide (Fig 1.19). The stability of S-nitrosothiols depends upon the
structure of the thiol which can inhibit Cu-catalysed decomposition by steric hindrance
of the S-N bond (Mathews & Kerr, 1993). Free thiols, and other reducing agents, will
accelerate the decomposition of S-nitrosothiols by reducing Cu(II) to Cu(I) ions (Dicks
et al., 1996; Singh et al., 1996; Al-Sa'doni et al., 1997; Holmes & Williams, 1998).
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Superoxide generation has also been shown to accelerate the decomposition of S-
nitrosothiols (Aleryani et al., 1998; Jourd'heiul et al., 1998; Trujillo et al., 1998). The
biological actions of S-nitrosothiols such as SNOC (Davisson et al., 1996) or S-
nitrosopenicillamine (Travis et al., 1996; Travis et al., 1997) show stereoselectivity,
suggesting the involvement of enzymes. A number of enzymes have been implicated in
the decomposition of S-nitrosothiols including SOD (Jourd'heuil et al., 1999),
glutathione peroxidase (Freedman et al., 1995; Hou et al., 1996), xanthine oxidase
(Trujillo et al., 1998), protein dulpshide isomerase (PDI; Zai et al., 1999;
Ramachandran et al., 2001) and an unidentified membrane bound protein in vascular
smooth muscle cells (Kowaluk & Fung, 1990). Despite variable half-lives, different S-
nitrosothiols have similar bioactivity, suggesting a common mechanism of action
(Kowaluk & Fung, 1990; Mathews & Kerr, 1993).
A unique feature of S-nitrosothiols is that they can directly transfer NO as a
nitrosonium ion (NO+) without the release of free NO ("transnitrosation"; Park, 1988;
Askew et al., 1995; Eqn 10).
R'SNO + R2SH -> R'SH + R2SNO (10)
Therefore, free thiols also accelerate the decomposition of S-nitrosothiols by providing
an acceptor for NO+. Transnitrosation of a thiol group could form a S-nitrosothiol
more susceptible to Cu-mediated decomposition (e.g. GSNO->SNOC), leading to the
release of free NO in specific subcellular sites (Park, 1988; Askew et al., 1995; Liu et
al., 1998). S-nitrosation of SH residues in enzymes and proteins modifies their
activity, providing another level of regulatory activity (Stamler et al., 1992; Lipton et
al., 1993; Molina et al., 1993; Bolotina et al., 1994; Melino et al., 1997; Clementi et
al., 1998; Bauer et al., 1999; Xie et al., 1999).
All S-nitrosothiols are potent inhibitors of platelet aggregation in vitro (Gordge
et al., 1998; Sogo et al., 2000) and inhibit platelet activation in vivo (Radomski et al.,
1992) at concentrations which do not effect blood vessel tone (De Belder et al., 1994).
S-nitrosothiols also show arterioselectivity, inhibiting vasodilatation at a concentration
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which causes little venodilatation (MacAllister et al., 1995). Because S-nitrosothiols
have a less stringent biotransformation pathway than organic nitrates, it is unsurprising
that S-nitrosothiols do not develop tolerance and remain effective in GTN-tolerant
vessels in vitro (Kowaluk et al., 1987; Kowaluk & Fung, 1990; Matsumoto et al.,
1995) and in vivo (Bauer & Fung, 1991; Shaffer et al., 1992).
1.8.6.3 Therapeutic applications
There is a large body of literature exploring the use S-nitrosothiols in animal models
and clinical studies. In general, most studies focus on the use of GSNO because of its
relative stability and likelihood that it generates non-toxic, or even beneficial, by¬
products (i.e. the antioxidant GSH or its disulphide, GSSG). The anti-platelet actions
of GSNO have beneficial actions in angina and myocardial infarction in patients
already receiving aspirin (Langford et al., 1996). In this study, GSNO was better
tolerated than GTN. GSNO also decreases the occurrence of cerebral embolism after
carotid endarterectomy in patients already receiving aspirin and heparin (Molloy et al.,
1998). GSNO prevents platelet activation following balloon angioplasty (Langford et
al., 1994), whilst SNO-Alb, administered as an infusion (Marks et al., 1995) or as a
stent-coating (Maalej et al., 1999), has been shown to reduce platelet adhesion and
neointimal thickening in balloon angioplasty-damaged blood vessels. GSNO also
reduces platelet adhesion in bypass grafts (Salas et al., 1998).
At present it is not clear whether S-nitrosothiols can be given orally, but
transdermal delivery of the S-nitrosothiol or (S-nitrosothiol-derived NO) is feasible
and may have a therapeutic role in Raynaud's syndrome and impotence (Butler et al.,




Recently, several novel analogues of the S-nitrosothiol S-nitroso-iV-acetylpenicillamine
(SNAP) were described. Structural modifications were made to the thiol group to
increase stability by creating steric hinderance of the S-N bond. However, an
additional property was discovered for one the compounds, N-(S-nitroso-jV-
acetylpenicillamine)-2-amino-2-deoxy-l,3,4,6,tetra-0-acetyl-(3-D-glucopyranose
(RIG200; Fig 1.20). RIG200 is essentially SNAP with a acetylated glycosamine group
(Megson et al., 1997). In perfused isolated vessels, a bolus of RIG200 into the vessel
lumen of endothelium-intact arteries produced a transient vasodilatation that recovered
rapidly after the compound washed out of the vessel. However, in endothelium-
denuded vessels, an identical bolus produced a vasodilatation which did not recover
rapidly, but was sustained for a number of hours (Fig 1.21). The sustained
vasodilatation could be reversed by the NO scavenger, Hb, but not the NOS inhibitor
L-NAME (Megson et al., 1997), showing that the effect was mediated by NO which
was not derived from NOS. The parent compound, SNAP, did not produce a
sustained vasodilatation in denuded arteries.
Other analogues of SNAP were synthesised containing N-substituted carbon
side-chains, which, as well as increasing stability, also had the effect of altering the
lipophilicity of the compound (Megson et al., 1999). It was shown that the lipophilic
compounds, such as S-nitroso-A-valeryl-penicillamine (SNVP; five carbon side-chain;
Fig 1.20) also produced a sustained vasodilatation in endothelium-denuded arteries.
Moreover, there was a strong correlation between the lipophilicity and the lack of
recovery of vasodilatation after 1 h (Fig 1.21). Again, the effect was reversed by Hb.
The authors hypothesised that the endothelium acts as a barrier to these compounds
and that, in endothelium-denuded arteries, the lipophilic S-nitrosothiols gain access to
the lipid-rich sub-endothelial layer, where they are retained. Here, they slowly











Figure 1.20 Chemical structures of SNAP, RIG200 and SNVP. Areas highlighted in bold represent the
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Figure 1.21 Results from experiments on phenylephrine-contracted isolated rat femoral arteries, (a)
In endothelium intact vessels (i), a bolus of RIG200 (10 (il; 10"' M) produces a transient
vasodilatation which recovers rapidly after the bolus washes through the vessel lumen. However, in
endothelial-denuded vessels (ii, iii), an identical bolus of RIG200 produces a vasodilatation which is
sustained for a number of hours. This vasodilatation can be reversed by the NO scavenger, Hb (10
(iM; ii), but not by the NOS inhibitor, L-NAME (200 |iM; iii). Taken from Megson et al. (1997).
Br. J. Pharmacol. 122, 1617-1624. (b) Data from boluses of SNAP analogues demonstrating that the
greater the lipophilicity of the S-nitrosothiol, the greater the degree of vasodilatation that remains after
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More recently, it has been shown that these lipophilic S-nitrosothiols produce a
sustained vasodilatation in human blood vessels in vitro (Sogo et al., 2000) and in
vivo (Sogo et al., 2000). Additionally, these compounds, like conventional S-
nitrosothiols, are potent anti-platelet agents in platelet-rich plasma (Sogo et al., 2000),
but not in mixed whole blood (Megson et al., 2000). This observation suggests that
these compounds can inhibit platelet activation in the red-blood cell free layer adjacent
to the endothelium in flowing blood in vivo, without extending bleeding time at sites of
injury where the red blood cells mix with platelets, inhibiting S-nitrosothiol activity




Despite the clear advantages of S-nitrosothiols, their mechanism of action is still poorly
understood. In particular, it has yet to be established if novel S-nitrosothiols behave in
a similar fashion to existing S-nitrosothiols, or whether their structural adaptations alter
their vasodilatation in additional ways, such as their ability to induce sGC-independent
vasodilatation or their susceptibility to vascular tolerance.
The sustained NO-mediated vasodilator effect of lipophilic S-nitrosothiols in
endothelium-denuded vessels is a particularly attractive feature. However, it remains to
be established whether the prolonged NO-mediated effects of these compounds has
other biologically relevant actions, such as inhibition of platelet activation.
Furthermore, it is as yet unclear whether the potentially beneficial properties of these
compounds are mirrored in therapeutically relevant applications, such as balloon
angioplasty.
This thesis focuses on cardiovascular effects of novel lipophilic S-nitrosothiols. The
thesis can essentially be split into two sections. The first section focuses on the action
of S-nitrosothiols in endothelium-intact blood vessels. Initially, isolated vessels are
used to clarify the mechanism of action of these novel compounds, by comparison to
established NO donor drugs. Secondly, the thesis deals with the effects of novel
lipophilic S-nitrosothiols in vessels with a damaged endothelium. Both the mechanism
of the sustained actions in denuded vessels in vitro and the therapeutic potential in vivo
are considered. It is hypothesised that;




sGC-independent vasodilatation is not mediated by peroxynitrite formation.
cell surface thiols are required for the vasodilatory actions of S-nitrosothiols.
intracellular thiols are required for the vasodilatory actions of all NO donors.
lipophilic S-nitrosothiols retain the tolerance-profile of their parent compound, i.e.
they do not induce self-tolerance and remain fully active in vessels made tolerant to
GTN.
a hydrophilic analogue of RIG200 does not cause a sustained vasodilatation in
isolated endothelium-denuded vessels.
SNVP selectively causes vasodilatation and reduces platelet adhesion to blood








2.1 DETECTION OF S-NITROSOTHIOLS USING
SPECTRO-PHOTOMETRY
S-nitrosothiols (1 ml; 1 mM) were dissolved in identical buffer used for experiments
with biological tissue. Sonication (35 (am, 5-10 s, x3; Soniprep 150 sonicator, Sanyo,
Uxbridge, U.K.) was needed to dissolve some S-nitrosothiols (GSNO, RIG200,
SNVP). Samples were kept in the dark at 24°C. Peak absorbance at a wavelength
corresponding to the S-N bond (330-340 nm) was measured using a
microspectrophotometer (Spectromate, World Precision Instruments, Stevenage,
U.K.). Extinction coefficients (850-1168 M 'cm"1) were compared to literature values
(Gordge et al., 1996; Megson et al., 1997; Megson et al., 1999) to ensure full
dissolution and lack of spontaneous decomposition.
2.2 MEASUREMENT OF NO USING NO ELECTRODE
Two ml samples of Krebs buffer solution were prewarmed to 37°C in cuvettes stirred
continuously at 1000 rpm. An isolated NO electrode (ISO-NO MARKII, World
Precision Instruments, Stevenage, UK) was introduced into the cuvette and allowed to
stabilise (10-30 min). Once a stable baseline was obtained, the electrode was calibrated
using 2-(N,N-diethylamino)-diazenolate-2-oxide (DEA/NO; 100-800 nM) in
phosphate buffer (pH 4). DEA/NO undergoes rapid, spontaneous decomposition at
pH<4 (Davies et al., 2001). Krebs buffer (pH 7.4) was used for subsequent
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protocols. NO donors were introduced into the cuvette and NO generation was
allowed to reach plateau, prior to further addition of drugs. In experiments to
determine the role of tissue components in superoxide generation, 1 cm segments of
rat aorta were homogenised in Krebs buffer (50 (il) using a micropestle (Eppendorf,
Cambridge, U.K.). Supernatant (40 (0,1) was removed and added to cuvettes, before
addition ofNO donors. Pilot experiments determined the limits for detection of NO in
this system as ~20 nM. Signals from the NO electrode were processed by a MacLab/4e
analogue-digital converter and displayed through Chart™ software (AD Instruments,
Sussex, U.K.) on a Macintosh Performa 630 microcomputer.
2.3 FUNCTIONAL STUDIES USING PERFUSED
ISOLATED RAT FEMORAL ARTERIES
All experiments using animals were carried out in accordance with the Animals
(Scientific Procedures) Act 1986 (U.K. Home Office).
2.3.1 Preparation of femoral arteries
Experiments were carried out on isolated segments of femoral artery from adult male
Wistar rats (250-350 g) in a perfusion system described previously (Megson et al.,
1997; Fig 2.1). Briefly, animals were killed by cervical dislocation and both femoral
arteries were dissected free. Segments of artery (7-8 mm long) were cannulated
immediately distal to the epigastric arterial branch. The vessels were transferred to
perspex organ chambers (1 ml volume) where they were perfused (0.6 ml rnin
Gilson Miniplus 3; Anachem, Luton, U.K.) and superfused (1 ml min"1: Watson
Marlow 302S; Falmouth, U.K.) with fresh oxygenated (95% 02, 5% C02) Krebs



















was measured by monitoring perfusion pressure with a differential pressure transducer
(Sensym SCX 15ANC; Farnell Electronic Components, Leeds, U.K.) located
upstream of the artery. The apparatus permits exclusive drug delivery to the luminal
surface of the vessel, either in the perfusate or by bolus microinjection (10 (il) through
a resealable rubber septum into the perfusate immediately upstream of the vessel
(transit time to artery ~3 s, through lumen -300 ms). All experiments were carried out
in a darkened laboratory in order to protect photolabile drugs, prevent photorelaxation
of vessels (Megson et al., 1995) and to minimise spontaneous superoxide generation
in oxygenated Krebs buffer (Beckman & Koppenol, 1996). Signals from pressure
transducers were processed by a MacLab/4e analogue-digital converter and displayed
through Chart™ software.
2.3.2 General experimental protocol
Vessels were preconstricted with phenylephrine (PE; 2-14 pM) in the presence of
supramaximal concentrations of the NO synthase inhibitor, L-NAME (20 flM), to
exclude endothelial NO-synthase activation in vasodilator responses. The
concentration of L-NAME was minimised to prevent toxicity in prolonged (>20 h)
perfusion. This concentration of L-NAME was shown to be supramaximal as Hb
caused no additional vasoconstrictor effect (see Chapter 3). Perfusion pressure
remained constant after prolonged perfusion ofL-NAME (Chapter 4 and 5), indicating
that iNOS expression was not sufficiently high to overcome the inhibitory effects of
this concentration ofL-NAME. An L-NAME-induced increase in pressure of >40% of
the existing PE-induced tone was deemed to beindicative of an active endothelium.
Unless stated, arteries were not denuded of endothelium in order to preserve the
potential endothelium-dependent superoxide generating systems (Holland et al., 1990;
Munzel et al., 1995), except that generated by NO synthase which may be inhibted by
L-NAME (Vasquez-Vivar et al., 1998; Xia et al., 1998; Munzel et al., 2000).
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Concentration response curves were carried out by sequential microinjections
of increasing concentrations (10 |il of 10"8 - 10"3 M; 0.1 pmol - 10 nmol) of NO
donors. Alternatively, prolonged administration of compounds could be achieved by
adding the compound to the perfusate or superfusate. At the end of experiments, all
drugs were washed out and the vessel removed to ensure pressure returned to
baseline. Microinjections of drug vehicle (Krebs buffer or saline) had no effect on
perfusion pressure. Sequential boluses of NO donors (10 |xl; 10~8 - 10~3 M) had no
effect on the magnitude of subsequent microinjections. Peak vasodilatation correlates
with the time course of vasodilatation (area under curve; AUC; %preconstriction.sec)
in both control vessels and vessels treated with modulators (r=-0.76; .P<0.001;

























Figure 2.2 Correlation between peak vasodilatation and time course of vasodilatation (both
expressed as % preconstriction pressure existing before drug bolus) in control vessels and vessels
treated with modulators (r=-0.76; PO.OOl; Pearson's correlation; n=32).
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2.4 ANGIOPLASTY OF RABBIT CAROTID ARTERIES
Adult male New Zealand white rabbits (2.5-3.5 kg; n=60) had unrestricted access to
water and standard chow. Animals were anaesthetised with an intramuscular injection
ofHypnorm (0.3 ml/kg; fentanyl citrate & fluanisine) and anaesthesia was maintained
with a halothane (1.5%) / nitrous oxide (2%) / oxygen (5 L.min"1) mixture (Hadoke et
al., 1995). The left femoral artery was exposed and a 3FG cannula (Portex Ltd.,
distributed by Mackay & Lynn Ltd, Edinburgh, U.K.) filled with heparinised-saline
(Hep-Sal; 25 U/ml; Multiparin) was advanced -15 mm into the artery for the
withdrawal of blood and the measurement of systemic blood pressure (BP). Five ml of
blood was withdrawn into a Monovette™ tube containing 0.4 ml sodium citrate (3.8%)
and gently mixed. BP was measured using a pressure transducer (CAPTO SP844
physiological pressure transducer, ADInstruments Ltd, East Sussex, U.K.), displayed
through Chart™ software. The external carotid artery was cannulated and a 2.5x20
mm angioplasty catheter (Boston Scientific SCIMED, Galway, Ireland) was
introduced into the common carotid artery (Fig 2.3). Angioplasty was performed on a
40 mm section of artery, using 30 s inflations (10 atmospheres of pressure; atm; 2
times with a 15 s interval). The balloon was withdrawn under 4 atm. Sham operations
involved cannulation of the common carotid artery without balloon inflation. The
artery was recannulated to administer drug boluses (200 nmoles; flushed through the
cannula with a further 0.2 ml of Hep-Sal) immediately upstream of the angioplastied
region. Blood was allowed to flow over the angioplastied region for 30 min after drug
administration (-35 minutes after angioplasty). Animals were killed with an overdose
ofpentobarbitone and both common carotid arteries were dissected free and placed in
Krebs buffer. Arteries were cleaned of connective tissue and divided into rings for
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2.5 FUNCTIONAL STUDIES USING ISOLATED RABBIT
CAROTID ARTERIES
2.5.1 Preparation of carotid rings
Rabbit common carotid arteries were isolated, cleaned of connective tissue and divided
into rings (3mm). Vessel rings were suspended between two intraluminal wires in a 10
ml myograph organ bath (Multi Tissue Bath System 700MO, Danish Myo Technology
A/S, Copenhagen, Denmark) to record isometric tension. Vessels were bathed in
oxygenated (95% 02, 5% C02) Krebs solution at 37°C. Tension was applied to
vessels in stepwise increments to obtain a resting tension of 7 g (Dong et al., 1997)
and allowed to equilibrate for 30-40 min. Signals from the myograph were processed
by a MacLab/4e analogue-digital converter and displayed through Chart™ software.
2.5.2 General experimental protocol
Rings were contracted three times to obtain the maximum contraction to high K'
Krebs, containing equimolar replacement of NaCl (4.7 mM) with KC1 (118 mM; see
Appendix I). Rings were subsequently exposed to cumulative concentrations of PE
(0.1-10 pM) and a suitable concentration chosen to produce -80% contraction (ECg0;
-3 pM). Following precontraction with ECg0 PE, responses to ACh (0.01-30 pM)
were measured to test endothelial cell function.




Citrated blood was centrifuged at 200 g for 10 min. Platelet-rich plasma (PRP) was
aspirated and centrifuged at 1300 g for 10 min with prostacyclin (PGI2; 300 ng/ml) to
pellet platelets. Platelet poor plasma was removed and the pelleted platelets were
resuspended and incubated for 20 min in 10 ml Tyrode's solution containing 100
pCiulInCl3 chelated to 2-mercaptopyridine-N-oxide (MERC; 400 jig/ml). Platelets
were washed three times by centrifugation at 1300 g for 10 min and resuspended in
PGI2/Tyrode's solution to remove unbound radiolabel. Finally, platelets were
resuspended in PGI2-ffee Tyrode's containing ~330 xlO6 platelets/ml (determined with
a Coulter Ac .T 8 Haematology Analyser, Coulter Electronics Ltd, Luton, U.K.). After
each wash cycle, 10 pi samples were taken to determine the labelling efficiency.
Approximately 1 ml platelet suspension (50-300 xlO6 platelets; radioactivity=50-800
xlO3 dpm) was obtained.
Radioactive blood samples (100 pi) and segments of carotid artery (~5 mm)
were added to 4 ml scintillation fluid. Radioactivity was assessed by a Tri-Carb™
1900TR Liquid Scintillation Analyser (Packard Instrument Company, Meriden,
U.S.A.)
2.7 PLATELET AGGREGATION IN RESPONSE TO
AGONISTS
Half-milliliter samples of PRP were pre-warmed to 37°C for 5 min in a two-channel
platelet aggregometer (Cronolog Ca560, Labmedics, Stockport, U.K.) capable of
measuring aggregation in PRP by turbidometry by a standard method (Megson et al.,
2000).
Samples of PRP were stirred at 1000 r.p.m. using disposable stirrer bars and
platelets were activated with supramaximal concentrations ofadenosine 5'-diphosphate
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(ADP; 8 jlM). Aggregation was measured by monitoring changes in light transmission
for a period of 5 min following agonist addition.
2.8 MEASUREMENT OF PLASMA CATECHOLAMINES
High performance liquid chromatography (HPLC) was used to measure plasma
adrenaline, noradrenaline and dopamine. This work was carried out by Dr R. Stephen,
Department of Child Life and Health, University of Edinburgh, by a published method
(Sedowofia et al., 1998). Briefly, PRP (0.5 ml) was frozen immediately after
centrifugation (Section 2.6). Plasma catecholamines were measured by dual-electrode
coulometric detection (ESA Coulochem Model 5100A) after separation on a reverse
phase HPLC column (Waters 510 pump with pulse dampener, equipped with a Promis
11 programmable auto-injection system; Spark Holland BU), using a modification of
the method of Davies et al. (Davies & Molyneux, 1982). The upstream and
downstream electrodes were set at +0.25 V and -0.4 V, respectively. A simple solvent
extraction system was used for the selective and quantitative isolation of
catecholamines, using a modification of the method of Smedes et al. (Smedes et al.,
1982). The limits of detection were <5 pg per injection for adrenaline and
noradrenaline and <10 pg per injection for dopamine. The interassay coefficients of
variation for adrenaline, noradrenaline and dopamine were 2.0%, 1.6% and 3.4%,
respectively. Dihydroxybenzylamine was used as the internal standard.




Blood vessels (3 mm) were carefully cut along the longitudinal axis to expose the
vessel lumen and pinned out on an agar bed. The vessel was then immersed in 3%
glutaraldehyde in 0.1 M sodium cacodylate buffer (SCB; pH 7.4; see Appendix I) for
8-10 h, followed by 1 h glutaraldehyde-ffee SCB wash. Vessels were postfixed in
osmium tetroxide in SCB (1-2 h), dehydrated in graded acetone (50-100%; 10 min
intervals) and critical point dried with C02 (E3000 SII CPD, Polaron Equipment Ltd,
Watford, U.K.). The vessel was coated with gold-palladium alloy (SC500 Sputter
coater, Emscope Laboratories Ltd, Kent, U.K.) and the intimal surface was examined
with a Phillips 505 scanning electron microscope (Eindhoven, Netherlands).
Representative surfaces were photographed.
Following fixation and dehydration, vessel rings were imbedded in 50:50
araldite:acetone. 60nm sections were cut (Reichert OMU4 Ultracut microtome, Leica,
Milton Keynes, U.K.) and mounted on 200 mesh copper grids. Uranyl acetate and
lead citrate were used to stain sections (LKB Ultrostainer, LKB, Surrey, U.K.) as per
manufacturer's instructions. Samples were examined with a Phillips CM12
transmission electron microscope (Eindhoven, Netherlands). Representative sections
were photographed.
2.10 HISTOCHEMICAL ANALYSIS OF BLOOD
VESSEL STRUCTURE
2.10.1 Preparation of sections
Blood vessels (3mm) were fixed in formalin (10%) for 24 hr and then placed in 70%
alcohol. Samples were embedded in parafin wax blocks and 3 |lm cross-sections were
cut (Leitz 1512 microtome, Carl Zeiss, Hertfordshire, U.K.). Sections were floated
out and placed on 3-aminopropyltriethoxy-saline (TESPA)-coated slides (see
Appendix I) and allowed to adhere overnight at 37°C. Sections were dewaxed in 100%
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xylene (2x5 min) and then rehydrated in in graded alcohol (100-70%, distilled water;
2-5 min intervals). Sections were then washed in phosphate buffered saline (PBS; pH
7.6; 3x3 min; see Appendix I). Following staining, sections were dehydrated in
graded alcohol (distilled water, 70-100%; 2 min intervals) and placed in xylene (2x5
min). Coverslips were attached with DePeX .
All washes were in PBS or Tris-buffered saline (TBS; pH 7.6; see Appendix I)
for 3x3 min. Serum and antibodies were diluted in 0.5% bovine serum albumin
(BSA).
2.10.2 Haematoxylin and eosin staining
Rehydrated sections were placed in Harris' haematoxylin for 10 min and then washed
in running water until the water ran clear (~2 min). Sections were placed in 1% acetic
acid (diluted in 70% alcohol) for 30s and then washed in running water for 5 min.
Sections were counterstained with eosin (1%) for 2 min, washed in distilled water,
dehydrated and coverslips affixed.
2.10.3 Immunohistochemistry
Rehydrated sections were warmed in TBS at 37°C for 10 min, followed by incubation
with trypsin-TBS (see Appendix I) at 37°C for 45 min and a PBS wash. Sections were
covered 50:50 rabbit serum:BSA-PBS (see Appendix I) for 30 min. Excess serum was
removed and the primary antibody (unconjugated Griffonia (Bandeiraea) Simplicifolia
Lectin I; GSL I) was used to specifically stain endothelial cells. GSL I was added at
dilutions of 1:400 and 1:800 in BSA-PBS and left overnight at 4°C. Negative controls
were incubated overnight with no primary antibody, i.e. BSA-PBS alone. Following a
PBS wash, the secondary antibody (rabbit, anti-GSL I) diluted 1:150 in BSA-PBS
was added at 20°C for 30 min. Following another PBS wash, the tertiary antibody
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(goat, anti-rabbit IgG) diluted 1:100 in BSA-PBS was added at 20°C for 30 min.
Sections were washed in TBS, placed in levamisole (1:100) for 30 min to remove
endogenous phosphatase, followed by another TBS wash. Alkaline phosphatase
(Vector Red) were added as per manufacturer's instructions and incubated in the dark
for 5-20 minutes until sufficient staining occurred.
Cell nuclei were stained with haematoxylin, washed with acid alcohol (see
above), and counterstained with methyl green (1%) for 1 min. Sections were rinsed in
distilled water for 30 s, dehydrated and coverslips affixed.
2.11 DRUGS AND REAGENTS
Key
Dilution
k/s: Diluted in Krebs buffer or saline.
DMSO: Diluted in dimethyl sulphoxide.
PBS: Phosphate-buffered saline,
solution: Supplied as a solution.
Storage
day: Stored as solids and dissolved on the day of use/supplied as a solution
(stored at 4°C) and diluted on day of use.
week: Diluted and stored as aliquots at 4°C and used within 1 week,
month: Diluted and stored as aliquots at -20°C and used within 1 month.
'Powder or aliquot stored under argon
"Dissolved immediately before use to prevent oxidation.
3Met-haemoglobin was reduced to the ferro-form with sodium dithionite (5-fold
excess; 57.4 pM) as described previously (Martin et al., 1985). Dithionite
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was then removed by dialysation. Spectrophotometrical analysis at
wavelength of 480-620 nm revealed that Hb existed in mostly as
oxyhaemoglobin (HbFe2+02).
Drug Dilution Storage Source
ACh k/s month Sigma
ADP k/s month Sigma
BSA PBS day Sigma
BSO k/s day Sigma
L-Cysteine k/s day Sigma
collagen k/s month Labmedics
DEA/NO 1 M NaOH month Alexis
DePeX solution day BDH
DETCA k/s month Sigma
DQ DMSO day Sigma
DTNB DMSO day Sigma
EA DMSO day Sigma
eosin solution day BDH
GSNO k/s month Sigma
GTN (nitrocine) k/s month Schwarz Pharma
GlycoSNAP-2 k/s month Alexis
haematoxylin solution day BDH
halothane solution day Genus Express
Hb (from bovine
erthrocytes) H20 month3 Sigma
heparin (Multiparin) k/s day Genus Express

















































































All basic laboratory chemicals, e.g. acetone, DMSO, ethanol etc, were supplied by





Baxter Healthcare Glasgow, U.K.
Biomol Distributed by: Affmiti Research Products, Exeter, U.K.
BDH Merck Ltd., Lutterworth, U.K.
BOC Manchester, U.K.
Fisher Loughborough, U.K.
Genus Express Falkirk, U.K.
Labmedics Salford, U.K.
NEN™ NEN1M Life Science Products, Zaventem, Belgium
Sigma Poole, U.K.
Schwarz Pharma Ltd. Chesham, U.K.
Tocris Cookson Bristol, U.K.
Vector Laboratories Ltd. Peterborough, U.K.
Synth: Synthesised in St. Andrews by Dr F.A.Mazzei and Dr A.R. Butler, by a
published method a(Megson et al., 1997), b(Miller et ai, 2000).
2.12 ANALYSIS OF RESULTS
Analysis of the results of individual techniques are given in the method sections of
relevant chapters.
P-values quoted in the text were accepted as statistically significant when
P<0.05. In figures, statistical significance is represented as */J<0.05, **JP<0.01,
***P<0.001, n.s.=non significant.
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Chapter 3
Soluble guanylate cyclase-independent
vasodilatation and its relationship to the site of
decomposition of NO donors
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3. SOLUBLE GUANYLATE CYCLASE-
INDEPENDENT VASODILATATION AND ITS
RELATIONSHIP TO THE SITE OF
DECOMPOSITION OF NO DONORS
3.1 INTRODUCTION
It is generally accepted that the vasodilator effects ofNO are mediated via activation of
smooth muscle cell sGC to generate cGMP (Waldman & Murad, 1987). However,
vasodilatation in response to high concentrations of NO is not exclusively cGMP
mediated (Trottier et al., 1998; Weisbrod et al., 1998). Using the selective sGC-
inhibitor, ODQ (Garthwaite et al., 1995), an sGC-independent component of
vasodilatation has been identified in response to several NO donors (Brunner et al.,
1996; Homer et al., 1999). S-nitrosothiols have also been shown to cause
vasodilatation in the presence ofODQ, despite complete abolition of cGMP generation
(Brunner et al., 1996; Moro et al., 1996).
The identity of the sGC-independent mechanism has not been fully elucidated,
although it appears that the mode of NO generation from NO donors influences their
actions (Campbell et al., 1996; Homer et al., 1999; Tseng et al., 2000; Wanstall et al.,
2001). In the majority of cases, the mechanism of action and site of decomposition of
NO donors has yet to be fully determined. The S-nitrosothiols, in particular, can be
bioactivated by a number of mechanisms, including decomposition by metal ions
(Dicks et al., 1996; Al-Sa'doni et al., 1997; Butler et al., 1998) or cellular enzymes
(Kowaluk & Fung, 1990; Freedman et al., 1995; Hou et al., 1996; Trujillo et al.,
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1998; Jourd'heuil et al., 1999), chemical reduction (Singh et al., 1996; Holmes &
Williams, 1998) and transnitrosation of thiols (Park, 1988; Askew et al., 1995). The
locations of these factors (e.g. intracellular, extracellular, membrane-bound) and the
ability of the S-nitrosothiol to permeate the plasma membrane, will influence the site of
release ofNO.
The NONOates are a novel class of NO donor drug that decompose by a
mechanism that is not catalysed by thiols or biological tissue (Mooradian et al., 1995).
Instead, decomposition occurs spontaneously in solution at physiological pH and
temperature (Morley & Keefer, 1993), at a rate that is dependent on the nucleophile
adduct. (Z)-1 - {N-[3 -Aminopropyl]-N- [4-(3 -aminopropyl-ammonio)butyl]-amino} -
diazen-l-ium-l,2-diolate (SPER/NO) contains spermine as the nucleophile and
decomposes at a relatively slow rate (half life = 39 min; 37°C, pH 7.4; Maragos et al.,
1991). The large size of the spermine adduct suggest that SPER/NO will not gain
access to cells. Subsequently, SPER/NO should generate specifically NO, entirely in
the extracellular space.
In an effort to clarify the role of sGC-independent vasodilatation and its
relationship to the site ofNO release, this chapter compares the vasodilator effect of S-
nitrosothiols with that of SPER/NO. The use of SPER/NO avoids the difficultly in
accurately preparing "authentic" NO solutions that are notoriously difficult to use and
tend to generate variable results (Wanstall et al., 2001). In addition, vasodilatation is
compared to a number of other NO donor drugs with different release mechanisms in
order to test the hypothesis that the sGC-independent activity of NO is exclusive to
agents that generate NO outside target smooth muscle cells. Experiments were also
designed to test the further hypothesis that sGC-independent vasodilatation is mediated
by peroxynitrite.
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3.2 METHODS
3.2.1 Preparation
Experiments were carried out on isolated segments of femoral artery from adult male
Wistar rats (250-350 g; n=93) in a perfusion system. Vessels were perfused (0.6 ml
min1) and superfused (1 ml min"1) with fresh oxygenated Krebs buffer solution.
Vessel tone was measured by monitoring perfusion pressure with a differential
pressure transducer. All experiments were carried out in a darkened laboratory (see
Section 2.3.1).
3.2.2 Experimental protocol
Vessels were preconstricted with phenylephrine (PE; 2-14 pM) in the presence of
supramaximal concentrations of the NO synthase inhibitor NG-nitro-L-arginine methyl
ester (20 pM; See Section 2.3.2). Sequential microinjections of increasing
concentrations (10 pi; 10"8 - 10"3 M) of NO donors were carried out before and after
perfusion ofmodulators. Treatment was restricted to one NO donor and one modulator
per vessel. Oxyhaemoglobin (Hb, 10 pM) was used to investigate the role of
extracellular NO release (Martin et al., 1985). Hb can be S-nitrosated to form S-
nitrosohaemoglobin, a potential NO donor itself (Jia et al., 1996), and is also
susceptible to oxidation to metWb by ODQ (Moro et al., 1996). For this reason, it was
necessary to use an alternative NO scavenger to facilitate co-perfusion with ODQ.
Hydroquinone (HQ; 100 pM) was also used to investigate extracellular NO release, as
HQ was confirmed to be a direct NO scavenger in rat vascular tissue (see results). An
excess concentration (20 pM) of ODQ was used as a selective inhibitor of sGC
(Garthwaite et al., 1995). Endogenous Cu/Zn SOD was inhibited using
diethyldithiocarbamic acid (DETCA; lOOpM; Misra, 1979; Cocco et al., 1981).
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Duroquinone (DQ; 100 pM; Lilley & Gibson, 1995) was perfused, following DETCA
pretreatment (Paisley & Martin, 1996), to elevate superoxide levels further, confirmed
by experiments using an NO electrode (Sect 3.2.3).
ODQ was perfused for 20 min and then washed out; the irreversible nature
(Garthwaite et al., 1995; Hobbs, 1997) of inhibition of sGC with ODQ ensured
activity throughout the experiment. DETCA was added to both the perfusate and
superfusate for 30 min, and then washed out. Perfusion of Hb, HQ and DQ began 20-
30 minutes before administration ofNO donors and was continued until the end of the
experiment to ensure these drugs were present during application of NO donors.
Where Hb, HQ or DQ and ODQ were used together, ODQ was co-perfused only
during the first 20 min treatment and Hb, HQ or IX) perfusion was continued alone
(see Fig 3.1.).
Following perfusion of modulators, PE concentrations were adjusted to re¬
establish the baseline pressure of the previous control concentration-response curve, to
eliminate pressure change as a possible cause of the subsequent changes in vasodilator
amplitude. Following each concentration-response curve, a microinjection (10 pi) of
the adenylate cyclase-activator isoprenaline (ISP; 10"3 M), was made before and after
modulator perfusion, to investigate the effect of the modulator on NO:sGC-
independent vasodilation.
3.2.3 NO electrode measurements
An isolated NO electrode was allowed to stabilise (10-30 min) and then was calibrated
using DEA/NO (100-800 nM) in phosphate buffer (pH 4; see Section 2.2). Krebs
buffer (pH 7.4) was used for subsequent protocols. SPER/NO (10 pM) was
introduced into the cuvette and NO generation was allowed to reach plateau, prior to
addition of either HQ (100 pM) or DQ (100 pM). Cu/Zn-SOD (250 U/ml) was added
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signal. In a second set of experiments, 1 cm segments of rat aorta were homogenised
in Krebs buffer (50 pi) using a micropestle. Supernatant (40 pi) was removed and
added to cuvettes, before addition of SPER/NO. In several experiments (n=4-8) the
aorta was pretreated with DETCA (100 pM) for 30 min and then thoroughly washed in
normal Krebs buffer, prior to homogenisation.
3.2.4 Analysis of results
Vasodilator response amplitude was expressed as a % of (PE+L-NAME)-induced
pressure existing before drug delivery (% pressure change; positive values represent
vasodilatation, where 100% represents complete abolition of agonist-induced tone).
Preliminary experiments showed that peak dilatation correlated well with the time
course of vasodilatation (area under curve), regardless of the modulator used. Changes
in tone induced by perfusion ofmodulators are expressed as a % of perfusion pressure
before drug perfusion.
In NO electrode experiments, maximum response (mV) to known
concentrations of DEA/NO, were used to calibrate the electrode. The effect of
modulators on NO measurement were then expressed as a % of the SPER/NO
response. Mean values are given ± S.E.M..
P-values in the text were obtained by two-factor, repeated measures analysis of
variance (ANOVA), unless otherwise stated. Paired and unpaired Student's /-tests
were all two-tailed. Only key comparisons are indicated in the figures.
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3.3 RESULTS
3.3.1 Vessel preconstriction
Vessels were preconstricted with PE (5.0±0.2 pM; n=186) to give pressures of ~50
mmHg (49±2 mmHg; n=186). L-NAME (20 pM) led to a 145±8% increase in pre¬
existing PE-induced pressure to generate a final pressure of 120±3 mmHg (n=l 86).
3.3.2 Vasodilator responses to bolus injections of NO
donors
Microinjections of NO donors (10 pi; 10~8 - 10"3 M) produced concentration-
dependent, transient vasodilatations in endothelium-intact vessels (Fig 3.2). Following
vasodilatation, perfusion pressure recovered fully and was not significantly different
from pre-injection pressure (P>0.05; paired Student's /-test; n=6 for each NO donor).
Sequential boluses ofNO donors (10 pi; 10~8 - 10~3 M) had no effect on the magnitude
of the response to subsequent microinjections. The maximum response to SNP (10~3
M) recovered slowly and, for this reason, a concentration range of 10"8 - 10"4 M was
used. All NO donors exhibited a similar concentration response relationship, with the
exception of SPER/NO which was ineffective at concentrations <10"6 M.
Microinjections of the parent compound, spermine (10 pi; 10"6 - 10"3 M) had no
vasodilator action (n=4).
3.3.3 The effect of modulators on baseline pressure
There was no significant difference in perfusion pressure before and after Hb (10 pM)
or ODQ (20 pM) perfusion, separately or when co-perfused (P>0.05 for all; n=6,
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pressure of 26.3±6.5%, which remained significantly greater than baseline after 30
min (P=0.018; n=6; paired Student's /-test). Washout of DETCA resulted in a fall in
pressure which often stabilised below baseline levels. HQ (100 jlM) produced a
significant increase in pressure of 17.5+3.9% (P=0.028; n=6; paired Student's /-test).
Preliminary experiments indicated that DQ caused sufficient increase in perfusion
pressure to permanently damage the vessel. As a precaution, PE concentration was
reduced (x0.5) prior to DQ perfusion, preventing a quantitative measurement of the
effect ofDQ on vessel tone being made.
3.3.4 NO electrode measurements
SPER/NO (10 jiM) generated NO reaching a plateau of -500 nM in 12-16 min. In the
presence of tissue homogenate, the amplitute of the NO signal for SPER/NO was
reduced to -150 nM. HQ (100 |iM) all but abolished the NO signal in both the absence
and presence of the aortic homogenate (n=6-8; Fig 3.3). This attenuation was not
reversed by SOD (250 U/ml). DQ (100 fiM) produced a small attenuation (-
15.3±3.4%; n=9) of the NO signal from SPER/NO in the absence of tissue
homogenate (Fig 3.3). However, in the presence of homogenate, DQ significantly
reduced the NO signal to 34.3±5.6% (P<0.001; unpaired /-test; n=10; Fig 3.3). This
effect was reversed by SOD (250 U/ml). SOD had no effect on the NO signal in the
absence of HQ/DQ, irrespective of the presence or absence of homogenate. Similar
results were found using homogenate from DETCA-pretreated aortae (n=8).
3.3.5 The effect of oxyhaemoglobin on responses to
vasodilators
Hb (10 |iM) produced a significant rightward shift in the concentration response
curves for GSNO, D-SNVP and SPER/NO (P=0.021, />=0.001 & P0.0001,
100
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t t t
10 |iM 10 |iM 250 U/ml
SPER/NO DQ SOD
Figure 3.3 Measurement of SPER/NO-derived NO using an NO electrode, a) Example trace of
the effect of DQ (100 pM) and SOD (250 U/ml) in the presence of crude aortic homogenate. b)
Summary of effect of HQ (100 pM; n=6-8), DQ (100 pM; n=9-10) and SOD (250 U/ml; n=6-10)
on NO generation in the presence and absence of tissue. Columns shown are means ± S.E.M.
Dotted line represents % maximum NO generated from SPER/NO before dmg administration.
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respectively; n=6 for all; Fig 3.4a-c). Hb (10 jiM) had no significant effect on the
response to microinjections of GTN or SNP (P>0.05; n=6; Fig 3.4d,e). Hb also had
no significant effect on the response to microinjection (10 3 M) of ISP (P=0.52; n=6;
one-factor ANOVA; Fig 3.4f).
3.3.6 The effect of HQ on responses to vasodilators
On account of the results from experiments using the NO electrode (Sect 3.3.4), HQ
(100 (iM) was used as an alternative NO scavenger. HQ (100 |iM) had a similar
inhibitory effect on SPER/NO-induced vasodilatation in both untreated and DETCA-
treated vessels (P=0.20; 2-way factorial ANOVA; n=6-7). Therefore, responses to
vasodilators in the presence of HQ in DETCA-pretreated vessels were compared to
those in vessels pretreated with DETCA alone (2-way, factorial ANOVA).
Addition of HQ produced a rightward shift in the concentration response
curves for GSNO, D-SNVP and SPER/NO (P<0.02; n=6-7; Fig 3.5a-c). In the
presence of HQ, responses to high concentrations (>10 5 M) of GTN were
significantly attenuated (.PO.OOl; n=6; Fig 3.5d) with a reduction in maximal
vasodilatation. DETCA and HQ perfusion had no effect on the response to SNP
(P=0.14; n=6; Fig 3.5e), or microinjections (10"3 M) of ISP (P=0.48; one-factor
ANOVA; n=l 1; Fig 3.5f).
3.3.7 The effect of DETCA and DQ on responses to
vasodilators
DETCA (100 jiM) alone had no effect on the response to microinjections of GSNO,
SPER/NO, GTN, SNP, or ISP (P>0.05; n=6-7). However, DETCA alone produced a
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Figure 3.4 Effect of haemoglobin (Hb; 10 (J.M) and ODQ (20 |iM) on vasodilator responses to
NO donors (10 pi); (a) GSNO, (b) D-SNVP, (c) SPER/NO, (d) GTN, (e) SNP and (f) ISP.
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Figure 3.5 Effect of hydroquinone (HQ; 100 (iM) and ODQ (20 |+M) on vasodilator responses
to NO donors (10 [i\); (a) GSNO, (b) D-SNVP, (c) SPER/NO, (d) GTN, (e) SNP and (f) ISP.
Points shown are means ± S.E.M. (n=6-7).
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Figure 3.6 Effect of diethyldithiocarbamic acid (DETCA; 100gM) on vasodilator responses to D-
SNVP (10 pi). Points shown are means ± S.E.M. (n=6).
DQ (100|iM) produced a large attenuation of the responses to all the NO donors tested
(P<0.0001; n=6-7; Fig 3.7a-e) and greater than the attenuation produced by HQ. DQ
also showed a trend to inhibit ISP-mediated relaxation, reducing vasodilatation from
46.8±2.5% to 25.1+3.0%, although this difference was not significant. (10~3 M;
P>0.05; Dunnett's post-hoc test, following one-factor ANOVA; n=25: Fig 3.7f).
Concentrations of NO donors producing a similar relaxation in control vessels,
showed a greater sensitivity to DQ, reducing vasodilatation from -45% to <15%. In
addition, DQ perfusion without DETCA pretreatment still exerted a potent inhibitory
effect on vasodilatations to SPER/NO, but had no effect on the vasodilator action of
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Figure 3.7 Effect of duroquinone (DQ; 100 pM) and ODQ (20 pM) on vasodilator responses to
NO donors (10 pi); (a) GSNO, (b) D-SNVP, (c) SPER/NO, (d) GTN, (e) SNP and (0 ISP- Pomts
shown are means ± S.E.M. (n=6-7).
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3.3.8 The effect of ODQ on responses to vasodilators
ODQ (20 fiM) abolished the response to lower concentrations (<10~5 M) of GSNO, D-
SNVP and SPER/NO. Higher concentrations of these agents produced vasodilatations
that were greatly attenuated compared to control (JD<0.004; n=6-7 for all). Responses
to the maximum concentration tested (10 3 M) were reduced from 68.9+8.1% to
22.4±5.8% for GSNO, 59.0±5.6% to 28.9±6.7% for D-SNVP and 75.0±1.3% to
48.2±4.7% for SPER/NO. ODQ completely abolished vasodilatations to GTN and
SNP (PO.OOl; n=6-7), but had no effect on the response to microinjection (10~3 M) of
ISP (P=0.53; paired Mest; n=6).
3.3.9 The effect of NO:sGC modulators and superoxide
on ODQ-treated vessels
To investigate the role of extracellular NO in sGC-independent effects, ODQ was co-
perfused with Hb (Fig 3.4), HQ (Fig 3.5) or DQ following DETCA pretreatment (Fig
3.7).
Hb, HQ or DQ had little or no effect on ODQ-resistant vasodilatation to GSNO
or D-SNVP. HQ and ODQ together produced a small, but statistically significant
attenuation of the vasodilatation produced by microinjections of GSNO and D-SNVP,
compared to ODQ perfusion alone (P<0.03\ 2-way, factorial ANOVA; n=6-7). The
maximum response to GSNO (10 3 M) was reduced from 22.4±5.8% to 14.2±3.1%
and D-SNVP reduced from 28.9±6.7% to 24.2+4.1 %.
Co-perfiision of Hb, HQ or DQ in ODQ-treated vessels almost abolished
vasodilator responses to SPER/NO, with the maximum response (10~3 M) reduced to
12.1 ±2.1%, 8.8±2.4%, 7.7±2.6% respectively (all PO.OOl; n=6). The remaining
vasodilatation was not significantly different from responses to SPER/NO in vessels
107
Ch.3 - sGC-lndependent Vasodilatation
pretreated with DETCA, ODQ and HQ together (/>=0.46; 2-way, factorial ANOVA;
n=6).
Microinjections (103 M) of ISP in the presence of ODQ caused vasodilatations
that were not significantly different from those to ISP in the presence of Hb, HQ or
DQ alone (103 M; P>0.05; Dunnett's post-hoc test, following one-factor ANOVA;
n=l 1-25).
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3.4 DISCUSSION
Here, we show that GTN and SNP release intracellular NO that causes vasodilatation
of isolated rat femoral arteries exclusively via activation of sGC. The S-nitrosothiols
and SPER/NO are NO donors that can release NO extracellularly and subsequently
induce a vasodilatation which is only partially mediated by sGC. The ODQ-resistant
vasodilatation of SPER/NO is attenuated by superoxide generation, suggesting that
sGC-independent vasodilatation is mediated by NO itself, and is unlikely to require
prior generation ofperoxynitrite.
3.4.1 Site of NO release from NO donors
These experiments use both Hb and HQ to scavenge extracellular NO.
Oxyhaemoglobin is a large protein and will not penetrate cell membranes (Foley et al.,
1993). Subsequently, Hb can be considered to be an extracellular scavenger of NO.
HQ, a much smaller molecule than Hb, can also be used as an NO scavenger. A
number of studies have found that the effects of the HQ are reversed by SOD
(Moncada et al., 1986; Kaley et al., 1989; Liu et al., 1994; Paisley & Martin, 1996),
indicating that superoxide mediates these actions. Results in other tissues (Hobbs et
al., 1991; Lilley & Gibson, 1995; Lefebvre, 1996; La & Rand, 1999), and our NO
electrode data (Fig 3.3), show that HQ acts as a direct scavenger of NO, without prior
generation of superoxide. In perfused femoral arteries, the effect of HQ was
comparable to that of Hb, even following DETCA pretreatment, suggesting that HQ
does not generate significant amounts of superoxide. Additionally, the minimal effects
of HQ on GTN and SNP (see below), especially in comparison to DQ, suggest HQ
acts only as an extracellular scavenger.
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A number of mediators are involved in the decomposition of S-nitrosothiols,
including metal ions, thiols and enzymes (Megson, 2000). The inhibitory effect of Hb
and HQ on the vasodilator actions of both GSNO and D-SNVP suggest that a
proportion of NO is released at an extracellular site and that this NO contributes to
vasodilatation. D-SNVP is far less susceptible to Cu(I)-mediated decomposition in
Krebs buffer than conventional S-nitrosothiols (Megson et al., 1999) and, therefore, it
is more likely that tissue components mediate NO release. GSH is a large tripeptide
that cannot enter cells intact (Meister, 1984; Li & Trush, 1993). Therefore GSNO is
unlikely to gain access to the intracellular environment, but the plasma membrane may
mediate its decomposition (Kowaluk & Fung, 1990).
SPER/NO belongs to the diazeniumdiolate (NONOate) class of NO donors
(Maragos et al., 1991; Hrabie et al., 1993). At physiological pH, NONOates
decompose spontaneously to generate NO without being affected by tissue factors
(Morley & Keefer, 1993; Mooradian et al., 1995). SPER/NO is a large molecule and is
thought unlikely to gain access into cells, suggesting that the vasodilator action of
SPER/NO is primarily through extracellular NO release. Hb and HQ did not abolish
the vasodilator action of SPER/NO, suggesting that a proportion of SPER/NO-derived
NO enters cells, or reacts with other extracellular factors, before scavenging can occur.
It is also possible that a proportion of SPER/NO-derived NO is generated
intracellularly and is therefore inaccessible to Hb and HQ. However, a mechanism by
which SPER/NO can cross plasma membranes has yet to be described.
Hb did not significantly attenuate the vasodilator actions of GTN, supporting
intracellular breakdown of this drug in target smooth muscle cells (Bennett et al., 1989;
Chung & Fung, 1990; Schror et al., 1991). Release of NO from SNP is often
considered to be spontaneous but SNP does not decompose at physiological pH unless
thiols, other reducing agents and mammalian tissue are present (Butler & Glidewell,
1987; Bates et al., 1991; Kowaluk et al., 1992; Butler & Megson, 2002). The lack of
effect of Hb and HQ on the vasodilatation of SNP also implies intracellular
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decomposition. Nitroprusside is a divalent ion and, although a mechanism by which
SNP can cross the plasma membrane has not been speculated on, SNP has been
shown to cross the plasma membrane, albeit slowly (Rodkey & Collison, 1977; Butler
et al., 1988).
3.4.2 sGC-independent vasodilatation and site of NO
generation
Experiments using the selective sGC inhibitor, ODQ, show that several NO donors,
SPER/NO in particular, have sGC-independent actions. Previous studies have shown
that NO donors are still able to cause vasodilatation (Brunner et al., 1996; Plane et al.,
1998; Homer & Wanstall, 2000) or inhibit platelet aggregation (Gordge et al., 1998)
even when increases in cGMP levels are abolished. In all of these studies, the
concentration ofODQ was lower (1-10 |0,M) than the concentration used here (20 jlM).
The lack of effect ofODQ, Hb and HQ on the AC-mediated vasodilator action of ISP,
demostrates the specificity of these drugs to the NO:sGC pathway and lack of toxicity
at the concentrations used.
The different mechanisms of action of endogenous NO and different NO
donors in blood vessels has been addressed recently (Tseng et al., 2000; Wanstall et
al., 2001) in studies that focus on the role of other redox forms of NO (NO", NO+) in
vasodilatation. The study concluded that redox status was not the main determinant of
sGC involvement. Homer et al (Homer et al., 1999) made the observation that NO
donors that require intracellular metabolism to generate NO (GTN, isosorbide dinitrate
and SNP), induce vasodilatation that is abolished by ODQ, whereas NO donors that do
not require tissue-activation to generate NO (SIN-1, NONOates) exhibit a sGC-
independent component of vasodilatation. The authors also demonstrate that the rate of
NO generation does not influence sGC-independent vasodilatation. The present
findings agree with these authors, although the results presented here suggest that the
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site of NO generation is more likely to influence sGC-independent mechanisms than
requirement for metabolism.
ODQ abolished the vasodilator actions of both S-nitrosothiols at low
concentrations, although a small vasodilatation was produced at high concentrations.
However, S-nitrosothiols are capable of generating both NO in solution as well as
tissue derived NO (Megson, 2000). To clarify the role of extracellular NO, we
investigated the vasodilator effect of SPER/NO. To the best of our knowledge, this
compound should generate NO only in the extracellular space (see above). Of all the
NO donors, SPER/NO was able to produce the greatest vasodilatation in ODQ-treated
tissues. Spermine itself has been shown to be hypotensive, although in general,
spermine does not cause vasodilatation (Maragos et al., 1991). In the present study,
spermine was found to be inactive and was therefore unlikely to account for sGC-
independent vasodilatation in response to SPER/NO.
Vasodilator responses to both GTN and SNP were abolished by the selective
sGC-inhibitor, ODQ, suggesting that NO released intracellularly by these agents
induces vasodilatation exclusively via a sGC-mediated pathway. It is likely that the
close proximity of the sGC to the site of NO release from GTN/SNP, and rapid
binding to the haem group, accounts for all the NO generated, although it is also
possible that the intracellular milieu lacks critical substituents necessary to mediate
sGC-independent actions.
3.4.3 Reactions of NO in the extracellular space
There are two possible reactions of NO in the extracellular space. Firstly, it can react
with superoxide to form peroxynitrite (Mayer et al., 1998; Vinten-Johansen, 2000;
Eqn 1).
NO + 02" -» ONOO (1)
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Concentrations of superoxide are negligible in healthy vascular tissue due to the
activity of antioxidant systems (Freedman & Crapo, 1982). However, Krebs buffer
contains glucose and trace metal ions, and subsequently, superoxide may be generated
due to the continuous bubbling of high concentrations of oxygen (Gillespie & Sheng,
1990; Beckman & Koppenol, 1996). Secondly, NO reacts with molecular oxygen to
form higher nitrogen oxides (Eqn 2,3).
2NO + 02 -> NO, (2)
NO, + NO -4 N203 (3)
The reaction ofNO with molecular oxygen is slower and second order with respect to
NO (Ford et al., 1993; Kharitonov et al., 1995; Keshive et al., 1996). However, the
reaction could be significant in oxygen saturated Krebs buffer, when concentrations of
NO reach micromolar levels (Beckman & Koppenol, 1996). Therefore, both reactions
are plausible, especially at the high concentrations of NO coinciding with the
concentrations ofNO donors that produce sGC-independent vasodilatation.
3.4.4 Role of peroxynitrite in the vasodilatation to NO
donors
To investigate the involvement of peroxynitrite in the vasodilator activity of NO
donors, superoxide levels were enhanced using DQ. High levels of superoxide might
affect the activity ofNO-releasing compounds in several ways. Firstly, superoxide will
scavenge free NO released from donors and prevent it from reacting with sGC.
Secondly, the reaction of NO with superoxide will generate significant amounts of
peroxynitrite, which in turn is believed to regulate cellular function through the
oxidation of biological molecules or through the nitration of tyrosine-containing
proteins (White et al., 1994; Beckman & Koppenol, 1996; Vinten-Johansen, 2000).
Nitration of tyrosine residues in proteins may affect phosphorylation processes and
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modify cellular transduction pathways (Naseem et al., 1997; Squadrito & Pryor,
1998). Thirdly, the rapid reaction rate of NO with superoxide will compete with the
reaction of NO with molecular oxygen, limiting the production of higher oxides of
nitrogen.
Inhibition of Cu/Zn SOD was combined with a superoxide generating system
to enhance superoxide. Firstly, DETCA was used to inactivate the Cu/Zn-SOD that
dismutates superoxide in the cytoplasm. It should be noted that DETCA is a non¬
selective inhibitor of copper-containing compounds and will indirectly affect a number
of cellular enzymes (Cocco et al., 1981; Kelner et al., 1989; De Man et al., 1996). The
concentration and period ofDETCA perfusion were minimised to limit indirect actions
(Lilley & Gibson, 1995; Lefebvre, 1996). DETCA had no effect on the vasodilator
response to the adenylate cyclase-activator ISP, suggesting that any non-specific
effects of DETCA are limited to the NO:sGC pathway. Interestingly, DETCA
pretreatment inhibited the vasodilator action ofD-SNVP (Fig 3.6). Because DETCA is
not present in the perfusate during administration of D-SNVP, it must permanently
inhibit part of the pathway needed for D-SNVP to induce vasodilatation. Unlike
GSNO, which is not inhibited be DETCA pretreatment, D-SNVP is lipophilic and is
more likely to cross the plasma membrane. In the intracellular environment, D-SNVP
will undergo transnitrosation reactions, passing its nitrosonium group onto other
thiols, such as GSH or cysteine. Both the resulting nitrosated thiols, GSNO and
SNOC, are more susceptible to copper-mediated breakdown than D-SNVP. Therefore,
DETCA could inhibit the vasodilator activity of D-SNVP by preventing the Cu-
mediated release of NO from intracellular S-nitrosothiols, formed by transnitrosation
reactions with D-SNVP.
Superoxide levels were further enhanced, using DQ as an exogenous
superoxide generator. DQ auto-oxidises very slowly in solution, but in the presence of
tissue factors, superoxide is formed (Rossi et al., 1986; Boersma et al., 1994).
Therefore, DQ was expected to generate superoxide in the close vicinity of tissue.
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Indeed, the electrode experiments showed that DQ could only reduce the amount of
detectable SPER/NO-derived NO in the presence of tissue; an effect that was reversed
by SOD (Fig 3.3). In femoral arteries, the vasodilator response to SPER/NO was
attenuated by DQ perfusion, especially in DETCA-pretreated arteries. This suggests
that DQ generates superoxide in femoral arteries that has access to the intracellular
environment (Lynch & Fridovich, 1978; Mao & Poznansky, 1992).
Similar to the findings of others, (Ignarro et al., 1988; Hobbs et al., 1991;
Alsip & Harris, 1992; Hussain et al., 1996), GTN was more resistant to superoxide
generation than other NO donors. In particular, superoxide generation produced a
reduction in the maximum response to GTN. This type of inhibition would not arise
from the scavenging ofNO by superoxide, but more likely reflects an inhibition of the
bioconversion ofGTN to NO (Servent et al., 1989; Laight et al., 1997; Hanspal et al.,
2002). Bioconversion of GTN and subsequent release of NO both occur
intracellularly, providing additional evidence that a significant proportion of the action
of DQ occurs at an intracellular site. The DQ-induced increase in perfusion pressure
and the small inhibitory effect on ISP, suggest that DQ has some actions that are not
related to NO scavenging. However, increasing superoxide levels in the absence of
SOD will unavoidably affect other antioxidant systems, including those related to
glutathione. Thiols like glutathione have been shown to be involved in ISP-induced
vasodilatation (Needleman et al., 1973) and GTN-metabolism (Ignarro et al., 1981;
Feelisch & Noack, 1987; see Chapter 4).
DQ further attenuated the sGC-independent vasodilatation of GSNO, D-SNVP
and SPER/NO in ODQ-treated vessels. Under these conditions, superoxide will
rapidly react with NO to form peroxynitrite (Beckman & Koppenol, 1996; Squadrito &
Pryor, 1998). Because superoxide generation did not potentiate the responses to NO
donors in the presence of ODQ, it is unlikely that peroxynitrite mediates sGC-
independent vasodilatation.
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3.4.5 Potential NO-mediated sGC-independent
mechanisms
The sGC-independent actions of SPER/NO were almost abolished when vessels were
perfused with an extracellular NO scavenger (Hb, HQ, DQ-derived superoxide). We
hypothesise that at high concentrations of SPER/NO, sufficient NO is released
extracellularly to react with molecular oxygen. This reaction can form nitrosating
species that interact with sulphydryl-containing molecules (Kharitonov et al., 1995;
Keshive et al., 1996). The sGC-independent actions of S-nitrosothiols, although small
in comparison to those of SPER/NO, were less susceptible to inhibition by
extracellular NO scavengers. However, these compounds can nitrosate sulphydryl
groups directly through transnitrosation reactions without the release of free NO (Park,
1988; Askew et al., 1995). Nitrosation of thiol-containing residues in enzymes has
been shown to regulate their function (Stamler et al., 1992; Lipton et al., 1993;
Bolotina et al., 1994; Clementi et al., 1998; Bauer et al., 1999; Xie et al., 1999). In
addition, modifiers of protein sulphydryl groups inhibit NO-mediated changes in the
activity channels (Bolotina et al., 1994; Campbell et al., 1996). Therefore, S-
nitrosation of thiol-containing proteins on the extracellular surface of the plasma
membrane, either by the reaction of extracellular NO with oxygen or direct
transnitrosation reactions, represent a plausible sGC-independent mechanism. Plasma
membrane ion channels are the most likely candidates, specifically voltage-sensitive
calcium channels (Travis et al., 2000) and calcium-dependent potassium channels
(Mistry & Garland, 1998; Plane et al., 1998; Homer & Wanstall, 2000).
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3.4.6 Physiological relevance of data
Further work is needed to ascertain the relative importance of these mechanisms in
vivo. One consideration is whether oxygen concentrations in vivo are sufficient to
interact with physiological concentrations of NO. This could be investigated in the
same experimental set-up by reducing oxygenation of the perfusate by bubbling with
argon. However, because the reaction of NO with Oz is second order with respect to
NO, oxygen is unlikely to be the rate limiting factor (Beckman & Koppenol, 1996).
Indeed, superoxide generation was used as a competitive inhibitor of this reaction, as it
is unlikely that the level of oxygen in the Kreb's solution could be lowered to such an
extent that the NO/Oz reaction could be significantly reduced without producing tissue
hypoxia.
Another consideration is whether physiological concentrations of NO are high
enough to produce sGC-independent effects. Levels of circulating S-nitrosoalbumin
have been estimated to be in the micromolar range (Stamler et al., 1992) (although, this
may be an overestimation; Marley et al., 2001). However, S-nitrosothiol-induced the
sGC-independent vasodilatation is small even at high concentrations and, therefore, are
unlikely to significantly influence vessel tone. A far more dramatic sGC-independent
component of S-nitrosothiol-mediated inhibition of platelet aggregation has been linked
to the proportion ofNO released extracellularly by these agents (Sogo et al., 2000). It
is possible that the sizeable sGC-independent actions of S-nitrosothiols account for the
platelet selectivity of these compounds (De Belder et al., 1994).
The extracellular NO generator SPER/NO produced a sizeable sGC-
independent vasodilatation. This sGC-independent vasodilatation may be mirrored by
endothelial derived NO as it passes across the extracellular space to VSMCs or by
application ofpharmacological doses ofNONOates. Finally, it should be noted that the
contribution of NO-related sGC-independent pathways may be upregulated in
cardiovascular conditions, such as hypercholesterolaemia (Najibi et al., 1994) or
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inflammatory conditions where iNOS is expressed (Davies et al., 1996; Hobbs et al.,
1999; see Sect 1.7).
3.4.7 Summary
SPER/NO releases NO extracellularly and induces a vasodilatation that is entirely
dependent on NO, but not exclusively mediated by sGC. S-nitrosothiols are also
capable of releasing extracellular NO and produce a small sGC-independent
vasodilatation, although only at high concentrations. The sGC-independent
vasodilatation of these compounds are not augmented, indeed they are attenuated, by
superoxide generation, suggesting that these effects are not mediated by peroxynitrite.
We suggest that sGC-independent vasodilatation may be mediated through the reaction
ofNO with molecular oxygen, forming higher nitrogen oxides which can regulate the
function of thiol-containing proteins (e.g. ion channels) through S-nitrosation (Fig
3.8). Alternatively, the S-nitrosothiols may be able to regulate protein function, by
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Chapter 4
The role of thiols in the vasodilator action of
NO donor drugs
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4. THE ROLE OF THIOLS IN THE
VASODILATOR ACTION OF NO DONOR
DRUGS
4.1 INTRODUCTION
The cells of the cardiovascular system, like other organs, contain high concentrations
of thiols. In VSMCs, endothelial cells, platelets and red blood cells, the low molecular
weight thiol glutathione (GSH) is present in almost millimolar concentrations (0.5-10
mM). Intracellular levels of another important low molecular weight thiol, cyst(e)ine
(Cys), are lower, but still significant (5-130 pM) (Griffith, 1981; Gruetter & Lemke,
1985; Thomas et al., 1985; Boesgaard et al., 1993; Mayer et al., 1995; Haj-yehia &
Benet, 1996; Mills & Lang, 1996; Gladwin et al., 2000). Additionally, many proteins
contain cysteine residues with reduced SH groups, including ion channels and
enzymes (Upchurch et al., 1995; Gaston, 1999). Thiols are also found in extracellular
fluids; blood plasma contains high concentrations of both low molecular weight thiols
and larger protein thiols such as albumin (2-20 pM & 300-750 pM, respectively)
(Peters, 1985; Mansoor et al., 1992; Boesgaard et al., 1993; Haj-yehia & Benet, 1996;
Jones et al., 2000; Jourd'heuil et al., 2000; Marley et al., 2001; Tsikas et al., 2001).
In all cells, thiols and particularly GSH, form a major part of the anti-oxidant system,
regulating the redox state of intracellular molecules and protecting against physiological
and pathophysiological formation of oxygen free radicals (Meister, 1994; Griffith,
1999). Thiols, therefore, influence NO bioactivity by protecting NO from scavenging
by reactive oxygen species. However, they have also been shown to have a number of
other functions that impact on NO bioactivity, including the sequestration of NO in the
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form of S-nitrosothiols and the regulation of enzymes like guanylate cyclase
(Upchurch et al., 1995; Gaston, 1999; Moore & Mani, 2002).
The large size and polarity ofmany NO donors will restrict their passage across
the plasma membrane, preventing them from reaching their intracellular targets. In
general, it is assumed that these drugs decompose to generate NO, which can freely
diffuse into cells. Interestingly, the vasodilator potency of S-nitrosothiols varies little
despite considerable differences in size, stability and lipophilicity (Kowaluk & Fung,
1990; Mathews & Kerr, 1993). Therefore, it is unlikely that decomposition in
extracellular solution is entirely responsible for their vasodilator action. S-Nitrosothiols
can pass their nitrosonium group (NO+) on to endogenous thiol groups without the
release of free NO (Park, 1988; Askew et al., 1995). Subsequently, it has been
suggested that S-nitrosothiols use these transnitrosation reactions to pass NO+ to cell
surface thiols and that this is the initial step in the passage of S-nitrosothiol-derived NO
across the plasma membrane (Scharfstein et al., 1994; Zai et al., 1999).
Thiols have also been implicated in the metabolism of most NO donors (see
Section 1.8), with the only likely exceptions being SIN-1 (Feelisch et al., 1989) and
the NONOates (Morley et al., 1993). In particular, intracellular thiols have been
proposed as a strict requirement for the metabolism of organic nitrates (Ignarro et al.,
1981). Often this proposal is based on the findings of studies that pharmacologically
supplement intracellular thiol levels or deplete them using alkylators or oxidising
agents (Fung et al., 1989; Lau & Benet, 1992; Boesgaard et al., 1993; De Man et al.,
1996; Haj-yehia & Benet, 1996). This was first demonstrated in 1973 by Needleman
et al, using ethacrynic acid (EA) as a thiol alkylator (Needleman et al., 1973). EA
inhibited the vasodilator effects of GTN, however, it is often overlooked that a non¬
specific inhibition of a wide range of other vasodilators was also observed (Needleman
et al., 1973). In almost 30 years there have been numerous pharmacological studies
that manipulate thiol levels, and yet it is still not clear whether thiols are specifically
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required to biotransform NO donors or whether their main role is downstream of NO
release, through the protection ofNO and target enzymes from oxidative stress.
This chapter aims to clarify the contradictory literature, by testing the effect of
different thiol inhibitors on the vasodilatation of a range of NO donors with different
NO release mechanisms. Responses to the adenylate cyclase (AC) activator,
isoprenaline (ISP) are also tested, to investigate the effect of thiol inhibition on
NO:sGC-independent vasodilatation. It is hypothesised that oxidation of cell surface
thiols will have an inhibitory effect on vasodilatation in response to S-nitrosothiols,
regardless of their ability to penetrate cell membranes. However, GTN and SNP,
which undergo intracellular metabolism (see Chapter 3), will not be affected by the
availability of cell surface thiols. Additionally, it is hypothesised that depletion of
intracellular thiols, will inhibit the vasodilatation of all NO donors, not just GTN,
through loss of antioxidant protection.
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4.2 METHODS
4.2.1 Preparation
Experiments were carried out on isolated segments of femoral artery from adult male
Wistar rats (250-350 g; n=73) in a perfusion system. Vessels were perfused (0.6 ml
min1) and superfused (1 ml min1) with fresh oxygenated Krebs buffer solution.
Vessel tone was measured by monitoring perfusion pressure with a differential
pressure transducer. All experiments were carried out in a darkened laboratory (see
Section 2.3.1).
4.2.2 Experimental protocol
Vessels were preconstricted with phenylephrine (PE; 2-14 pM) in the presence of
supramaximal concentrations of the NO synthase inhibitor L-NAME (20 pM; see
Section 2.3.2). Sequential microinjections of increasing concentrations (10 pi; 10 s -
10"3 M) ofNO donors were carried out before and after pretreatment of modulators of
endogenous thiols. Treatment was restricted to one NO donor and one modulator per
vessel. 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB; 100 pM) was used to block
extracellular SH groups (Ellman, 1959; Tang & Aizenman, 1993). Buthionine
sulfoximine (BSO; 100 pM; Griffith & Meister, 1979), a cell permeable inhibitor of
the rate-limiting enzyme which mediates the de novo synthesis of GSH, y-
glutamylcysteine synthase, was used to deplete tissue of the free GSH. The availability
ofboth free thiols and the thiol groups of proteins was inhibited by perfusion with the
cell permeable thiol alkylator, ethacrynic acid (EA; 100 pM; Daniel et ai, 1971).
Due to the long-lasting inhibitory effects of DTNB and EA, these compounds
were perfused for 20 min and then washed out to prevent any direct chemical reactions
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used in cellular functions and exported from cells (see discussion). Vessels were
perfused with BSO and perfusion pressure was monitored for 1 h. PE was then
removed from the internal perfusate and the perfusion rate lowered to 0.1 ml min"1
overnight, at 25°C, to optimise vessel survival. At t=20 h, the original PE-containing
solution was re-perfused at the original flow rate (0.6 ml min'), at 37°C. Unlike,
DTNB and EA, BSO was retained in the perfusate during administration of boluses to
ensure continued inhibition ofGSH synthesis (Fig 4.1b; Griffith, 1999).
Following perfusion of modulators, PE concentrations were adjusted to re¬
establish the baseline pressure of the previous control concentration-response curve, to
prevent pressure change from influencing the amplitude of responses to bolus
injections. Following each concentration-response curve, a microinjection (10 (il) of
the adenylate cyclase-activator isoprenaline (ISP; 10"3 M; ~EC50), was made before and
after modulator perfusion, in order to investigate the effect of the modulator on
NO:sGC-independent vasodilatation.
4.2.3 Analysis of results
Vasodilator response amplitude was expressed as a % of (PE+L-NAME)-induced
pressure existing before drug delivery (% pressure change; positive values represent
vasodilatation, where 100% represents complete abolition of agonist-induced tone).
Changes in tone induced by perfusion ofmodulators are expressed as a % of perfusion
pressure before drug perfusion. Mean values are given ± S.E.M..
P-values in the text were obtained by two-factor, repeated measures analysis of
variance (ANOVA), unless otherwise stated. Paired and unpaired Student's /-tests
were all two-tailed.
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4.3 RESULTS
4.3.1 Vessel preconstriction
Vessels were preconstricted with PE (5.4±1.9 |lM) to give pressures of -50 mmHg
(51±2 mmHg; n=142). L-NAME (20 )iM) led to a 135±7% increase of pre-existing
PE-induced pressure to generate a final pressure of 120±3 mmHg (n=142).
4.3.2 Vasodilator responses to bolus injections of NO
donors
Microinjections of NO donors (10 (il; 10 8 - 10"3 M) produced concentration-
dependent, transient vasodilatations in endothelium-intact vessels. All the NO donors
used produced vasodilatation over a similar concentration range (Fig 4.2). There was a
small, but significant difference between the vasodilatations to D-SNVP and L-SNVP
(P<0.001; two-way, unrelated ANOVA; n=20).
4.3.3 The effect of modulators on baseline pressure
DTNB (100 (jM) and BSO (100 |iM) did not cause any significant change in baseline
pressure over their perfusion period (P=0.14 and P=0.80, respectively; paired /-test;
n=6), whereas EA (1 00|iM) produced an increase in pressure of 49.9±9.2%
(P=0.003; n=6; paired /-test).
4.3.4 The effect of DTNB on responses to vasodilators
DTNB (100 (iM) had no significant effect on the response to microinjections of any of
the vasodilators tested (P>0.27 for all; n=6-l 1; Fig 4.3).
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Figure 4.2 Log concentrations response curves to vasodilators (10 pi). GSNO (circles; n=23),
RIG200 (squares; n=18), D-SNVP (filled triangles pointing up; n=20), L-SNVP (filled triangles
pointing down; n=20), GTN (diamonds; n=21) and SNP (open triangles; n=24). Points shown are
means ± S.E.M..
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Figure 4.3.1 Effect of DTNB (100 pM) on vasodilator responses to NO donors (10 pi); (a)
GSNO, (b) RIG200, (c) D-SNVP and (d) L-SNVP. Points shown are means ± S.E.M. (n=6-7).
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Figure 4.3.2 Effect ofDTNB (100 |lM) on vasodilator responses to NO donors (10 pi); (a) GTN,
(b) SNP and (c) ISP. Points shown are means ± S.E.M. (n=6 for all).
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4.3.5 The effect of BSO on responses to vasodilators
20 h of BSO perfusion (100 |iM) attenuated the response to microinjections of all NO
donors (P<0.005; n=6-9), with the exception of D-SNVP where the degree of
inhibition did not reach statistical significance (P=0.08; n=7; Fig 4.4). BSO also
attenuated the response to microinjection (10~3 M) of ISP from 43.0+4.4% to
28.4±3.5% (P=0.018; paired r-test; n=13; Fig 4.4.2). Vasodilator responses to ISP
were inhibited to a lesser extent than vasodilatation to NO donors, where a control
response of -43% was reduced to between 15-25% for all NO donors, except for
GTN which was reduced to -12%.
4.3.6 The effect of EA on responses to vasodilators
EA (100 pM) produced a significant attenuation of responses to all the NO donors
tested (P<0.003 for all; n=6-l 1; Fig 4.5). EA also significantly attenuated the response
to ISP (10"3 M), reducing vasodilatation from 45.9±5.4 to 18.0±2.5% (P=0.007;
paired t-test; n=6: Fig 4.5.2). GSNO, GTN and SNP in particular, showed the
greatest attenuation, with a control response of -45% reduced to -10%, compared to
RIG200, D-SNVP, L-SNVP and ISP where a control response of -45% was reduced
to -20-25%. In all cases, the degree of inhibition caused by EA was greater than that
of BSO, although this difference was only statistical significance for SNP and GSNO
(P=0.04 for both; 2-way-unrelated ANOVA; n=6-l 1).
131
Ch.4 - Role of Thiols
Figure 4.4.1 Effect of BSO (100 (J.M) on vasodilator responses to NO donors (10 (J.1); (a)
GSNO, (b) RIG200, (c) D-SNVP and (d) L-SNVP. Points shown are means ± S.E.M. (n=6-7).
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Figure 4.4.2 Effect of BSO (100 pM) on vasodilator responses to NO donors (10 pi); (a) GTN,
(b) SNP and (c) ISP. Points shown are means ± S.E.M. (n=6-13).
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Figure 4.5.1 Effect ofEA (100 (iM) on vasodilator responses to NO donors (10 pi); (a) GSNO,















100- —i 1 1 r~










—i 1 1 r~
-9 -8 -7 -6 -5
logfSNP] (M)
100 J ISP (1 mM)
□ control
■ EA
Figure 4.5.2 Effect ofEA (100 |iM) on vasodilator responses to NO donors (10 pi); (a) GTN, (b)
SNP and (c) ISP. Points shown are means S.E.M. (n=6-l 1).
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4.4 DISCUSSION
At face value, the results show that intracellular, but not extracellular, thiol groups
modulate the activity ofNO donors. Furthermore, it is apparent that intracellular GSH
is a highly important reservoir of anti-oxidant thiols and that protein thiol groups are
important for both the vasodilator activity of NO donors and compounds that act
independently of the NO:sGC pathway.
4.4.1 Vasodilator potency of NO donors
Given the different activation mechanisms of NO donors, their ability to cause
vasodilatation is strikingly similar. Interestingly, there was a significant difference
between the D- and L-stereoisomers of SNVP. Other investigators have demonstrated
that stereoisomers of both endogenous (SNOC; Davisson et al., 1996) and exogenous
(S-nitrosopenicillamine; Travis et al., 1997; Travis et al., 1996) S-nitrosothiols cause
different haemodynamic effects in vivo. The authors suggest that this may reflect the
ability of stereoisomers to bind to an endogenous S-nitrosothiol receptor. However,
these effects were masked by the use of anaesthetics (Travis et al., 1997) and appear to
be mediated through the central nervous system (Davisson et al., 1997) rather than the
vascular system. In the current study, the difference in the vasodilator potency of D-
and L-SNVP was modest and unlikely to be physiologically relevant. Together with
the findings of Kawamoto et al, who, despite extensive experimentation, were unable
to provide evidence for a nitrate receptor (Kawamoto et al., 1988), these results
suggest that the primary mechanism ofNO donors is not through binding to a receptor,
but through biotransformation to NO. Stereoselectivity of NO donors is, therefore,
more likely to be due to differences in binding to enzymes that metabolise these drugs.
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4.4.2 The role of cell surface thiols
DTNB, or Ellman's reagent, blocks reduced SH groups by forming a mixed
disulphide with the thiol and is often used to estimate the level of available SH groups
(Ellman, 1959; Gergel & Cederbaum, 1997). Because DTNB is a large molecule, it
does not cross the cell membrane (Tang & Aizenman, 1993) and subsequently it can be
used as a specific inhibitor of cell surface thiols, leaving intracellular thiols intact. As
expected, DTNB pretreatment had no effect on the vasodilator activity of either GTN
or SNP, in accordance with their intracellular metabolism (Bennett et al., 1989; Chung
& Fung, 1990; Schror et al., 1991; see Chapter 3). However, DTNB also had no
effect on any of the S-nitrosothiols, regardless of their lipophilicity. The lack of effect
ofDTNB suggests that transnitrosation of cell-surface thiols is not a pre-requisite for
S-nitrosothiol-mediated vasodilatation.
Evidence has been presented to show that proteins containing a reduced SH
group are involved in the transfer of NO across cell membranes. In red blood cells,
anion exchange protein 1 (AE1) has been implicated in the export of NO from
intracellular S-nitrosated-Hb (SNO-Hb; Pawloski et al., 2001). It was proposed that
SNO-Hb transnitrosates a thiol group ofAE1, which then mediates the passage of NO
across the red blood cell membrane to plasma thiols. This mechanism could act to
protect SNO-Hb-derived NO from direct scavenging by the haem group of Hb. More
recently, attention has focused on cell surface protein disulphide isomerase (csPDI), a
protein in the cell membrane which is involved in the maintenance of the redox status
of cell surface thiols (Jiang et al., 1999; Zai et al., 1999). It was demonstrated that S-
nitrosothiols transnitrosated one of the SH groups of csPDI, and that this process was
required for stimulation of sGC (Zai et al., 1999). More recently, another group
suggested that the thiol groups of csPDI cleave NO from S-nitrosothiols without the
need for S-nitrosation of PDI (Ramachandran et al., 2001). NO is taken up into the
lipid regions of the cell membrane, where it reacts with oxygen, and the resulting
nitrogen oxides (e.g. N02, N203, N204) then transnitrosate intracellular thiols.
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The results of the AE1 and csPDI experiments are convincing, but both
proposals require a reduced SH group to be available. This begs the question as to
whether the present results using DTNB are misleading. There are two potential
limitations in the use of DTNB as an extracellular thiol inhibitor. Firstly,
concentrations of DTNB may not be sufficient to block all available surface thiols,
especially in the presence of SH-replenishing antioxidant systems, such as csPDI.
However, the concentrations of DTNB could not be increased due to the cytotoxicity
of this compound. Also, the large size ofDTNB may actually be a limitation. Reduced
sulphydryl groups of proteins can be buried within the molecule, in hydrophobic clefts
(Leeuwenkamp et al., 1986). Therefore, the bulky structure of DTNB may restrict
access to crucial SH groups that can be regulated by smaller molecules such as
nitrogen oxides. Indeed, Jiang et al. demonstrate that DTNB was not capable of
oxidising all of the available SH groups of csPDI (Jiang et al., 1999). Experiments
with smaller extracellular thiol alkylators are now needed to clarify the role of csPDI,
AE1 and other SH-containing cell surface proteins, as well as test the hypothesis that
sGC-independent actions of NO donors are mediated by S-nitrosation of cell surface
SH groups (see Chapter 3).
4.4.3 The role of intracellular thiols
GSH is the most common intracellular thiol in VSMCs (Gruetter & Lemke, 1985;
Boesgaard et al., 1993; Haj-yehia & Benet, 1996). GSH levels are maintained through
the recycling of oxidised GSSG by GSH reductase and the de novo synthesis of GSH
by y-glutamylcysteine synthase (Griffith, 1999; Sies, 1999). BSO specifically inhibits
y-glutamylcysteine synthase and prolonged incubation (20 h) depletes intracellular
GSH as it is used in enzymatic processes, transported out of the cell and metabolised
to Cys-glycine and glutamate (Meister, 1983; Griffith, 1999; Sies, 1999). The loss of
an essential thiol such as GSH, will undoubtedly compromise antioxidant defence in
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VSMCs, resulting in the accumulation of oxygen free radicals from normal cellular
metabolism (Meister, 1994). Depletion of GSH could affect the vasodilator actions of
NO donors in several ways; by influencing their metabolism, by the loss of protection
against NO-scavenging superoxide or by regulation of sGC activity through
modulation of the redox state of the SH groups in its catalytic site (Kamisaki et al.,
1986).
BSO attenuated the vasodilator actions of the NO donors to variable extents.
The S-nitrosothiols tended to be less susceptible to GSH depletion. Loss of thiols may
inhibit the release ofNO from S-nitrosothiols by preventing the reduction of Cu(II) to
Cu(I) (Dicks et al., 1996; Singh et al., 1996; Al-Sa'doni et al., 1997; Holmes &
Williams, 1998) or by limiting the availability of thiols that undergo transnitrosation
reactions (Park, 1988; Askew et al., 1995). Subsequently, the relatively stable S-
nitrosothiols used in this study would not be able to release NO to stimulate sGC.
However, both these mechanisms could still occur via the residual thiols remaining
after BSO pretreatment. Additionally, the transport ofNO as an S-nitrosothiol may act
as a mechanism to protect NO from scavenging by superoxide (Upchurch et al., 1995;
Gaston, 1999; Moore & Mani, 2002). SNP was also relatively resistant to GSH
depletion. Thiols have been shown to chemically reduce SNP, but it is unclear if this
process is required for NO release (Butler & Megson, 2002).
Both in vivo (Boesgaard et al., 1993), and in vitro (De Man et al., 1996),
administration of BSO has been demonstrated to inhibit the vasodilator response of
GTN. Responses to GTN were found to be inhibited by BSO in the current study, to a
much greater extent than the other NO donors. Previously, the inhibitory effects of
thiol depletion on GTN contributed to the hypothesis that depletion of free thiols was
the underlying cause of nitrate tolerance, by preventing thiol-mediated
biotransformation of GTN (Needleman et al., 1973). However, vasodilatation to ISP
is also attenuated in vessels that have been depleted of thiols (discussed below), but
remains fully active in vessels that have been made tolerant to nitrates (Needleman &
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Johnson, 1973). Although reduced biotransformation ofGTN may still be the cause of
tolerance, it is now generally accepted that free thiols alone are not responsible for
release of NO from GTN under physiological conditions (Megson, 2000; see
Chapter 5).
ISP was also inhibited by BSO pretreatment, albeit to a lesser extent than the
NO donors. Cell death was not the cause of this inhibition as viability was confirmed
by the restoration of perfusion pressure in response to PE after the PE-free period
during incubation with BSO. Indeed, GSH levels need to be depleted by over 90%
before there is a loss of cell viability (Dethmers & Meister, 1981; Rossi et al., 1986)
and this is unlikely to occur with less than 24 h BSO incubation, unless additional
stresses are applied (Moore et al., 1987; Griffith, 1999).
The non-specific inhibition of NOrsGC-independent vasodilators following
depletion of intracellular thiols is not necessarily surprising. As shown in Chapter 3,
an increase in oxidative stress following inhibition of the antioxidant protection of SOD
led to a small reduction in ISP-induced vasodilatation. Reduced SH groups are present
in many Cys-containing proteins and if GSH is sufficiently compromised to allow
oxygen free radicals to accumulate, then non-specific oxidation of these SH groups
will occur.
To investigate this further, the thiol-alkylator, EA, was used to induce non¬
specific alkylation of both free thiols and the SH groups of proteins (Komorn &
Cafruny, 1965). The non-specific nature of EA is highlighted by the large increase in
pressure on perfusion of EA, despite the absence of endothelium-derived NO. EA
produced a large attenuation of the responses to all vasodilators particularly GTN and
SNP, consistent with earlier findings (Needleman et al., 1973; Lau & Benet, 1992).
EA also decreased the vasodilator response to ISP, a compound that acts through AC
rather than sGC, confirming the findings ofNeedleman et al (Needleman et al., 1973).
Vasodilatation in response to ISP could have been inhibited by the oxidation of
sulphydryl groups of AC (Guillon et al., 1981), the receptor-AC coupling protein
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(Mukheijee & Mukherjee, 1981; Suen et al., 1982) or at a common site downstream of
AC activation (Needleman et al., 1973), such as the SH groups of myosin (Kubberod
et al., 1974; Stamler et al., 1992).
Although it would be unproductive to speculate further on the exact mechanism
of thiol depletion on the widespread inhibitory effect to vasodilators, this study
highlights that caution should be exercised when interpreting the results from
experiments using thiol-depletors. The lack of specificity of agents that deplete reduced
thiols is not unique to vascular tissue and has been noted in other biological models,
particularly platelet aggregation (Stamler & Slivka, 1996).
4.4.4 Summary
Despite the fact that DTNB is commonly used to block extracellular thiol groups, it has
yet to be established that DTNB can sufficiently block crucial SH groups on cell
surface proteins. Subsequently, the results of this study only allow speculation of the
role of cell surface thiols in the decomposition of NO donors and the transduction of
NO across the plasma membrane. However, this study clearly demonstrates that
intracellular thiols are required for the vasodilator action of all NO donors, particularly
GTN. Care should be taken in the interpretation of results from the use of thiol-
depletors in experiments that investigate NO physiology, as thiol availability is also




Novel S-nitrosothiols do not engender vascular
tolerance and remain effective in glyceryl
trinitrate-tolerant rat femoral arteries
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5. NOVEL S-NITROSOTHIOLS DO NOT
ENGENDER VASCULAR TOLERANCE AND




Organic nitrates, such as GTN, are currently used for angina, and the symptomatic
relief in severe cardiac ischaemia, myocardial infarction and heart failure (Abrams,
1985). However, the therapeutic use of nitrates is limited by the development of
tolerance, where a diminished effectiveness of these drugs is seen within 24 h of
continuous therapy (Parker & Fung, 1984). Tolerance can be demonstrated in vitro,
suggesting direct impairment of a vascular mechanism, such as inefficient
biotransformation ofGTN (Brien et al., 1986; Bennett et ai, 1989; Slack et al., 1989;
Feelisch & Kelm, 1991), desensitization of the target enzyme, guanylate cyclase
(Needleman & Johnson, 1973; Axelsson & Andersson, 1983; Waldman et al., 1986)
or upregulation of cGMP-metabolising phosphodiesterases (Axelsson & Andersson,
1983; Kim et al., 2001). Recently, it has been demonstrated that tolerance induction in
vivo is associated with elevated superoxide production due to enhanced activity of
endothelial NAD(P)H oxidases (Munzel et al., 1995; Munzel et al., 1996), expression
of a dysfunctional form of eNOS (Kaesemeyer et al., 2000; Munzel et al., 2000), and
reduced levels of vascular Cu/Zn-SOD (Munzel et al., 1999). Superoxide reacts with
NO, forming cytotoxic products, such as peroxynitrite, and reducing NO
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bioavailability (White et al., 1994). Weight is added to this arguement by clinical
studies demonstrating that tolerance can be prevented or partially reversed with anti¬
oxidant vitamins (Watanabe et al., 1997; Bassenge et al., 1998; Watanabe et al., 1998;
Bassenge et al., 2001).
The induction of tolerance appears to be unique to the organic nitrates, as other
classes ofNO donors, such as SNP (Kieth et al., 1982; Kowaluk et al., 1987; Hinz &
Schroder, 1998; Sage et al., 2000; Minamiyama et al., 2001), SIN-1 (Sutsch et al.,
1989; Rudolph & Dirschinger, 1991; Hinz & Schroder, 1998) and the NONOates
(Hinz & Schroder, 1998) do not show susceptibility to tolerance. This may be because
they lack the strict metabolic requirements of the organic nitrates and subsequently
release NO more readily. S-Nitrosothiols, in particular, do not appear to require
biotransformation to activate guanylate cyclase (Ignarro et al., 1981), suggesting that
they may not be susceptible to tolerance. Indeed, a number of S-nitrosothiols,
including SNAP, have been shown to develop little or no self-tolerance with
continuous treatment, and also to remain effective in GTN-tolerant vessels in vitro
(Kowaluk et al., 1987; Kowaluk & Fung, 1990; Matsumoto et al., 1995; Hanspal et
al., 2002) and in vivo (Bauer & Fung, 1991; Shaffer et al., 1992).
At present it is unknown if the structural alterations made to SNAP to improve
stability and lipophilicity affect its tolerance profile. In order for the benefits of SNAP
analogues such as RIG200 and SNVP to be maximally exploited therapeutically, it is
eseential that these novel compounds do not engender tolerance with continued use.
This study uses a model of nitrate tolerance in isolated rat femoral arteries to test the






Experiments were carried out on isolated segments of femoral artery from adult male
Wistar rats (250-350 g; n=93) in a perfusion system. The vessels perfused (0.6 ml
min"1) and superfused (1 ml min"1) with fresh oxygenated (95% 02, 5% C02) Krebs
buffer solution. Vessel tone was measured by monitoring perfusion pressure with a
differential pressure transducer. All experiments were carried out in a darkened
laboratory (see Section 2.3.2).
5.2.2 Experimental protocols
Vessels were preconstricted with phenylephrine (PE; 2-10 |nM) in the presence of
supramaximal concentrations of the NO synthase inhibitor L-NAME (20 flM; see
Section 2.3.2).
5.2.2.1 Induction of tolerance
Vessels were perfused with equivalent concentrations ofNO donor (10 flM), or Krebs
buffer as a control, and perfusion pressure was monitored for 2 h. PE was then
removed from the internal perfusate and the perfusion rate lowered to 0.1 ml min"1
overnight, at 25°C, to optimise vessel survival. At t=20 h, the original PE-containing
solution was re-perfused at the original flow rate (0.6 ml min"1), at 37°C (Fig 5.1).
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5.2.2.2 Cross-tolerance
In GTN-treated and control vessels (t=20 h), bolus injections of increasing
concentrations of NO donor (10 (ll; 10"8-10"3 M) were made sequentially into the
perfusate. Responses were deemed to have recovered once pressure was maintained
for more than 2.5 min, at which time the next concentration was injected (Fig 5.1a).
5.2.2.3 Washout of NO donor
To confirm the viability of vessels that did not develop tone on exposure to PE
following 20 h of S-nitrosothiol perfusion, the S-nitrosothiol was washed out and the
time taken for maximum pressure to be restored was measured.
5.2.2.4 Nature of NO donor vasodilatation
In S-nitrosothiol-treated vessels at t=20 h, the NO scavenger, Hb (10 pM; (Martin et
al., 1985) was added to the internal perfusate, and subsequently to the superfusate to
allow Hb to infiltrate the vascular smooth muscle, as it has been shown previously that
the endothelium may act as a barrier to Hb (Foley et al., 1993). Hb-induced responses
were deemed complete after pressure was maintained for 5 min. A supramaximal
concentration (20 pM) of the soluble guanylate cyclase inhibitor, ODQ (Garthwaite et
al., 1995), was added to the internal perfusate and rapidly washed out once pressure
had reached plateau (Fig 5. lb).
5.2.3 Analysis of Results
Vasodilator response amplitude is the decrease in pressure, expressed as a % of
preconstriction pressure existing before the application of each drug concentration (%
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pressure change; positive values represent vasodilatation, where 100% represents
maximum vasodilatation). Mean values are given ± S.E.M..
P-values in the text were obtained by two-factor, unrelated analysis of variance





Vessels were preconstricted with phenylephrine (6.7±0.3 pM) to give pressures of
~50 mmHg (49±3 mmHg; n=60). L-NAME (20 pM) led to a 151 ±13% increase of
pre-existing PE-induced pressure to generate a final pressure of 110±5 mmHg;
(n=60).
5.3.2 Vasodilator responses to continuous NO donor
perfusion
Perfusion ofGTN (10 pM) caused an initial vasodilatation of 72+3% (n=33). Pressure
gradually recovered to 35±10% vasodilatation remaining at t=2 h (Fig 5.2a and 5.3).
After overnight incubation with GTN (t=20 h), pressure was not significantly different
from control (-10+10%; P=0.64; unpaired /-test; n=45).
Perfusion of supramaximal concentrations of S-nitrosothiols (10 pM) produced
greater vasodilatation (91 ±2, 93±1, 84±3% for GSNO, RIG200 & D-SNVP
respectively; n=12-15), which were maintained throughout the 20 h period of
























Figure 5.2 Pressure recordings showing vasodilator responses, a) continuous perfusion (10 uM)
of (i) GTN or (ii) RIG200. b) responses to sequential micro-injections ofGTN (10 (0.1; 10~4, 10~3
M) into the perfusate of (i) control and (ii) GTN-tolerant vessels, c) responses to sequential








































Figure 5.3 Effect of perfusing NO donors (10 |iM) on perfusion pressure in preconstricted rat
femoral arteries. 100% vasodilatation represents abolition of tone, with NO donor perfusion beginning
at t=0 h. Points shown are means with vertical lines indicating S.E.M. (n=45, 33, 15, 12, 12 for
Control, GTN, GSNO, RIG200 & D-SNVP respectively).
5.3.3 Vasodilator responses to bolus injections of NO
donors in control and GTN-tolerant vessels
Bolus injections ofGTN (10 |il; 10"8-10"3 M) produced transient vasodilatations which
recovered within 5 min. In vessels perfused overnight in the absence of GTN
(control), the highest concentration of GTN tested (10 3 M) produced a vasodilatation
of 65 ±7% (n=6). In vessels perfused with GTN for 20 h (GTN-tolerant vessels) the
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Figure 5.4 Log concentration response curves showing the vasodilator effect (% preconstriction
pressure) of bolus microinjections (10 (il) of a) GTN, b) GSNO, c) RIG200, d) D-SNVP in control
(open symbols) and GTN-tolerant (filled symbols) vessels. Points shown are means with vertical
lines indicating S.E.M. (n=6-9).
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Equivalent injections of S-nitrosothiols also produced transient vasodilatations of a
similar amplitude to GTN (69±6, 70±3 & 70+6% for GSNO, RIG200 and D-SNVP
respectively; Fig 5.2b and 5.4b-d). However, the concentration-response curves for
the S-nitrosothiols in GTN-tolerant vessels were not significantly different from those
in control vessels (P>0.21; n=6-9).
5.3.4 Washout of S-nitrosothiols
At t=20 h, the internal perfusate was replaced with Krebs solution containing PE and
L-NAME, but without NO donor. On washout of GSNO, RIG200 or D-SNVP,
pressure recovered to levels that were not significantly different from the
preconstriction pressure before the perfusion of NO donor (P=0.15; paired /-test;
n=18; Fig 5.5). Pressure rapidly recovered in 5.5±0.9, 6.5±0.8 and 11.1+4.5 min,
respectively (n=6 for all).
5.3.5 Reversal of S-nitrosothiol vasodilatation with Hb
and ODQ
Following perfusion of GSNO for 20 h, addition of Hb (10 |lM) to the internal
perfusate caused a significant increase in pressure of -40% (P=0.005, paired/-test;
n=6). Hb had no effect on the vasodilatation produced by RIG200 or D-SNVP
(/A>0.15 for both; n=6; Fig 5.5). Addition of Hb (10 |lM) to the external perfusate
caused no additional effect (n=6).
Full restoration of pressure could be achieved by the addition of the soluble
guanylate cyclase inhibitor, ODQ (20 |iM), to the internal perfusate (Fig 5.5). The
perfusion pressure in the presence of these compounds was not significantly different




Treatment of control vessels with Hb and ODQ had no significant effect on


















Figure 5.5 The effect of Hb (10 (J.M), ODQ (20 |iM) and S-nitrosothiol washout on the
vasodilatation produced by perfusing S-nitrosothiols (10 jiM) for 20 h. Points shown are means with




The results show that tolerance to GTN develops rapidly in isolated rat femoral arteries
within 2-20 h of continuous exposure, resulting in a marked attenuation of the
responses to additional bolus concentrations of GTN. The endogenous S-nitrosothiol,
GSNO, and novel S-nitrosothiols, RIG200 and D-SNVP, did not induce tolerance
within 20 h or exhibit cross-tolerance in vessels made tolerant to GTN.
5.4.1 Model of tolerance
The amplitude of GTN-induced vasodilatation diminished despite continued perfusion
of the drug, and was not evident after 20 h. Down-regulation of NO synthase by NO
from GTN (Moncada et al., 1991) could be excluded as a possible explanation for the
results because the NO synthase inhibitor, L-NAME, was present throughout.
Following perfusion with GTN (10 5 M), the vasodilator response to boluses of high
concentrations of GTN (10"4, 10"3 M) were attenuated, confirming nitrate tolerance in
these vessels. Perfused isolated femoral arteries are, therefore, an effective in vitro
model for the investigation ofnitrate tolerance and cross-tolerance to NO donor drugs.
In addition, tolerance to GTN can be induced rapidly, facilitating studies to investigate
the prevention and reversal of nitrate tolerance.
5.4.2 Tolerance profile of S-nitrosothiols
All the S-nitrosothiols (10 |iM) that were investigated cause relaxation of arteries to a
similar extent, producing -90% vasodilatation. Vasodilatation to S-nitrosothiols was
maintained throughout the 20 h perfusion period, despite the slow decomposition of
the compounds in the perfusate reservoir. Our results demonstrate that, despite
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structural modifications, RIG200 and D-SNVP retain the characteristics of existing S-
nitrosothiols in that they do not engender tolerance (Kowaluk et al., 1987; Kowaluk &
Fung, 1990; Matsumoto et al., 1995; Hanspal et al., 2002). Following 20 h S-
nitrosothiol perfusion, pressure was rapidly restored by washing out the S-
nitrosothiol, confirming the reversibility of the effect and indicating that vessels were
still viable. RIG200 and D-SNVP have previously been demonstrated to induce
vasodilatation which persists after washout in endothelium-denuded vessels (Megson
et al., 1997; Megson et al., 1999). Therefore, the rapid restoration of pressure
following S-nitrosothiol washout suggests that the endothelium was functionally intact
after 20 h, consistent with the vasoconstrictor effect of L-NAME at the beginning of
the experiment.
GSNO-induced vasodilatation was partially inhibited by perfusion with Hb,
adding weight to the hypothesis that GSNO releases NO at a site that is susceptible to
extracellular NO scavengers (Chapter 3). It also reflects the sensitivity of GSNO to
catalyzed decomposition by metal ions in Krebs solution (Dicks et al., 1996; Gordge et
al., 1996), or by elements of the vascular cell surface (Kowaluk & Fung, 1990; Al-
Sa'doni et al., 1997). The lesser effects of Hb on the vasodilatation to RIG200 and D-
SNVP, concurs with the greater stability of these compounds in Krebs solution
(Megson et al., 1997; Megson et al., 1999). S-Nitrosothiol-induced vasodilatation was
completely reversed by addition of the soluble guanylate cyclase inhibitor, ODQ. As in
Chapter 3, this finding suggests that S-nitrosothiols produce a vasodilatation that is
predominantly mediated through the NO:sGC pathway.
5.4.3 Consequences for current theories of nitrate
tolerance
Our finding that S-nitrosothiols do not induce tolerance implies that the underlying
cause of nitrate tolerance in vitro is upstream of NO release. Desensitization of the
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target enzyme, sGC (Axelsson & Andersson, 1983; Waldman et al., 1986; Mulsch et
al., 2001), or upregulation of cGMP-phosphodiesterase activity (Axelsson &
Andersson, 1983; Kim et al., 2001) have been suggested as potential mechanisms of
tolerance induction. However, our results show that S-nitrosothiols remain fully active
in GTN-tolerant vessels. Additionally, the vasodilatation to S-nitrosothiols is
predominantly mediated by sGC, alteration of sGC or PDE activity is, therefore,
unlikely to be the underlying cause of nitrate tolerance. Tseng et al proposed that S-
nitrosothiols may be able to activate sGC, through a haem-independent, ODQ-
insensitive mechanism that might involve the SH groups of sGC (Tseng et al., 2000).
Subsequently, tolerance-induction, and ODQ inhibition (Schrammel et al., 1996), may
be mediated by the haem-group of sGC and S-nitrosothiol can bypass this step by
transnitrosation of the SH-groups of sGC (Ignarro et al., 1981; Tseng et al., 2000). A
number of findings contradict this proposal. Firstly, haem-deficient sGC show little
responsiveness to NO (Gerzer et al., 1981; Hobbs, 1997) and redox modulation of the
SH groups of sGC has a limited ability to generate cGMP (Braughler, 1983; Kamasaki
et al., 1986). Additionally, it is unclear why some compounds that contain a NO+
moiety are unable to stimulate purified sGC (Dierks & Burstyn, 1996) or, in the case
of SNP, produce a vasodilatation that is resistant to ODQ (Brunner et al., 1996;
Garcia-Pascual et al., 1999; Homer et al., 1999; Wanstall et al., 2001). Additionally,
many studies have shown that NO and NO donors can cause an ODQ-resistant
vasodilatation when cGMP levels are abolished (Brunner et al., 1996; Olson et al.,
1997; Weisbrod et al., 1998; Homer & Wanstall, 2000). Therefore, it is unlikely that
S-nitrosothiols are able to generate sufficient cGMP by a mechanism that is not
dependent on the haem-sGC moiety to account for their resistance to tolerance.
Overall, sGC-desensitization and PDE upregulation are highly unlikely to be the
underlying cause of tolerance.
At present, there is much interest in the role of oxidative stress in tolerance
(Munzel et al., 1995; Fink et al., 2000; Kaesemeyer et al., 2000; Munzel et al., 2000;
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Loscalzo, 2001; Mulsch et al., 2001; Munzel, 2001; Bassenge et al., 2001; Parker &
Gori, 2001; Paulus, 2002). The current results dispute the involvement of superoxide
generation in tolerance, because S-nitrosothiols retain their full activity in GTN-tolerant
vessels. It could be argued that the S-nitrosothiols used in this study may release NO at
a site that is inaccessible to scavenging by superoxide. However, elevated superoxide
levels would at least be able to inactivate extracellular NO from GSNO in tolerant
vessels. Indeed, the results from Chapter 3 showed that S-nitrosothiol-induced
vasodilatation was more susceptible to superoxide generation than GTN, and
subsequently if the oxidative stress hypothesis held true, then S-nitrosothiols should
be more susceptible to nitrate tolerance than GTN. Additionally, the results from
Chapter 4 suggest that if oxidative stress was significantly induced in nitrate tolerance,
there would be a non-specific inhibitory effect on vasodilators. The results of other in
vitro studies also dispute the oxidative stress hypothesis (Laight et al., 1997; Mihm et
al., 1999). Munzel et al have argue that tolerance-induced superoxide production is
more prominent in vivo (Munzel et al., 1999), where neurohormonal mechanisms
including the renin-angiotensin and endothelin systems may exacerbate oxidative stress
(Munzel & Bassenge, 1996). However, the findings of a number of other in vivo
studies contradict this suggestion (Milone et al., 1999; Ratz et al., 2000; Csont et al.,
2001; Minamiyama et al., 2001; Wang et al., 2002). Confusingly, one study has
shown that superoxide levels were raised by prolonged GTN treatment in vitro (Fink et
al., 2000). Although, superoxide levels were not measured in the present study, the
contradictory literature suggests that, although oxidative stress may be associated with
nitrate tolerance, it is not the underlying cause of the condition (Mihm et al., 1999;
Sage et al., 2000).
In conclusion, the results suggest that events prior to NO release or S-
nitrosothiol formation (Ignarro et al., 1981) limit the effectiveness of GTN in
tolerance. S-nitrosothiols decompose in physiological solutions at varying rates to
generate NO (Williams, 1985) and are able to undergo transnitrosation reactions.
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Therefore, S-nitrosothiols are unlikely to be dependent on the same co-factors needed
to release of NO from GTN. This property could be the underlying reason why S-
nitrosothiols do not induce tolerance, supporting the hypothesis that desensitization or
depletion of the nitrate biotransformation system is the underlying cause of tolerance
(Brien et al., 1986; Bennett et al., 1988; Bennett et al., 1989; Slack et al., 1989;
Feelisch & Kelm, 1991; Sage et al., 2000).
5.4.4 Summary
The two novel analogues of SNAP, RIG200 and D-SNVP, do not induce tolerance
with 20 h of continuous perfusion, in an in vitro model of tolerance. In addition, they
retain full vasodilator potency in vessels made tolerant to GTN, despite its continued
presence. Our results lend weight to the argument that RIG200 and D-SNVP may be
viable clinical alternatives to organic nitrates and existing S-nitrosothiols, because,
added to their previously described increased stability and selectivity for areas of
endothelial damage, they do not appear to engender tolerance. These features suggest
that RIG200 and D-SNVP could have potential benefits in the treatment of a number of
cardiovascular diseases including angina, atherosclerosis, cardiac ischaemia and heart




Acetylation of the glucosamine group ofRIG200
is required for a marked sustained
vasodilatation in endothelium-denuded arteries
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6. ACETYLATION OF THE GLUCOSAMINE




Recently, Megson et al described several novel analogues of the S-nitrosothiol S-
nitroso-A-acetylpenicillamine (SNAP), including N-(S-nitroso-A-acetylpenicillamine)-
2-amino-2-deoxy-l,3,4,6,tetra-(9-acetyl-p-D-glucopyranose (RIG200; SNAP with a
acetylated glucosamine group; Megson et al., 1997) and S-nitroso-A-valeryl-
penicillamine (SNVP; SNAP with a five carbon side-chain; Megson et al., 1999).
These structural modifications increased stability by inhibiting metal ion-mediated
catalysis through steric hindrance. Additionally, bolus administration ofRIG200 to the
perfusate of endothelium-denuded isolated arteries caused a vasodilatation that was
sustained for a number of hours. A sustained effect was not seen in parallel
experiments with RIG200 in endothelium-intact vessels, or with SNAP, irrespective of
the integrity of the endothelium. The sustained vasodilatation was reversed by the NO
scavenger, Hb, but not by the NOS inhibitor, L-NAME, indicating that the
vasodilatation was mediated by NO that was not derived from NOS (Megson et al.,
1997; Megson et al., 1999).
N-substituted analogues of SNAP with increasing lengths of alkyl side chains
were found to have increasing lipophilicity (Megson et al., 1999). In similar
experiments to those with RIG200, strong correlation was observed between
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lipophilicity and sustained vasodilatation (see Fig 1.21). The authors hypothesised that
the endothelium acts as a barrier to these compounds, resulting in transient responses
to bolus injections that recover rapidly once the bolus is washed out of the lumen of the
vessel. Endothelial denudation removes the barrier, allowing lipophilic S-nitrosothiols
to gain access to lipid-rich sub-endothelial structures, where they are retained and
slowly decompose to NO, producing a sustained vasodilatation (see Fig 1.22).
Although, it has been established that lipophilicity affects the ability of N-
substituted analogues of SNAP to cause sustained vasodilatation, it has not been
determined whether the same property affects the vasodilator activity of glucosamine-
containing analogues of SNAP. RIG200 contains a acetylated glucosamine group.
Removal of the acetyl groups generates a highly water-soluble compound, N-(S-
nitroso-N-acetylpenicillamine)-2-amino-2-deoxy-a,p-D-glucopyranose (glyco-SNAP;
Ramirez et ai, 1996; Fig 6.1), which retains the glucosamine group. Here, isolated rat
femoral arteries were used to test the hypothesis that, unlike RIG200, bolus















Figure 6.1 Chemical structure for RIG200 and glyco-SNAP. Area highlighted in bold represents the





Experiments were carried out on isolated segments of femoral artery from adult male
Wistarrats (250-350 g; n=19) in a perfusion system. The vessels were perfused (0.6
ml min1) and superfused (1 ml min1) with fresh oxygenated (95% 02, 5% C02) Krebs
buffer solution. Vessel tone was measured by monitoring perfusion pressure with a
differential pressure transducer. All experiments were carried out in a darkened
laboratory (see Section 2.3.2).
6.2.2 Endothelial denudation
Several vessels were denuded of their endothelium prior to cannulation and mounting
in the perfusion system (Megson et al., 1997). Following dissection, a stainless steel
wire was passed through the lumen and then removed. Loss of the endothelium was
confirmed by showing that sub-maximally constricted vessels (2 pM) were no longer
responsive to Hb (10 pM) or L-NAME (20 pM).
6.2.3 Experimental protocol
6.2.3.1 Preconstriction
Vessels were preconstricted with phenylephrine (PE; 2 pM) prior to treatment with a
supramaximal concentration of the NO synthase inhibitor L-NAME (20 pM).
Following 40 min L-NAME treatment, additional PE (2-8 pM) was added to obtain a
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6.2.3.2 Administration of NO donor
Following preconstriction, a bolus (10 (xl; 10~3 M) of either RIG200 or glyco-SNAP
was administered into the perfusate. Previous experiments (Megson et al., 1997) have
shown that drug boluses pass through the vessel lumen in <1 s. Perfusion pressure
was monitored for 1 h after administration. At this time, Hb (10 jlM) was added to the
internal perfusate to reverse NO-mediated vasodilatation (Fig 6.2).
6.2.4 Analysis of Results
Vasodilator response amplitude was expressed as a % of (PE+L-NAME)-induced
pressure existing before drug delivery (% pressure change; positive values represent
vasodilatation, where 100% represents complete abolition of agonist-induced tone).
Mean values are given ± S.E.M..





In endothelium-intact arteries, 2 pM PE caused a vasoconstriction of 23.1 ±2.1 mmHg
(n=17). L-NAME (20 pM) caused further vasoconstriction to generate a pressure of
77±9 mmHg (n=17). In endothelium-denuded arteries, 2 |iM PE produced a
vasoconstriction of 90±10 mmHg (n=16) that was unaffected by L-NAME.
Additional PE (2-8 pM) was added to obtain a final pressure of 120-150
mmHg. The final pressure in endothelium-intact arteries (136±6 mmHg) was not
significantly different from that of endothelium-denuded arteries (121±10 mmHg;
P=0.19; unpaired /-test; n=16-17).
6.3.2 Vasodilatation to NO donors
Bolus injections ofRIG200 (10 pi; 10"3 M) produced a maximum vasodilator response
of 68+3% (n=6) in endothelium-intact arteries and 77±3% (n=6) in endothelium-
denuded arteries. Perfusion pressure in endothelium-intact arteries recovered rapidly to
-35 % vasodilatation within 5 min, whereas in endothelium-denuded arteries a
vasodilatation of -65 % remained after 5 min and persisted throughout the 1 h
perfusion period. Vasodilatation remaining at 1 h was significantly greater in
endothelium-denuded arteries (51 ±5%) than in endothelium-intact arteries (21 ±7%;
P=0.01; unpaired /-test; n=6; Fig 6.3).
Bolus injections of glyco-SNAP produced similar responses in endothelium-
intact and -denuded arteries. Peak vasodilatation was 68±4% in both intact and
denuded arteries, (n=6 and 8, respectively). Vasodilatation remaining at 1 h was not
significantly different in endothelium-intact arteries (20±3%) compared to
endothelium-denuded arteries (25±7%; P=0.55; unpaired /-test; n=6-8; Fig 6.3).
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6.3.3 Hb-induced reversal of vasodilator responses
Hb (10 pM) had no significant effect on the vasodilator responses to RIG200 that
remained after 1 h in endothelium-intact arteries (P=0.37; paired t-test; n=5).
However, Hb partially reversed the sustained vasodilatation to RIG200 in
endothelium-denuded arteries fP=0.008; paired /-test; n=5; Fig 6.4).
Hb (10 pM) completely reversed the remaining vasodilatation to glyco-SNAP
at t=l h, although, this reversal was only significant in endothelium-denuded
(P<0.00 \; paired /-test; n=8), and not in endothelium-intact (P=0.14; paired /-test;


























Figure6.4Reversaloftheasodilatation=lhbyHb(10pM).)IG200,glyco-SNAPinend thelium-intact(opc l ns)nd endothelium-denuded(fillc l mns)art ries.Dotlinr pr s tstmax umvasodilatationusbyus fNOd ort=0h).
Ch.6 - Glyco-SNAP
6.4 DISCUSSION
RIG200 causes a marked NO-mediated sustained vasodilatation (-50%) in
endothelium-denuded blood vessels, but not endothelium-intact, isolated rat femoral
arteries. A small (-20%) non-specific element of this effect is seen in endothelium-
intact vessels and, therefore, this component is not selective for endothelial
denudation. Glyco-SNAP, an analogue of RIG200 containing a non-acetylated
glucosamine group, causes only a modest sustained vasodilatation (-20%) that is not
dependent on endothelial denudation and is entirely NO mediated.
6.4.1 Ability to induce sustained vasodilatation
Bolus administration of RIG200 to the lumen of isolated perfused endothelium-intact
femoral arteries, produces a transient vasodilatation. As shown previously (Megson et
al., 1997), an identical bolus of RIG200 administered to endothelium-denuded
arteries, produces a prolonged vasodilatation, despite the apparent washout of the
bolus in <1 sec. In the current study, perfusion pressure only returned to -50% of the
preconstriction level 1 h after the bolus injection, equating to -66% of maximum
vasodilatation observed immediately after bolus injection. The sustained vasodilator
actions of RIG200 in denuded blood vessels have also been observed in vitro in
human arteries and veins used for bypass grafting in coronary artery disease (Sogo et
al., 2000) and in vivo in human hand vein (Sogo et al., 2000).
Other analogues of SNAP with N-substituted carbon side-chains have also
been shown to produce a sustained vasodilatation in isolated perfused femoral arteries
(Megson et al., 1999). The degree of sustained vasodilatation was shown to strongly
correlate with the lipophilicity of the compound (Megson et al., 1999). Glyco-SNAP is
composed of SNAP linked to glucosamine (Ramirez et al., 1996). This compound is
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identical to RIG200, except that the acetyl groups have been removed from the
glucosamine moiety. Acetylation of compounds increases their lipophilicity and,
consequently, glyco-SNAP represents a highly water-soluble analogue of RIG200. As
expected, glyco-SNAP was unable to cause a substantial sustained vasodilatation in
endothelium-denuded arteries. These results support the hypothesis that the
lipophilicity of S-nitrosothiols is a major factor in facilitating sustained vasodilatation
in blood vessels with a damaged endothelium.
6.4.2 Mechanism of sustained vasodilatation
Previously, it had been shown that the sustained vasodilatation produced by RIG200
and SNVP was reversible with the NO scavenger, Hb, but not by the NOS inhibitor,
L-NAME. Subsequently, it has been hypothesised that the endothelium acts as a
barrier to S-nitrosothiols, allowing only transient vasodilatation due to the release of
NO as the drug bolus passes through the blood vessel. However, results from
experiments with endothelium-denuded arteries are consistent with the theory that
lipophilic S-nitrosothiols are retained in lipid-rich regions, where they slowly
decompose to NO, causing sustained vasodilatation that is susceptible to scavenging
by Hb.
In the current study, the sustained vasodilatation induced by RIG200 was only
partially reversed by Hb. At present, it is not clear why Hb was unable to completely
reverse vasodilatation. The small (-20%) Hb-resistant effect may not be due to the
glucosamine group of RIG200, because responses to SNAP, a compound that does
not contain this group, have previously been shown to cause similar vasodilatation in
endothelium-intact arteries 1 h after bolus administration (Megson et al., 1997). Given
that this effect is only seen at high concentrations, it is possible that the remaining
vasodilatation to RIG200 is due to an sGC-independent mechanism. However, the
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results of Chapter 3 demonstrate that sGC-independent vasodilatations caused by S-
nitrosothiols are practically abolished by extracellular scavengers such as Hb.
Assuming that the Hb-resistant vasodilator effect of RIG200 is not due to an
unidentified non-specific action of the structure of the compound, the most likely
explanation is that the high lipophilicity of RIG200 facilitates its retention in
extracellular areas that Hb cannot access. RIG200 may even enter cells, as has been
suggested for lipophilic analogues of SNO-Cys (Clancy et al., 2001), perhaps
explaining why R1G200 also causes a small sustained Hb-resistant vasodilatation in
endothelium-intact vessels. Membrane bound glucose transporters may also be
involved in the transport of sugar-linked S-nitrosothiols into cells (Cantuaria et al.,
2000).
A small residual vasodilator effect of glyco-SNAP was also seen at 1 h.
Although this vasodilatation was of a similar size to that for RIG200 (-25%), it is
unlikely to be caused by its retention in the same compartments as RIG200, because
glyco-SNAP is a highly water-soluble compound (Ramirez et al., 1996). However,
the finding that Hb can reverse the vasodilatation supports a role for NO in this effect.
At present, the most likely explanation is that this vasodilatation is caused by small
concentrations of glyco-SNAP that become associated with hydrophilic regions of the
endothelial or sub-endothelial surface. Generation of NO at this site is susceptible to
Hb, as glyco-SNAP is not sufficiently lipophilic to penetrate deeper into the tissue,
where Hb cannot penetrate (Foley et al., 1993). This hypothesis could be tested in
similar experiments to the one described here, using radiolabelled S-nitrosothiols.
6.4.3 Summary
This study demonstrates high lipophilicity is required for S-nitrosothiols, such as
R1G200, to cause a marked sustained vasodilatation in endothelium-denuded vessels.
These results suggest that lipophilic S-nitrosothiols may be able to produce sustained
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NO-mediated effects selectively at areas of endothelial-damage, from a single bolus
administration. This is a particularly attractive feature in the treatment of cardiovascular
conditions where the endothelium may be damaged, such as atherosclerosis, or
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Percutaneous transluminal coronary angioplasty is a common clinical intervention used
to improve blood flow through stenosed coronary arteries, although its long-term
benefit is limited by restenosis. The underlying causes of restenosis have not yet been
fully characterised, but proliferation and vascular remodeling are evident within a few
days of injury (Wei Liu et al., 1989; Lincoff et al., 1994). The procedure inevitably
damages the vascular endothelium, leading to activation and adhesion of platelets
within an hour of angioplasty (Clowes & Karnovsky, 1977; Groves et al., 1979; Wei
Liu et al., 1989). Platelet adhesion to the exposed sub-endothelium and release of their
cytoplasmic granules are a key event in the initiation of restenosis (Friedman et al.,
1977; Goldberg & Stemerman, 1980; Fingerle et al., 1989).
Current anti-thrombotic therapies reduce the incidence of thrombosis and
restenosis. However, their use is limited by undesirable systemic effects and, despite
current advances in drug delivery catheters and deployment of stents, endothelial
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damage and neointimal hyperplasia remain major problems leading to a 15-30%
incidence of restenosis (Topol & Serruys, 1998; Bult, 2000; Swanson et al., 2001).
Loss of the protective effects of endothelium-derived nitric oxide (NO) is
critical to increased platelet adhesion. NO has powerful anti-platelet actions and NO
donors can reduce platelet activation (Langford et al., 1994) and adhesion (Lam et al.,
1988; Groves et al., 1993) following angioplasty. However, existing NO donor drugs
are not selective for areas of endothelial damage and dosing is limited by systemic
hypotension. In contrast, lipophilic S-nitrosothiol NO donor drugs have a prolonged
vasodilator activity that is selective for blood vessels with experimentally denuded
endothelium (Megson et al., 1997; Megson et al., 1999).
Using a rabbit model, this study tests the hypothesis that platelet adhesion to
the intimal surface of common carotid arteries following angioplasty is inhibited to a





Adult male New Zealand white rabbits (2.5-3.5 kg; n=60) were anaesthetised as
described in Section 2.4. The left femoral artery was cannulated for the measurement
of systemic blood pressure (BP) and heart hate (HR) throughout the procedure and
withdrawal of blood. Angioplasty was performed on a 40 mm section of the common
carotid artery. Sham operations involved cannulation of the common carotid artery
without balloon inflation. The carotid artery was recannulated to administer a 0.2 ml
bolus of heparinised saline (Hep-Sal; 25 U/ml), GTN or SNVP (both 200 nmoles)
immediately upstream of the angioplastied region (Fig 7.1, 7.2). Both SNVP (Megson
et al., 1999) and GTN (Bennett el al., 1989) release 1 molar equivalent of NO. Blood
flow over the angioplastied region was restored and animals were killed 35 min after
angioplasty. Both common carotid arteries were dissected free and divided into rings
for further assessment (Fig 7.1; See Section 2.4).
7.2.2 Preparation and measurement of radiolabeled
platelets
Citrated blood was centrifuged with prostacyclin (PGI2; 300 ng/ml) to obtain pelleted
platelets. Platelets were radiolabelled with ulInCl3 and re-suspended in PGI2-free
solution (Norman et al., 1997). Approximately 1 ml platelet suspension (50-300 xlO6
platelets; radioactivity=50-800 xlO3 decays per minute; dpm) was re-injected into the
donor rabbit via a marginal ear vein ~10 min before angioplasty. Radioactivity of blood
samples (100 jil) and segments of carotid artery (~5 mm) were assessed using a liquid
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Figure 7.10 Representative images of sections of carotid arteries, with cell nuclei stained with
haematoxylin (purple) and general tissue structure stained with eosin (pink), (a) Contralateral
(uninjured) artery, (b) Angioplastied artery; note that there are no nucleated cells in the intimal
layer (i). Media (m), adventitia (ad). Vessels were isolated and fixed 30 minutes after drug
treatment. Black bar represents 50 pm.
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ANGIOPLASTY
CATHETER
Figure 7.2 Photographic stills of the surgical procedure, (a) Angioplasty catheter. Ruler and one
pence piece used as indicators of size, (b) Tips of two angioplasty catheters, with inflated (top) and
deflated (bottom) balloon, (c) exposed left femoral artery. The artery (FA; red) has been isolated
with suture, in between the femoral nerve (FN; white) and the femoral vein (FV; purple), (d)
cannulated femoral artery is attached to a transducer to measure systemic blood pressure, (e) Initial
incision to the neck. Anaesthesia is maintained by inhaled halothane through the grey funnel, (f)
Exposed left common carotid artery. The bifurcation of the common carotid artery (COM) is clearly
seen, with the internal (INT) and external (EXT) carotid arteries also visible, (g) Following injection
of radiolabelled platelets via the marginal ear vein, the deflated angioplasty balloon is introduced
into the external carotid artery and passed into the common carotid artery. The gold band (GB) at the
tip of the balloon can be seen faintly through the common carotid artery, (h) the balloon is passed 1
cm beyond the regions that might have been damaged by sutures controlling blood flow, and inflated
twice, (i) The Angioplasty balloon is removed and the external carotid artery is recannulated for
drug delivery. Boluses are administered immediately upstream of the angioplastied region, (j) Drug
bolus cannula is removed, the external carotid is sutured and blood flow is restored through the
common carotid. Thirty min after drug administration, the animal is sacrificed, both left and right




Five ml blood samples were taken from the femoral artery before angioplasty and
immediately before the animal was killed. Platelet-rich plasma (PRP; 0.5 ml) was pre-
warmed to 37°C for 5 min in a two-channel platelet aggregometer. Platelet aggregation
in response to supramaximal concentrations of adenosine 5'-diphosphate (ADP; 8 (J.M)
was measured turbidometrically (Megson et al., 2000; see Section 2.7).
7.2.4 Plasma catecholamines
Plasma catecholamines in samples were measured before and after angioplasty and
adminstration ofNO donors (Sedowofia et al., 1998; see Section 2.8).
7.2.5 Organ bath studies
Vessel rings (3 mm) were suspended in a 10 ml myograph and bathed in Krebs
solution at 37°C. Tension was applied to vessels in stepwise increments to obtain a
resting tension of 7 g (Dong et al., 1997) and allowed to equilibrate for 30-40 min.
Rings were contracted (x3) to obtain the maximum contraction to high K+ Krebs
(NaCl: 4.7 mM; KC1: 118 mM). Rings were exposed to PE (0.1-10 (iM) to
investigate the effect of in vivo NO donor administration on blood vessel contractility.
Following precontraction with EC80 PE (~3 jlM), endothelial cell function was
assessed using ACh (0.01-30 (iM). Vessels were precontracted with EC50 PE (~1 |aM)
and the response to the NO scavenger oxyhemoglobin (Hb; 10 (iM; to inhibit both
endogenous and exogenous NO) and the NO synthase inhibitor L-NAME (200 |lM; to
inhibit only endogenous NO) was measured (see Section 2.5).
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7.2.6 Electron microscopy (EM)
Segments of carotid artery (3 mm) were fixed in 3% glutaraldehyde and osmium
tetroxide and examined by scanning and transmission electron microscopy (see Section
2.9).
7.2.7 Histochemistry and immunohistochemistry
Segements of carotid artery were fixed in formalin (10%) and embedded in paraffin
wax prior to sectioning (3 |0m). Sections were stained using haematoxylin and eosin or
unconjugated Griffonia (Bandeiraea) Simplicifolia Lectin I (GSL; see Section 2.10)
7.2.8 Analysis of results
In organ bath experiments, changes in tone are expressed as a % of maximal response
to the third administration of high K+ Krebs. Changes in BP/HR were expressed as
maximum % change in BP/HR existing before drug bolus administration. Results from
aggregation studies are expressed as the change in aggregation of platelets withdrawn
immediately before sacrifice, compared to those withdrawn before angioplasty.
Radiolabelled-platelet adhesion was expressed as an index, standardised by vessel
length (cm) and whole blood radioactivity (decays per minute/100 pi blood). Thus, an
index of 1.0 indicates that all the radiolabelled platelets in 100 pi of blood adhered to a
1 cm segment of vessel. Mean values are given ± S.E.M.. ANOVAs and paired and




7.3.1 Effect of angioplasty on vessel function
Compared to contralateral control vessels, angioplastied vessels showed a 29±8%
decrease in vasoconstriction to high K+ Krebs (P=0.02; paired t-test; n=6; Fig 7.3a).
In addition, vasoconstrictor responses to PE (0.1-10 pM) were also attenuated
(P=0.002; 2-way repeated-measures ANOVA; n=6; Fig 7.3b). Responses to high K+
Krebs and PE in sham-operated vessels were not different from those in contralateral
vessels (P=0.36; paired t-test; n=7 and P=0.68; 2-way repeated-measures ANOVA;
n=7, respectively).
Following precontraction with PE (EC80;2.7±0.2 pM; n=12), ACh (0.01-30
pM) produced a similar degree of concentration-dependent vasodilatation in un-injured
contralateral and sham vessels, with almost complete loss of tone with 30 pM ACh
(Fig 7.4a). There was marked attenuation of the maximum vasodilatation to ACh in
angioplastied vessels, from 90+2 to 20±10% (P<0.001; 2-way repeated-measures
ANOVA; n=6).
In the presence of PE (EC50;1.3±0.1 pM; n=ll), Hb (10 pM) increased tone
from 54±3% to 92±5% (n=7) of the maximal K+ Krebs-induced contraction in the
contralateral vessels (Fig 7.4b). In the same vessels, L-NAME (200 pM) increased
vessel tone from 59±1% to 73±2% (n=6; Fig 7.4b). The responses to Hb and L-
NAME were similar in sham-operated in comparison to contralateral vessels (P=0.37
and P=0.06, respectively; paired t-test; n=6-7). In angioplastied vessels, Hb and L-


































Figure 7.3 Vasoconstrictor responses in carotid rings from sham-operated (hatched column/filled
circles), angioplastied (filled column/filled triangles) and their corresponding contralateral (open














C o o V)
SI d)












































Figure7.4Vasodilatorresponsesincarotidr ngfromsham-opera ed(fillcircles/hatchedc u ns),ang oplastied(filledtriangles/filledcolum )a d theircorrespondingcont alateral(opensymb ls/opencolum s)vess s,(a)ResptACh(0.01-30pM).Ringarepr c n trictedwithaECdo f PE(~3pM).bRes onsetHb(10p )andL-NAME(20pM).Ringsarepr constrictedwithEC50dosefPE(~pM).Chang sitensionar expresseda%maximumrespon etohighK+rebs.M n±S.E.M.(n=6-7)
Ch.7 - Angioplasty
7.3.2 Effect of drug bolus on vessel function ex vivo
In both angioplastied and contralateral vessels, bolus administration of either NO
donor immediately after angioplasty in vivo had no significant effect on responses to
high K+ Krebs (P=0.18 and P=0.08, for angioplastied and contralateral vessels
respectively; 1-way unrelated ANOVA; n=5-6), PE (EC50=0.6-1.5 |iM; P=0.33 for
both; 1-way unrelated ANOVA; n=5-6), ACh (EC50=47-120 nM; P=0.14 for
contralateral arteries; 1-way unrelated ANOVA; n=5-6), Hb (P=0.76 and P=0.88,
respectively; 1-way unrelated ANOVA; n=5-6) or L-NAME (P=0.46 and P=0.35,
respectively; 1-way unrelated ANOVA; n=5-6).
7.3.3 Effect of drug bolus on blood pressure
Before angioplasty, baseline systolic and diastolic BP was 61 ±4 and 44±3 mmHg
(n=21) respectively, and heart rate (HR) was 220±9 bpm (n=17). Hep-Sal bolus (0.2
ml) had no effect on BP or HR (P>0.43 for all; paired t-test; n=9; Fig 7.5). GTN
bolus (200 nmol) caused a significant transient reduction in both systolic BP (-31 ±6%)
and diastolic BP (-30±6%; P=0.02 for both; paired t-test; n=6; Fig 7.5), whereas
SNVP (200 nmol) had no significant effect on systolic BP (-7±3%) or diastolic BP (-
6±3%, P=0.07 and P=0.08, respectively; n=6 for both; Fig 7. 5).
7.3.4 Effect of drug bolus on plasma catecholamines
Drug boluses had no effect on plasma adrenaline (pre - post; nM; Hep-Sal, 0.5±0.1-
0.5±0.2; GTN, 0.9±0.3-0.7±0.3; SNVP, 0.7±0.2-0.5±0.2; n=3-4) or noradrenaline
(pre - post; nM; Hep-Sal, 1.8±0.3-1.3±0.3; GTN, 2.1±0.3-1.6±0.4; SNVP,


































Figure 7.5 Changes in blood pressure induced by drug boluses, (a) Representative pressure
recordings of the response to Hep-Sal (control), GTN and SNVP (both 200 nmoles). Vertical dotted
line represents drug administration, (b) Effect of boluses (0.2 ml) of Hep-Sal, GTN and SNVP on
systolic (open columns) and diastolic (filled columns) blood pressure and heart rate (hatched






Figure 7.6 Effect of drug boluses on plasma catecholamines (noradrenaline and adrenaline). Open




7.3.5 Effect of drug bolus on platelet aggregation
Following angioplasty with Hep-Sal, there was a 9.3+2.6 mV increase (-20%) in
platelet aggregation to ADP (8 |lM) compared to pre-angioplasty results (P=0.04;
paired /-test; n=4; Fig 7.7a). In contrast, angioplasty rabbits that received GTN or
SNVP, there was no increase in aggregability (P>0.24; paired /-test; n=5 for both; Fig
7.7a).
7.3.6 Radiolabeled platelet adhesion to carotid arteries
Platelet labelling efficiency was ~35%. Adhesion of radiolabeled platelets was
standardised to account for vessel length (0.4-0.6 cm) and radioactivity in whole blood
(9570±169 dpm/100 pi; n=20). In angioplastied vessels, there was an almost 20-fold
increase in platelet adhesion (index=0.25±0.04; Fig 7.7b) compared to contralateral
vessels (index=0.013±0.01 dpm). GTN did not significantly reduce platelet adhesion
in angioplastied vessels in comparison to Hep-Sal (P=0.30; unpaired /-test; n=6 and 7,
respectively), whereas SNVP reduced it by 62±7% (P=0.003; unpaired /-test; n=7; Fig
7.7b). The inhibitory effect was significantly greater than GTN (P=0.01; unpaired /-
test; n=7 for SNVP and 6 for GTN).
7.3.7 Electron microscopy
Adhesion of platelets to the intimal surface of blood vessels was confirmed using
scanning EM (Fig 7.8). In contralateral vessels, the luminal ridges can be seen with
few cells adhering (Fig 7.8a). Following a Hep-Sal bolus, angioplastied vessels
showed platelets covering the entire luminal surface (Fig 7.8b). Extended pseudopodia
and connective strands can be seen to form a mesh between activated platelets. In







































Figure 7.7 Effect of Hep-Sal (open columns), GTN (filled columns) and SNVP (hatched columns) on
platelet activation, (a) In vitro platelet aggregation in response to ADP (8 pM). Responses expressed
as change in aggregation after angioplasty and drug administration, compared to before the procedure,
(b) Platelet adhesion to angioplastied and contralateral (uninjured) carotid arteries following drug
treatment (0.2 ml; 200 nmoles). Radiolabelled-platelet adhesion is expressed as dpm, standardised to
vessel length and whole blood radioactivity. Vessels were isolated and platelet adhesion measured 30
min after drug treatment. Mean+S.E.M. (n=4-7).
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Figure 7.8 Representative scanning electron micrographs of the luminal surface of the carotid
artery, (a) Contralateral (uninjured) artery, (b) angioplastied artery receiving Hep-Sal bolus
(0.2 ml), (c) angioplastied artery receiving SNVP bolus (200 nmoles). Vessels were isolated
and fixed 30 min after drug treatment. White bar represents 10 pm.
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the luminal surface was substantially reduced (Fig 7.8c). The flattened, distended
ridges of the angioplastied vessel can now be seen.
Transmission EM revealed platelets without cytoplasmic granules and
pseudopodia extending over the intimal surface, confirming both adhesion and
activation (Fig 7.9).
7.3.8 Histochemistry and immunohistochemistry
Haematoxylin and eosin staining demonstrated the presence of nucleated cells on the
luminal surface of the internal elastic lamina of contralateral uninjured arteries (Fig
7.10a). In contrast, in angioplastied vessels, there were no nucleated cells present in
the intima (Fig 7.10b).
There was intense GSL staining of nucleated cells on the luminal surface of
contralateral uninjured arteries (Fig 7.1 la). In contrast, in angioplastied vessels, there
was only weak staining of the intima with no nucleated cells present (Fig 7.11b).
Small areas stained more intensely and were granular in appearance, showing regions
of the damaged intima with greater numbers of adherent blood cells.
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Figure 7.10 Representative images of sections of carotid arteries, with cell nuclei stained with
haematoxylin (purple) and general tissue structure stained with eosin (pink), (a) Contralateral
(uninjured) artery, (b) Angioplastied artery; note that there are no nucleated cells in the intimal
layer (i). Media (m), adventitia (ad). Vessels were isolated and fixed 30 minutes after drug
treatment. Black bar represents 50 pm.
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Figure 7.11 Representative images of sections of carotid arteries, showing immunoreactivity
against GSL (red/pink staining), (a) Contralateral (uninjured) artery. There is intense red staining
of the nucleated cells of the endothelium, (b) Angioplastied artery. There is only weak staining of
the intimal layer (i). Media (m), adventitia (ad). Vessels were isolated and fixed 30 min after drug
treatment. Counterstaining of nuclei with Harris' haematoxylin (purple/dark blue) and general




This study demonstrates that a novel S-nitrosothiol, SNVP, reduces adhesion of
radiolabeled platelets to rabbit carotid arteries following angioplasty in vivo, without
significantly affecting systemic BP. In contrast, equimolar GTN caused an undesirable
decrease (~30%) in systemic BP, but failed to inhibit local platelet adhesion. Both NO
donors prevented circulating platelet hyper-aggregability induced by angioplasty,
suggesting that the added benefits of SNVP are due to prolonged antiplatelet action
selectively at sites of endothelial cell damage.
7.4.1 Limitations of angioplasty and current therapies
The primary limitation of angioplasty is restenosis of treated arteries within six months
of intervention. The underlying causes of restenosis have not be fully characterised,
although cellular proliferation, migration and vascular remodeling are evident several
days after injury (Wei Liu et al., 1989; Lincoff et al., 1994). The technique inevitably
damages the vascular endothelium, and subsequent platelet adhesion is a key early
event of restenosis (Friedman et al., 1977; Fingerle et al., 1989). Platelets form a
monolayer on the exposed subendothelium and release the majority of their granules,
containing chemotactic agents, vasoconstrictors and growth factors, within an hour
after angioplasty (Clowes & Karnovsky, 1977; Groves et al., 1979; Wei Liu et al.,
1989). Current anti-thrombotic therapies, including aspirin, clopidogrel and GPIIb/IIIa
antagonists, have been shown to reduce platelet adhesion and intimal thickening
following angioplasty (Topol & Serruys, 1998; Bult, 2000; Swanson et al., 2001).
However, maintaining sufficiently high local drug concentration over a number of
hours can be problematic (Groves et al., 1986; Lincoff et al., 1994; Wolinsky, 1994).
Recently, sirolimus (rapamycin)-eluting stents have been shown to be particularly
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effective at inhibiting neointimal hyperplasia, (Sousa et al., 2001; Suzuki et al., 2001;
Swanson et al., 2001) but this approach does not have anti-platelet actions and the
long-term effectiveness (> 1 yr) has yet to be established. Despite current advances in
drug delivery catheters (Lincoff et al., 1994) and deployment of stents, (Swanson et
al., 2001) endothelial cell damage and platelet activation still remain a significant
problem, highlighting the need for additional therapies which counteract the multiple
factors involved in the restenotic process (Bult, 2000; Janero & Ewing, 2000).
7.4.2 Role of conventional NO donors
Delivery of NO is an attractive alternative to conventional anti-thrombotic agents,
because NO exhibits a range of beneficial actions, including vasodilatation, regulation
of inflammatory cell function, inhibition of smooth muscle cell mitogenesis and
inhibition of platelet activation (Janero & Ewing, 2000; Megson, 2000; Vural &
Bayazit, 2001). Indeed, NO donors inhibit platelet activation following angioplasty
(Lam et al., 1988; Groves et al., 1993; Langford et al., 1994). The most common
clinically used NO donors are the organic nitrates, such as GTN, although the
selectivity profile of traditional nitrates (veins>arteries>platelets; MacAllister et al.,
1995) is unfavourable. The current results are in keeping with the recognised
selectivity profile of GTN; it caused a profound systemic hypotension (~30 %),
demonstrating that vasoactive concentrations ofGTN were being used that may induce
unwanted complications in patients undergoing angioplasty. Baroreceptors unloading
in response to hypotension could activate the sympathetic nervous system, with release
of catecholamines. In turn, this may enhance platelet activation in response to agonists
(Haslam & Taylor, 1971) and could counterbalance any direct inhibitory effects of
GTN on platelet adhesion. However, plasma catecholamines and HR were not affected
by the administration of NO donors, therefore, baroreceptor unloading did not
importantly influence the actions ofGTN.
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GTN is a poor inhibitor of platelet aggregation in vitro, (Megson & Webb,
2000) possibly because PRP lacks the factors necessary for its biotransformation to
active NO (Weber et al., 1996). In vivo, GTN infusion can inhibit platelet activation,
presumably via vascular tissue-mediated biotransformation ofGTN to NO (Folts et al.,
1991). GTN reduced platelet hyperaggregability ex vivo, however, it failed to prevent
adhesion of radiolabelled platelets to the intimal surface of angioplastied carotid
arteries. These results suggest that bolus GTN can influence activation of circulating
platelets, but its short-term effects are not capable of preventing adhesion to the
exposed subendothelial surface (Lam et al., 1988). Chronic administration is,
therefore, necessary for GTN to show benefit, but is limited by tolerance (Parker &
Fung, 1984; Abrams et al., 1998). Similarly, other drugs, such as aspirin, have also
been shown to prevent platelet hyper-responsiveness without reducing platelet
adhesion (Clowes & Karnovsky, 1977).
7.4.3 Potential of S-nitrosothiols
S-Nitrosothiols exhibit a number of properties that might prove advantageous in
angioplasty. They show greater selectivity for arteries than veins (MacAllister et al.,
1995) and, unlike organic nitrates, are also powerful inhibitors of platelet aggregation
both in vitro (Sogo et al., 2000) and in vivo (De Belder et al., 1994). S-nitrosothiols
can generate sufficient NO in PRP to inhibit platelet aggregation (Sogo et al., 2000). It
has previously been shown that SNVP causes sustained NO-mediated vasodilatation
selectively in blood vessels with damaged endothelium (Megson et al., 1999). In
addition, other novel lipophilic S-nitrosothiols produce sustained vasodilatation in
human arteries and veins both ex vivo (Sogo et al., 2000) and in vivo, (Sogo et al.,
2000) which may potentially be of great benefit in preventing vasospasm in
angioplastied arteries. This evidence strongly suggests that SNVP is able to
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specifically target areas of endothelial damage, a feature that is not shared by
conventional NO donors.
Equimolar concentrations of SNVP were compared with GTN, because both
compounds release 1 molar equivalent of NO (Bennett et al., 1989; Megson et al.,
1999). In contrast to GTN, SNVP had minimal effects on systemic BP, but caused a
>60% reduction in platelet adhesion to angioplastied carotid arteries. Both SNVP and
GTN inhibited in vitro platelet aggregation in response to ADP, however, only SNVP
inhibited platelet adhesion following angioplasty. Here, SNVP was administered as a
concentrated bolus immediately upstream of the angioplastied region (Fig 7.1).
Previous results (Megson et al., 1999) are consistent with the hypothesis that SNVP is
retained in the exposed subendothelial layers, where it decomposes slowly, generating
sufficient NO to inhibit platelet adhesion locally. S-nitrosated albumin appears to act in
a similar fashion (Marks et al., 1995). The inhibitory effect of SNVP on platelet
adhesion suggests that this compound may have therapeutic potential in the prevention
of acute thrombosis at the site of angioplasty, possibly from a single administration.
Novel lipophilic S-nitrosothiols may also be of therapeutic benefit in preventing
the progression of atherosclerosis. Small areas of denudation and thrombus deposition
are a common finding on the surface of atheromatous plaques (Mann & Young, 1994;
Davies, 2000). The prolonged presence of residual thrombus over an eroded plaque
promotes plaque expansion and destabilisation. By targeting delivery ofNO to areas of
erosion, novel lipophilic S-nitrosothiols could reduce thrombus deposition and,
subsequently, plaque progression. Although spectulative, this opens the question of





Damaged vessels lose their hypereactivity to platelets within 8 h after injury, despite
incomplete endothelial regrowth (Dewanjee et al., 1984; Groves et al., 1986). From
the present study, it is unknown whether the antiplatelet effects of SNVP persist for
>30 min after angioplasty. In endothelium-denuded rat femoral arteries, up to 75% of
the vasodilatation to another lipophilic S-nitrosothiol, RIG200, is still present at 4 h,
(Megson et al., 1997) emphasising the long-acting nature of these compounds. This
complementary vasodilator effect would be beneficial in limiting vasospasm following
angioplasty and perhaps preclude the need for stenting. However, the results of
functional experiments in the current study failed to confirm a prolonged vasodilator
effect in rings from angioplastied carotid arteries treated with SNVP. There was no
difference in the maximum contraction to KC1 or PE between vessels that received
different NO donors and no evidence from Hb experiments of NO-mediated, sustained
vasodilatation in SNVP-treated vessels. However, these results do not preclude the
possibility that sufficient S-nitrosothiol remains in the vessel to inhibit platelet
adhesion, but not to cause vasodilatation. Alternatively, the setup time and processing
of the isolated carotid ring experiments may reduce the concentrations of drug retained
in the tissue. Further experiments are needed to investigate the mechanism and duration
of action of drugs like SNVP, and will help to establish their therapeutic potential in
the prevention of restenosis.
7.4.5 Summary
The lipophilic S-nitrosothiol, SNVP, markedly reduces platelet adhesion to damaged
arteries, following angioplasty, from a single bolus administration that does not cause
systemic hypotension. The long-lasting antiplatelet effects could be of therapeutic
potential in the prevention of restenosis and the progression of atherosclerosis, either
alone or as an adjunct to current thrombolytic therapies and stenting.
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8. GENERAL DISCUSSION
8.1 INTRODUCTION
The vascular endothelium has many functions, one of the most important of which is
the synthesis of vasoactive substances, including NO. The bioavailability of NO is
diminished in a number of cardiovascular diseases, and subsequently, the delivery of
exogenous NO is an attractive therapeutic option in the treatment of these conditions
(Vallance & Chan, 2001; Ignarro et al., 2002).
Conventional nitric oxide donor drugs are used in suprisingly few clinical
applications. One explanation for this is that established NO donors, such as organic
nitrates and SNP have limitations, especially in that they cannot be used continuously
long-term due to the development of tolerance or toxicity of by-products, respectively
(Megson, 2000; Ignarro et al., 2002). S-nitrosothiols are an attractive alternative, as
they are unlikely to generate toxic by-products and do not induce tolerance. Recently,
Megson et al described several lipophilic S-nitrosothiols, including RIG200 (Megson
et al., 1997) and SNVP (Megson et al., 1999), that cause sustained vasodilatation in
endothelium-denuded arteries. Therefore, these compounds may be able to selectively
deliver NO to areas of endothelial damage and thus limit systemic side-effects.
This thesis investigates the mechanism of action of these novel lipophilic S-
nitrosothiols in comparison to established NO donors, using isolated rat femoral
arteries in an in vitro perfusion system. Compounds can be given as a bolus or in the
vessel perfusate and, therefore, mimic in vivo administration by injection or infusion,
through selective delivery to the vessel lumen. In addition, an in vivo rabbit model is
used to investigate the potential of lipophilic S-nitrosothiols in the prevention ofplatelet
adhesion to areas of endothelial damage caused by balloon angioplasty.
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8.2 MECHANISM OF THE VASODILATOR ACTION OF
S-NITROSOTHIOLS IN COMPARISON TO OTHER NO
DONORS
Nitric oxide initiates vasodilatation by binding to the haem moiety of sGC, catalysing
the synthesis of cGMP in VSMCs. cGMP stimulates PKG, which ultimately reduces
cytosolic calcium and inhibits the contraction of vascular smooth muscle, causing
vasodilatation (Waldman & Murad, 1987; Moncada et al., 1991; Carvajal el al., 2000).
However, NO and several NO donors have been shown to have sGC-independent
actions at high concentrations (Gordge et al., 1998; Homer & Wanstall, 2000; Sogo et
al., 2000; Wanstall et al., 2001). In Chapter 3, the vasodilator effect of NO donors is
investigated in isolated arteries that have been treated with the highly specific sGC
inhibitor, ODQ. The results show that NO donor drugs that release NO at an
intracellular site cause vasodilatation that is abolished by ODQ. However, compounds
that release NO extracellularly, particularly SPER/NO, produce an NO-mediated
vasodilatation that is partially resistant to ODQ. Therefore, it is likely that the proximity
and rapid binding of intracellular NO to sGC competes with the reaction of NO with
other cytosolic components that may mediate sGC-independent effects. However, in
the extracellular space, high concentrations ofNO can react with other factors, such as
molecular oxygen (Ford et al., 1993; Kharitonov et al., 1995; Keshive et al., 1996) or
superoxide (Freedman & Crapo, 1982; Mayer et al., 1998; Vinten-Johansen, 2000).
sGC-independent vasodilatation is inhibited by superoxide generators, suggesting that
NO instead reacts with molecular oxygen to produce higher nitrogen oxides.
Subsequently, these products are able to nitrosate membrane associated SH-containing
molecules, leading to sGC-independent vasodilatation. In contrast, peroxynitrite, the
reaction product with superoxide, is unlikely to mediate sGC-independent
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vasodilatation. Unlike SPER/NO, the S-nitrosothiols, GSNO and SNVP, cause
vasodilatation that is largely sGC-dependent. Only very high concentrations of S-
nitrosothiols were able to elicit vasodilatation with a small sGC-independent
component. Consequently, this sGC-independent vasodilatation is unlikely to be of
physiological significance in terms of vascular tone, although sGC-independent actions
may be of importance in mediating their potent antiplatelet actions (Sogo et al., 2000).
It is possible that the sizeable sGC-independent actions of S-nitrosothiols accounts for
the platelet selectivity of these compounds (De Belder et al., 1994).
Chapter 4 investigates the role of thiols in the vasodilatation of NO donors,
using agents that block or deplete free thiols and the SH groups of thiol-containing
proteins. The results highlight the importance of thiols in the vasodilator action of all
the NO donors, particularly GTN. Additionally, thiol depletion also produced a small
inhibition of the vasodilatation caused by the NO:sGC-independent vasodilator, ISP.
GSH is the most common intracellular thiol and a highly important cellular antioxidant
(Meister, 1994; Griffith, 1999). Subsequently, depletion of GSH leads to increased
oxidative stress. As shown in Chapter 3, enhanced superoxide levels when antioxidant
systems are compromised by Cu/Zn-SOD inhibition, lead to a marked attenuation of
the vasodilator actions of NO donors, and a small attenuation of responses to ISP.
Global modification of endogenous thiols using EA causes further non-specific
inhibition, highlighting the critical role of SH groups in vasodilatation. Candidate
regulatory molecules include the SH groups of sGC (Braughler, 1983; Kamasaki et
al., 1986), AC (Guillon et al., 1981), receptor coupling proteins (Mukherjee &
Mukherjee, 1981; Suen et al., 1982) and myosin (Kubberod et al., 1974; Stamler et
al., 1992).
Importantly, NO donors were differentially affected by thiol depletion. S-
nitrosothiols and SNP were relatively less susceptible to thiol depletion than GTN.
This suggests that thiols are not an essential requirement for the release of NO from
these compounds. Additionally, it could be suggested that these drugs are less
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susceptible to oxidative stress. However, Chapter 3 shows that superoxide inhibits S-
nitrosothiol-induced vasodilatation to a greater extent than that induced by GTN; an
NO donor which is relatively resistant to superoxide generation, but particularly
susceptible to thiol depletion. It is generally accepted that thiols alone are not capable of
metabolising organic nitrates (Schroder, 1985; Megson, 2000) and it has been
proposed that enzymatic pathways, such as cP450 enzymes, mediate the bioconversion
of nitrates (Schroder & Schror, 1990; Yeates, 1992; Bennett et al., 1994). However,
the susceptibility of GTN to thiol depletion suggests that the enzyme mediating the
biotransformation of organic nitrates may require thiols to act as co-factors. This could
explain why specific thiols, such as cysteine, seem to be required for the activation of
sGC by GTN (Ignarro et al., 1981).
The identification of the enzyme systems that metabolise organic nitrates and
other NO donors will undoubtedly shed some light on the mechanism of tolerance
induction. Tolerance was investigated in Chapter 5 by perfusing isolated arteries for 20
h with NO donors. Cross-tolerance could then be investigated using bolus
administration of NO donors in vessels after long-term perfusion with GTN. The
results show that GTN induces tolerance rapidly; within ~2 h of continuous perfusion.
In contrast, S-nitrosothiols do not induce self-tolerance and remain fully active in
nitrate-tolerant vessels. Recently, two theories to explain the underlying cause of
tolerance have received much attention (Parker & Gori, 2001). The first of these
suggest that prolonged administration of organic nitrates leads to generation of
superoxide, that scavenges nitrate-derived NO (Munzel et al., 1995). The current
results dispute this hypothesis, as S-nitrosothiols are fully active in nitrate-tolerant
vessels, yet far more susceptible to superoxide than GTN (Chapter 3). Secondly, it has
been suggested that prolonged GTN desensitises sGC (Axelsson & Andersson, 1983;
Waldman et al., 1986) or upregulates PDEs (Axelsson & Andersson, 1983; Kim et al.,
2001). Again, these theories are contradicted by the finding that S-nitrosothiols are
resistant to tolerance, yet cause a vasodilatation that is almost entirely mediated by
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sGC. Overall, it is concluded that tolerance induction is a symptom of dysfunction of
the metabolic process required to release NO from nitroxy ester groups, perhaps
through downregulation of the enzyme that biotransforms organic nitrates (Bennett et
al., 1994).
From a pragmatic standpoint, it is important to note that, similarly to other S-
nitrosothiols (Kowaluk et al., 1987; Bauer & Fung, 1991; Shaffer et al., 1992), the
novel lipophilic S-nitrosothiols do not induce tolerance. These results demonstrate that
the structural adaptations made to RIG200 and SNVP do not affect the resistance to
tolerance of these compounds, and implies a further therapeutic benefit over organic
nitrates in cardiovascular conditions where long-term continuous therapy is required.
A summary of the speculated mechanisms of action of NO donors used in the
above experiments is shown in Fig 8.1.
8.3 SUSTAINED ACTIONS OF LIPOPHILIC S-
NITROSOTHIOLS IN ARTERIES WITH A DAMAGED
ENDOTHELIUM
8.3.1 Role of lipophilicity in the vasodilatation in
response to glucosamine-linked S-nitrosothiols
Chapter 5 focuses on the sustained vasodilator actions of lipophilic S-nitrosothiols in
denuded femoral arteries. The experiments employed use an in vitro perfusion system
in order to facilitate delivery of S-nitrosothiols as boluses, selectively to the vessel
lumen. This negates the possibility that lipophilic S-nitrosothiols could adhere to the
adventitial surface, irrespective of endothelial integrity. Traditional organ bath systems
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bathe vessels in drugs and therefore would expose the adventitial surface to lipophilic
compounds.
Previously, Megson et al. demonstrated that sustained vasodilatation is
correlated with the lipophilicity of N-substituted analogues of SNAP (Megson et al.,
1999). Chapter 5 considered the question of whether lipophilicity is important in
sustained vasodilatation produced by glucosamine-linked SNAP analogues. Glyco-
SNAP contains an non-acetylated glucosamine group and subsequently is highly water
soluble (Ramirez et al., 1996) in comparison to RIG200, where the hydroxyl groups
of the glucosamine moiety are acetylated.
The results from experiments using bolus injections into the perfusate show
that RIG200 produced a marked, substantially NO mediated, sustained vasodilatation
(~50-65 %) 1 h after bolus administration to endothelium-denuded vessels. A small
Hb-resistant, non-specific vasodilatation remained in both endothelium-intact and
denuded vessels. However, glyco-SNAP was found to cause a small sustained effect,
irrespective of endothelial integrity. Interestingly, the sustained effect in response to
glyco-SNAP was reversed by Hb and is clearly due to a different mechanism that the
effect seen with RIG200 in endothelium-denuded vessels. It is likely that the difference
reflects the degree of penetration of the two compounds into the vascular tissue.
RIG200 may penetrate deeper into the tissue, or even access cells, whereas small
concentrations of glyco-SNAP may be retained in superficial water-soluble
compartments that are accessible by Hb.
8.3.2 Effect of lipophilic S-nitrosothiols following balloon
angioplasty
Previous studies had demonstrated that the lipophilic S-nitrosothiols were capable of
producing sustained vasodilator effects in human arteries and veins in vitro (Sogo et
al., 2000) and in vivo (Sogo et al., 2000). However, in vivo studies did not
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investigate the systemic effects of bolus administration of high concentrations of
lipophilic S-nitrosothiols. Additionally, it remained to be established whether lipophilic
S-nitrosothiols have prolonged antiplatelet actions at sites of endothelial damage in
vivo. In Chapter 7, the antiplatelet effects of SNVP were investigated in an in vivo
rabbit model of balloon angioplasty. Angioplasty itself (Hep-Sal control) increased the
responsiveness of circulating platelets ex vivo. Additionally, angioplasty led to a large
increase in the number of radiolabelled platelets adhering to arteries that had been
denuded of endothelium by the procedure. Bolus administration of the conventional
NO donor, GTN, produced a large reduction in systemic blood pressure (-30%) and
prevented the increase in platelet aggregability. Despite having anti-platelet actions,
presumably via tissue-mediated decomposition to NO (Folts et al., 1991), GTN was
unable to reduce platelet adhesion to the angioplastied region. In contrast, equimolar
SNVP prevented the hyperaggregability ofplatelets and also caused a >60% reduction
in platelets adhering to the angioplastied artery. Moreover, SNVP did not cause an
undesireable fall in systemic blood pressure. Both NO donors prevented the
hyperaggregability of circulating platelets, but had different abilities to inhibit platelet
adhesion. Consequently, the inhibitory effect of SNVP on platelet adhesion is likely to
be due to the sustained actions of this class of compound at sites of endothelial
denudation. Overall, the results support the hypothesis that sufficient SNVP is retained
at the site of angioplasty to inhibit platelet adhesion, but not to produce systemic
vasodilatation. Platelet adhesion, and release of their cytoplasmic granules, is a key
event in the initiation of restenosis, the major limitation of angioplasty (Friedman et al.,
1977; Goldberg & Stemerman, 1980; Fingerle et al., 1989). Subsequently, the
sustained anti-platelet actions of lipophilic S-nitrosothiols may be of therapeutic benefit
in reducing thrombosis and restenosis following balloon angioplasty.
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8.4 FUTURE DIRECTIONS AND FURTHER STUDIES
Despite extensive research over the last decade, the mechanism of action ofNO donors
is still poorly understood. That said, many misconceptions about compounds acting
via the NO pathway are being disregarded and it is slowly becoming recognised that
different classes of NO-releasing compounds act in very different ways. One of the
most important milestones to be reached is the identification of the enzyme system(s)
that release NO from donors in vivo. In particular, the identification of the thiol-
dependent enzyme mediating the biotransformation of organic nitrates will help clarify
three decades of contradictory literature and open up a new avenue of therapeutic
alternatives to avoid the induction of tolerance.
As this thesis highlights, S-nitrosothiols are rapidly rising to attention as
therapeutic alternatives to existing NO donor drugs. Subsequently, it is crucial that the
endogenous factor(s) responsible for their metabolism is identified. Cell surface thiol
groups are an obvious candidate for the factor initiating NO release and transfer into
the cell (Zai et al., 1999), accounting for the equipotent vasodilator actions of
chemically diverse S-nitrosothiols (Kowaluk & Fung, 1990; Mathews & Kerr, 1993).
However, existing pharmacological agents that block extracellular thiols, such as
DTNB, may not access biologically relevant SH groups (Jiang et al., 1999), making it
difficult to draw accurate conclusions as to the involvement of cell surface thiols. An
in-depth study using structurally modified cell impermeable thiol inhibitors may clarify
this point. Additionally, the characterisation of the membrane bound S-nitrosothiol-
metabolising protein/enzyme identified by Kowaluk et al (Kowaluk & Fung, 1990),
offers the prospect of developing antisense to this protein, for use as a specific
inhibitor of this step of the NO pathway, in a similar way to the antisense developed
against csPDI (Zai et al., 1999).
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The ultimate aim of the pharmacologist is to develop drugs that are specific to
certain regions of the body. At present, many NO donors show some degree of
selectivity for large arteries, resistance beds, veins or platelets. Often though, the
limited delivery methods require administration of systemic concentrations,
overcoming regional selectivity. Headway is being made in the targeted delivery of
NO, and already there are reports ofNONOates (Saavedra et al., 1997; Saavedra et al.,
1999; Saavedra et al., 2000; Tang et al., 2001; Wu et al., 2001) and S-nitrosothiols
(Al-Sa'doni et al., 2000; Cantuaria et al., 2000; Babich & Zuckerbraun, 2001; Hou et
al., 2001) that can only generate NO following cleavage by cell-specific factors, such
as those within tumour cells. However, until recently there have been no reports ofNO
donors that specifically donate NO at regions where the bioavailability of endogenous
NO is impaired. This thesis focuses on the mechanism of S-nitrosothiols that have
selective vasodilator actions in endothelium-denuded arteries. It is hypothesised that
these compounds are selectively retained at areas of endothelial damage (Megson et al.,
1997; Megson et al., 1999). A similar proposal was offered for the anti-platelet effects
ofS-nitroso-Alb in arteries damaged by balloon angioplasty, but the effect of SNO-Alb
on systemic BP was not measured (Marks et al., 1995). Although a satisfactory
alternative explanation for the sustained actions of these compounds has not been
suggested, the 'retention hypothesis' still requires confirmation with radiolabelled S-
nitrosothiols.
The lipophilic S-nitrosothiol, SNVP, was particularly effective in reducing
platelet adhesion to angioplastied carotid arteries in comparison to GTN. However,
GTN is relatively selective for veins over arteries (MacAllister et al., 1995) and,
therefore, the effectiveness of SNVP may have been due to its preferential metabolism
within arteries, rather than its sustained effects. Now that a suitable model of platelet
adhesion following angioplasty has been established, lipophilic S-nitrosothiols need to
be compared to other arterioselective compounds. The parent S-nitrosothiol, SNAP,
would be ideal for this purpose. Additionally, the more important consideration is to
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look at the effectiveness of lipophilic S-nitrosothiols to inhibit platelet adhesion at time
points longer than 30 min after angioplasty. It remains to be clarified if sufficient
SNVP is retained in damaged blood vessels to prevent platelet activation until the
injured vessel surface loses its reactivity to platelets, suggested to be ~8 h (Dewanjee et
ai, 1984; Groves et al., 1986). Furthermore, the consequences of this degree of
platelet inhibition on restenosis need to be tested in a recovery model of angioplasty,
such as the porcine coronary angioplasty model.
8.5 CLINICAL IMPLICATIONS
Novel S-nitrosothiols have a range of potential advantages over conventional NO
donors and other therapies used for the treatment of cardiovascular conditions. These
are summarised below:
• NO-releasing compounds have many beneficial actions in the cardiovascular
system, including vasodilatation, inhibition of platelet activation, aggregation and
adhesion, inhibition of inflammatory cells and inhibition of VSMC proliferation
and migration.
• S-Nitrosothiols, such as SNO-Cys, mimic the actions of endogenous EDRF.
• S-Nitrosothiols are likely to be more easy to titrate than SNP.
• Existing S-nitrosothiols are unlikely to generate toxic by-products, and it is
possible that thiol by-products may have antioxidant actions.
• S-Nitrosothiols can be used to selectivity dilate arteries over veins.
• S-Nitrosothiols show selectivity towards platelets over blood vessels.
• S-Nitrosothiols do not have strict metabolic requirements to release NO, in
comparison to drugs like the organic nitrates
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• S-Nitrosothiols do not induce self-tolerance and remain effective in nitrate-tolerant
blood vessels
• S-Nitrosothiols may directly regulate protein function without the release of free
NO (transnitrosation of SH groups).
• S-Nitrosothiols might protect NO against scavenging by oxygen free radicals.
• Novel lipophilic S-nitrosothiols are less susceptible to breakdown by trace metal
ions found in physiological solutions, in comparison to conventional S-
nitrosothiols.
• Lipophilic S-nitrosothiols can cause sustained vasodilatation at areas of endothelial
damage.
• Lipophilic S-nitrosothiols prevent platelet adhesion to areas of endothelial damage
in vivo.
Subsequently, S-nitrosothiols have show great potential in the treatment of
cardiovascular disease. In contrast to the common used organic nitrates, S-
nitrosothiols do not induce tolerance with continuous use. Importantly, the structural
modifications made to the thiol groups to provide stability and lipophilicity, do not
affect their tolerance profile. Therefore, these compounds could be used in the
treatment of cardiovascular conditions where long-term therapy may be required, such
as chronic angina.
A particularly attractive feature of these novel compounds is their sustained
actions at sites of endothelial damage. As demonstrated in Chapter 7, lipophilic S-
nitrosothiols have a use in the prevention of thrombosis following angioplasty.
Additionally, the multifaceted nature of NO may also provide benefits by preventing
vasospasm and restenosis through vasodilatation and inhibition of inflammatory cells,
smooth muscle proliferation and migration. The success of lipophilic S-nitrosothiols
will, therefore, depend on the relative contribution of each factor to the restenotic
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process. The concentration and site of S-nitrosothiol retention will also affect their
ability to attenuate the extent of each factor in the development of restenosis. S-
nitrosothiol retention will be determined by a number of factors, such as degree of
vessel damage, dosage and means of delivery, all of which offer a means to optimise
the angioplasty and drug administration techniques. Also, the release rate of NO from
retained S-nitrosothiols will also affect their bioactivity. Appealingly, a slow prolonged
release ofNO would be more effective in preventing VSMC proliferation, an important
factor in neointimal growth after angioplasty (Mooradian et al., 1995). Overall,
lipophilic S-nitrosothiols show great promise in the prevention of restenosis following
angioplasty, and may also be beneficial in the prevention of thrombosis following
coronary artery bypass grafting or used as an adjunct or coating for stents.
Endothelial dysfunction is prevalent in many cardiovascular conditions (see
Section 1.7.2). However, in many cases the structural integrity of the endothelium
may not necessarily be lost, despite functional impairment (Harrison, 1997; Vallance &
Chan, 2001). NO bioavailability may be lost through other mechanisms such as
increased oxidant stress (Gryglewski et al., 1986; Nakazono et al., 1991) or
desensitisation of vascular smooth muscle (Robinson et al., 1982; Calver et al., 1992),
rather than endothelial removal. Therefore, it could be argued that the presence of the
intact endothelium would act as a barrier to lipophilic S-nitrosothiols, negating their
unique therapeutic potential. However, the loss of endothelium-dependent
vasodilatation and the occurrence of fatty streaks are commonly associated and both are
early indicators of atherosclerosis (Ross, 1993; Davies, 2000). Therefore, these lipid
rich lesions may retain lipophilic S-nitrosothiol, without the complete structural
removal of the endothelium. In the later stages of atherosclerosis, endothelial erosion is
common and is associated with the formation of microthrombi on the vessel surface
(Mann & Young, 1994; Davies, 2000). These areas of erosion present a means for
novel S-nitrosothiols to gain access to the subendothelial layers, where their prolonged
generation of NO should limit the extent of thrombus formation. By targeting these
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regions, other actions ofNO come into play, such as the scavenging of oxygen derived
radicals and inhibition of lipid peroxidation (Rubbo et al., 1994; Bult et al., 1999; Patel
et al., 1999). Therefore, although speculative at present, these novel lipophilic S-
nitrosothiols are promising agents in the treatment of vascular disease.
8.6 SUMMARY
This thesis provides insight into the mechanism of action of lipophilic S-nitrosothiols
as novel NO donor drugs. The structural adaptations made to form these compounds
does not alter their ability to induce sGC-independent vasodilatation, their resistance to
tolerance, or their susceptibility to superoxide or thiol depletion. However, the
structural adaptations improve the lipophilicity of the compounds, a feature that allows
S-nitrosothiols to cause a marked sustained vasodilatation that is selective for areas of
endothelial damage. Furthermore, the results of this thesis demonstrate that lipophilic
S-nitrosothiols can be used in vivo to prevent platelet adhesion to arteries that have
been damaged by balloon angioplasty, at a concentration that does not cause significant
systemic hypotension. Therefore, novel lipophilic S-nitrosothiols show great
therapeutic potential over existing therapies in the treatment of cardiovascular diseases,







9. APPENDIX I - PREPARATION OF
SOLUTIONS
Krebs-Henseleit buffer
Amounts stated are to make 1 L Krebs (final concentration in mM).
Stock Normal Krebs Hiuh K+ Krebs
NaCl g/10% sol. 6.9 g (118) 2.8 ml (4.7)
NaHC03 g 1 g (25) 1 g (25)
Glucose g 2.1 g (5.7) 2-1 g (5.7)
KC1 10% sol./g 3.5 ml (4.7) 8.8 g (118)
MgS047h20 10% sol. 2.9 ml (0.6) 2.9 ml (0.6)
kh2po4 10% sol. 1.6 ml (1.2) 1.6 ml (1.2)
Make up to 950 ml. Bubble with 95% 02, 5% C02 for 10 min.
CaCl2 0.68 M 3.7 ml (2.5) 3.7 ml (2.5)
Make up to 1 L.
Sodium cacodylate buffer (SCB)
Dissolve 21.4 g sodium cacodylate (0.1 M) in 900ml distilled water.
Adjust to pH 7.4 with HC1 (0.1 M).




Wash slides for 10 s in the following;
1) 10% HC1 (S.G.I. 18), diluted in 70% alcohol
2) distilled water
3) 100% acetone
Air dry (~1 h).
Ten seconds in following;




Phosphate Buffered Saline (PBS)
To make 1 litre;
NaCl 80 g




To make 0.5 % BSA;




To make 1 litre;
Dissolve 6.04 g TRIZMA® base in 800 ml distilled water.
Adjust to pH 7.6 with HC1 (S.G.I. 18).
Make up to 1 L.
Trypsin-TBS
To make 50ml;
Dissolve 1 trypsin tablet in 1 ml distilled water.
Add 0.5 ml trypsin solution to 49.5 ml TBS.
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1 am writing to you to ask for permission to reproduce two diagrams from the British
Journal of Pharmacology for use in a Ph.D. thesis. I wish to reproduce the two
diagrams showing the vasodilator effects of novel S-nitrosothiols;
Megson, I.L., Grieg, I.R., Gray, G.A., Webb, D.J. & Butler, A.R. (1997),
Prolonged etlect of a novel S-nitrosated glyco-amino acid in endothelium-denuded rat
tumoral arteries: potential as a slow release rutric oxide donor drug. Br. J. Pharmacol.
122, pi622; Figj)
Megson, I.L., Morton, S., Grieg, I.R., Mazzei, F.A., Field, R.A., Butler, A.R.,
Caron, G., Gasco, A., Fruttero, R. & Webb, D.J. (1999). N-substituted analogues of
S-nitroso-A'-acetyl D,[.-penicillamine: chemical stability and prolonged nitric oxide
vasodilatation in isolated rat femoral arteries. Br J. Pharmacol. 126; p646;
1 wish to use these diagrams in the introduction to my Ph.D. thesis, which focuses on
further research using these compounds. The author of these publications, Dr I.L.
Megson, is the supervisor of this Ph.D. thesis and has already obtained consent to use
these diagrams from the co-authors of these publications, Two copies of this thesis are
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Abstract
Organic nitrates, such as glyceryltrinitrate, are nitric oxide (NO) donor drugs that engender tolerance with long-term use. Here, we
tested the hypothesis that our novel S-nitrosothiols, N-(S-nitroso-,/V-acetylpenicillamine)-2-amino-2-deoxy-l,3,4,6,tetra-0-acetyl-(3-d-
glucopyranose (RIG200) and S-nitroso-/V-valeryl-d-penicillamine (d-SNVP), do not induce vascular tolerance ex vivo. Femoral arteries
from adult male Wistar rats were preconstricted with phenylephrine and perfused with the NO synthase inhibitor V'-nitro-l-arginine
methyl ester (l-NAME). Perfusion pressure was measured during 20 h treatment with supramaximal concentrations of NO donor (10
p,M). Perfusion with glyceryltrinitrate caused a vasodilatation, which recovered over 2-20 h. In contrast, the S-nitrosothiols caused
vasodilatations that were maintained throughout the 20 h perfusion period. Responses to S-nitrosothiols were partially reversed by the NO
scavenger ferrohaemoglobin and fully reversed by the soluble guanylate cyclase inhibitor [lH-[ 1,2,4] oxadiazole [4,3-a]quinoxaline-l-one
(ODQ). Glyceryltrinitrate-tolerant vessels were fully responsive to bolus injections of S-nitrosothiols. Resistance to tolerance is an
attractive property of our novel compounds, particularly in view of their sustained activity in arteries with damaged endothelium. © 2000
Elsevier Science B.V. All rights reserved.
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1. Introduction
Nitric oxide (NO) is synthesised by endothelial cells in
blood vessels (Palmer et al., 1987, 1988; Palmer and
Moncada, 1989) and stimulates smooth muscle cell soluble
guanylate cyclase, leading to relaxation of vascular tissue
(Waldman and Murad, 1987). Synthesis of NO is now
recognised to be a major factor in the control of blood
pressure and local blood flow in animals (Aisaka et al.,
1989; Rees et al., 1989; Gardiner et al., 1990; Chu et al.,
1991) and man (Vallance et al., 1989; Haynes et al., 1993).
Delivery of exogenous NO to areas of diminished NO
*
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activity (Drexler et al., 1991; Calver et al., 1992a,b) is an
attractive therapeutic option in the management of many
cardiovascular conditions.
Organic nitrates are the most commonly used NO donor
drugs in cardiovascular medicine. Glyceryltrinitrate (Fig.
1(a)) is currently used for angina, and for symptomatic
relief in severe cardiac ischaemia, myocardial infarction
and heart failure. The beneficial action of nitrates is thought
to involve NO-mediated systemic venodilatation and di¬
latation of large arteries, including affected coronary arter¬
ies, resulting in reduced venous return and increased blood
flow to cardiac tissue (Abrams, 1985). However, the thera¬
peutic use of nitrates is limited by the development of
tolerance, where a diminished effectiveness of these drugs
is seen after 24 h of continuous therapy (Parker and Fung,
1984). Tolerance can be demonstrated ex vivo, suggesting
impairment of a direct vascular mechanism, such as ineffi¬
cient biotransformation of glyceryltrinitrate (Brien et al.,
1986; Slack et al., 1989), or desensitization of the target
0014-2999/00/$ - see front matter ©2000 Elsevier Science B.V. All rights reserved.
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Fig. 1. Structural formulae and full generic names for NO donors used in this study: (a) glyceryltrinitrate (GTN); (b) S-nitrosoglutathione (GSNO); (c)
RIG200; (d) d-SNVP.
enzyme, guanylate cyclase (Needleman and Johnson, 1973;
Axelsson and Andersson, 1983; Waldman et al., 1986).
Recently, in vivo and clinical evidence suggest that contin¬
uous nitrate therapy is associated with elevated superoxide
production from the endothelium (Munzel et al., 1995,
1996). Superoxide reacts with NO, forming cytotoxic
products, such as peroxynitrite, and reducing NO bioavail¬
ability (White et al., 1994).
S-Nitrosothiols (general formula R—S—N=0) are ni-
trosated derivatives of sulphydryl-containing compounds,
some of which have been identified as endogenous va¬
sodilators (Stamler et al., 1992a,b). S-Nitrosothiols do not
require biotransformation to activate guanylate cyclase,
suggesting that S-nitrosothiols may not induce self-toler¬
ance. Indeed, one such agent, S-nitroso-A-acetylpenicil-
lamine has been shown to develop less tolerance than
glyceryltrinitrate and to remain effective in glyceryltrini-
trate-tolerant vessels ex vivo (Kowaluk et al., 1987;
Kowaluk and Fung, 1990; Matsumoto et al., 1995) and in
vivo (Bauer and Fung, 1991; Shaffer et al., 1992).
Most existing S-nitrosothiols, including S-nitroso-A-
acetylpenicillamine and S-nitrosoglutathione (Fig. 1(b)),
rapidly decompose in an unpredictable manner due to the
catalytic effect of trace Cu+ ions (Dicks et al., 1996;
Gordge et al., 1996), thus limiting their therapeutic poten¬
tial (Megson et al., 1997). We have recently described
several novel S-nitrosothiols. A-(S-nitroso-A-acetylpenicil-
lamine)-2-amino-2-deoxy-l,3,4,6,tetra-0-acetyl-B-d-gluco-
pyranose (RIG200) consists of S-nitroso-A-acetylpenicil-
lamine coupled to glucosamine tetra-acetate by an amide
bond (Fig. 1(c); Megson et al., 1997) and S-nitroso-A-
valeryl-d-penicillamine (d-SNVP) which is an A-sub-
stituted analogue of S-nitroso-A-acetylpenicillamine, with
a five carbon side-chain (Fig. 1(d); Megson et al., 1999).
Both compounds are significantly more stable than S-
nitroso-A-acetylpenicillamine in solution (half-life; ~ 40
and ~ 220 min for S-nitroso-A-acetylpenicillamine and
RIG200, respectively, d-SNVP exhibits a similar rate of
decomposition to RIG200), and are less susceptible to
trace Cu+-catalyzed decomposition (Megson et al., 1997,
1999). Another potential advantage of these compounds
over existing NO donors is that they induce sustained
vasodilatation in endothelium-denuded rat femoral arteries,
suggesting that they may be able to selectively deliver NO
to areas of endothelial damage (Megson et al., 1997,
1999).
For these benefits to be maximally exploited therapeuti¬
cally, it would be valuable if these novel compounds did
not engender tolerance with continued use. Here, we used
an isolated rat femoral artery model of nitrate tolerance to
test the hypothesis that RIG200 and d-SNVP do not induce
vascular tolerance or show cross-tolerance with glyceryl-
trinitrate.
2. Materials and methods
2.1. Preparation
Experiments were carried out on isolated segments of
femoral artery from adult male Wistar rats (300-450 g;
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n = 60) in a perfusion system described previously (Meg-
son et al., 1997). Briefly, animals were killed by cervical
dislocation and both femoral arteries were dissected free.
Segments of the artery (7-8 mm long) were cannulated
immediately distal to the epigastric arterial branch. The
vessels were transferred to Perspex organ chambers (1 ml
volume) where they were perfused (0.6 ml min -1: Gilson
miniplus 3; Anachem, Luton, UK) and superfused (1 ml
min-1: Watson Marlow 302S; Watson Marlow, Falmouth,
UK) with fresh oxygenated (95% 0,, 5% CCL) Krebs
buffer solution (composition in mM: NaCl 118, NaHC03
25, Glucose 5.7, KC1 4.7, MgS04-7H20 0.6, KH:P04
1.2, CaCL 2.5; dissolved in distilled and de-ionised water)
at 37°C. The contractile state of the vessel was measured
by perfusion pressure, monitored by a differential pressure
transducer (T; Sensym SCX 15ANC; Farnell Electronic
Components, Leeds, UK). The apparatus permits exclusive
drug delivery to the luminal surface of the vessel in the
a (i) (ii)
perfusing 10 _5M GTN
25%
perfusing 10 "5M RIG200
1 h
5 min
Fig. 2. Pressure recordings showing vasodilator responses, (a) Continuous perfusion (10-5 M; 0.6 ml min~ ') of (i) GTN or (ii) RIG200. (b) Responses to
sequential micro-injections of GTN (10 p.1; 10~4, 10-3 M) into the perfusate of (i) control and (ii) GTN-tolerant vessels, (c) Responses to sequential
micro-injections of RIG200 (10 p.1; 10-4, 10-3 M) into the perfusate of (i) control and (ii) GTN-tolerant vessels.
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internal perfusate or by bolus injection (10 p.1) through a
resealable rubber septum into the perfusate, immediately
upstream of the vessel (transit time to artery ~ 3 s,
through lumen ~ 300 ms).
All experiments were carried out in a darkened labora¬
tory in order to protect photolabile drugs and to prevent
photorelaxation of vessels (Megson et al., 1995).
Vessels were preconstricted with phenylephrine (2-10
p,M) in the presence of the NO synthase inhibitor N"-
nitro-l-arginine methyl ester (l-NAME; Rees et al., 1990)
to exclude endothelial and inducible NO-synthase activa¬
tion in vasodilator responses. Preliminary experiments were
carried out to minimise the concentration of l-NAME (20
p,M) used to produce a supramaximal response. An l-
NAME-induced increase in pressure of > 40% of the
existing phenylephrine-induced tone was indicative of an
active endothelium.
2.2. Experimental protocols
2.2.1. Induction of tolerance
Vessels were perfused with equivalent concentrations of
NO donor (10 p,M), or Krebs as a control, and perfusion
pressure was monitored for 2 h. Phenylephrine was then
removed from the internal perfusate and the perfusion rate
lowered to 0.1 ml min-1 overnight, at 25°C, to optimise
vessel survival. At t — 20 h, the original phenylephrine-
containing solution was re-perfused at the original flow
rate (0.6 ml min-'), at 37°C.
2.2.2. Cross-tolerance
In glyceryltrinitrate-treated and control vessels (f = 20
h), bolus injections of increasing concentrations of NO
donor (10 p.I; 10 8—10 3 M) were made sequentially into
the perfusate. Responses were deemed to have recovered
once pressure was maintained for more than 2.5 min, at
which time the next concentration was injected.
2.2.3. Washout of NO donor
To confirm viability in vessels that did not re-develop
tone with phenylephrine following 20 h of S-nitrosothiol
perfusion, the S-nitrosothiol was washed out and the time
taken for maximum pressure to be restored was measured.
2.2.4. Nature ofNO donor vasodilatation
In S-nitrosothiol-treated vessels at t = 20 h, the NO
scavenger, ferrohaemoglobin (10 pM; Martin et al., 1985)
was added to the internal perfusate, and subsequently, to
the superfusate to allow ferrohaemoglobin to infiltrate the
vascular smooth muscle, as it has been shown previously
that the endothelium may act as a barrier to ferro¬
haemoglobin (Foley et al., 1993). Responses were deemed
complete after pressure was maintained for 5 min. A
supramaximal concentration of the soluble guanylate cy¬
clase inhibitor [lH-[ 1,2,4] oxadiazole [4,3-a]quinoxaline-l-
one (ODQ; Garthwaite et al., 1995) was added to the
internal perfusate and rapidly washed out once pressure
had reached plateau.
2.3. Drugs and reagents
RIG200 was synthesised by a published method (Meg-
son et al., 1997). d-SNVP was synthesised by the follow¬
ing procedure. Sodium valerate was synthesised by react¬
ing sodium hydroxide pellets (8 g, 0.2 mol) in distilled
water (100 ml) with valeric acid (21.6 ml, 200 mmol).
Sodium valerate (3.9 g, 40 mmol) was added to d-penicil-
lamine (3 g, 20 mmol) in a chilled solution of tetrahydro-
furamwater, 4:1 (20 ml). Valeric anhydride (4 ml, 20
mmol) was added and the mixture stirred at room tempera¬
ture overnight. The tetrahydrofuran was evaporated in
vacuo and water (30 ml) was added. Concentrated HC1
was added dropwise until a white precipitate formed. This
was filtered and recrystallised from hexane to yield N-
valeryl-D-penicillamine, which was then dissolved in a
minimum amount of dichloromethane. Concentrated HC1
was dropped onto sodium nitrite and the resulting nitrogen
dioxide were bubbled into the penicillamine solution to
yield A'-valeryl-S-nitroso-d-penicillamine. Identity of the
products was confirmed by mass spectrometry (EPSRC
Mass Spectroscopy Service, University College, Wales,
UK) and nuclear magnetic resonance spectroscopy. ODQ
was obtained from Tocris Cookson (Langford, Bristol,
UK). All other chemicals were obtained from Sigma (Poole,
Dorset, UK) Methaemoglobin was reduced to the ferro-
form with sodium dithionite (fivefold excess; 57.4 p,M) as
described previously (Martin et al., 1985).
All drugs were stored as solids and dissolved on the day
of use with the exception of ferrohaemoglobin, aliquots of




Fig. 3. Effect of perfusing NO donors (10 p.M) on perfusion pressure in
preconstricted rat femoral arteries. Vasodilatation at 100% represents
abolition of tone, with NO donor perfusion beginning at t = 0 h. Points
shown are means with vertical lines indicating S.E.M. (n = 45, 33, 15,
12, 12 for control, GTN, GSNO, RIG200 and d-SNVP respectively).
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drugs were diluted in Krebs buffer or saline with the
exception of ODQ, which was dissolved in dimethyl
sulphoxide (DMSO). The final concentration of DMSO in
the perfusate was <0.1% and preliminary experiments
showed that this concentration of DMSO does not affect
vessel tone.
vasodilatation). Mean values are given ± standard error of
the mean (S.E.M.).
P-values in the text were obtained by two-factor, unre¬
lated analysis of variance (ANOVA). Paired and unpaired,
two-tailed Student's /-tests were also used where appropri¬
ate. P < 0.05 was accepted as statistically significant.
2.4. Analysis of results 3. Results
Signals from pressure transducers were processed by a
MacLab/4e analogue-digital converter and displayed
through Chart software (AD Instruments, Sussex, UK) on
a Macintosh Performa 630 microcomputer.
Vasodilator response amplitude is the decrease in pres¬
sure, expressed as a percentage of preconstriction pressure
existing before the application of each drug concentration
(percent pressure change; positive values represent vaso¬
dilatation, where 100% represents maximum possible
3.1. Preconstriction offemoral arteries
Vessels were preconstricted with phenylephrine (6.7 ±
0.3 p,M) to give pressures of ~ 50 mm Hg (49 + 3 mm
Hg; n = 60). l-NAME (20 |xM) led to a 151 ± 13%
increase of pre-existing phenylephrine-induced pressure
(110 + 5 mm Hg; n = 60). Bolus injections of drug vehi¬
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Fig. 4. Log concentration response curves showing the vasodilator effect (% pressure change) of bolus microinjections (10 p.1) of (a) GTN. (b) GSNO, (c)
R1G200, (d) d-SNVP in control (open circles) and GTN-tolerant (filled squares) vessels. Points shown are means with vertical lines indicating s.e.M.
(n = 6-9). " * * represents statistical significance at P< 0.001 (two-factor, unrelated ANOVA).
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3.2. Vasodilator responses to continuous NO donor perfu-
Perfusion of glyceryltrinitrate (10 jjlM) caused an initial
vasodilatation of 72 ± 3% (n = 33). Pressure gradually
recovered to 35 ± 10% vasodilatation remaining at f = 2h
(Figs. 2(a) and 3). After overnight incubation with glyc¬
eryltrinitrate (t = 20 h), pressure was not significantly
different from control (10 ± 10% below preconstriction;
P = 0.64; 2-tailed, unpaired Student's f-test; n = 45).
Perfusion of supramaximal concentrations of S-nitro-
sothiols (10 p,M) produced greater vasodilatation (91 ±
2%, 93+ 1%, 84 + 3% for S-nitrosoglutathione, RIG200
and d-SNVP, respectively; n = 12-15), which were main¬
tained throughout the 20 h period of perfusion (Figs. 2(a)
and 3).
3.3. Vasodilator responses to bolus injections ofNO donors
in control and glyceryltrinitrate-tolerant vessels
Bolus injections of glyceryltrinitrate (10 |xl; 10~8-10~3
M) produced transient vasodilatations which recovered
within 5 min. In vessels perfused overnight in the absence
of glyceryltrinitrate (control), the highest concentration of
glyceryltrinitrate tested (10~3 M) produced a vasodilata¬
tion of 65 ±7% (n = 6). In vessels perfused with glyceryl-
trinitrate for 20 h (glyceryltrinitrate-tolerant vessels) the
response to 10"1 M GTN bolus was markedly attenuated
(19 ± 4%; P < 0.001; two-factor, unrelated ANOVA; n =
7; Figs. 2(b) and 4(a)).
Equivalent injections of S-nitrosothiols also produced
transient vasodilatations of a similar amplitude to glyceryl-
trinitrate (69 ± 6%, 70 ± 3% and 70 ± 6% for S-nitro¬
soglutathione, RIG200 and d-SNVP, respectively; Figs.
2(c) and 4(b), (c), (d)). However, the concentration re¬
sponse curves for the S-nitrosothiols in glyceryltrinitrate-
tolerant vessels were not significantly different from those
in control vessels (P > 0.21; two-factor, unrelated
ANOVA; n = 6-9).
3.4. Washout of S-nitrosothiols
At t = 20 h, the internal perfusate was replaced with
Krebs solution containing PE and l-NAME, but without
NO donor. On washout of S-nitrosoglutathione, RIG200 or
d-SNVP, pressure recovered to levels that were not signifi¬
cantly different from the preconstriction pressure before
the perfusion of NO donor (P = 0.15; 2-tailed, paired
Student's r-test; n=18). Pressure rapidly recovered in
5.5 ± 0.9, 6.5 ± 0.8 and 11.1 ± 4.5 min, respectively (n =
6 for all). The time course of d-SNVP washout was
significantly slower than S-nitrosoglutathione and RIG200
(P = 0.001; two-way, unrelated ANOVA).
□ t=20 h s +odq □ washout
gsno rig200
S-nitrosothiol
Fig. 5. The effect of ferrohaemoglobin (ferrohaemoglobin; 10 |xM), ODQ
(20 |xM) and S-nitrosothiol washout on the vasodilatation produced by
perfusing S-nitrosothiols (10 p.M) for 20 h. Points shown are means with
vertical lines indicating S.E.M. (n — 6 for all). Preconstriction pressure is
represented by the dotted line.
3.5. Reversal of S-nitrosothiol vasodilatation with ferro¬
haemoglobin and ODQ
Following perfusion of S-nitrosoglutathione for 20 h,
addition of ferrohaemoglobin (10 p,M) to the internal
perfusate caused a significant increase in pressure of ~
40% (P = 0.005, 2-tailed, paired Student's f-test; n = 6).
ferrohaemoglobin had no effect on the vasodilatation pro¬
duced by RIG200 or d-SNVP (P > 0.15 for both; n = 6;
Fig. 5). Addition of ferrohaemoglobin (10 p.M) to the
external perfusate caused no additional effect (n = 6).
Full restoration of pressure could be achieved by the
addition of the soluble guanylate cyclase inhibitor, ODQ
(20 |xM), to the internal perfusate (Fig. 5). The perfusion
pressure in the presence of these compounds was not
significantly different from the preconstriction pressure,
before addition of NO donor (P = 0.73; 2-tailed, paired
Student's t-test; n = 18).
Treatment of control vessels with ferrohaemoglobin and
ODQ had no significant effect on perfusion pressure ( P >
0.05; paired Student's r-test; n = 6).
4. Discussion
Our results show that tolerance to glyceryltrinitrate
develops rapidly in rat femoral arteries, within 20 h of
continuous exposure, resulting in a marked attenuation of
the responses to additional bolus concentrations of glyc¬
eryltrinitrate. The endogenous S-nitrosothiol, S-nitro-
soglutathione, and novel S-nitrosothiols, RIG200 and d-
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SNVP, did not induce tolerance within 20 h or exhibit
cross-tolerance in vessels made tolerant to glyceryltrini-
trate.
The amplitude of glyceryltrinitrate-induced vasodilata¬
tion diminished despite continued perfusion of the drug,
and was not evident after 20 h. Down-regulation of NO
synthase by NO from glyceryltrinitrate (Moncada et al.,
1991) could be excluded as a possible explanation for the
results because the NO synthase inhibitor, l-NAME, was
present throughout. Given the long duration of the experi¬
ments it was necessary to continuously perfuse l-NAME
to prevent NO generation from the inducible form, as well
as the constitutive, NO synthase. The vasodilator response
to boluses of high concentrations of glyceryltrinitrate
(10 4, 10~3 M) were attenuated in the presence of perfus¬
ing glyceryltrinitrate (10~5 M), confirming nitrate toler¬
ance in these vessels. Perfused isolated femoral arteries
are, therefore, an effective ex vivo model for the investiga¬
tion of nitrate tolerance and cross-tolerance to NO donor
drugs. In addition, tolerance to glyceryltrinitrate can be
induced rapidly, facilitating studies investigating the pre¬
vention and reversal of nitrate tolerance.
All the S-nitrosothiols (10 |xM) that were investigated
relaxed arteries to a similar extent, producing ~ 90%
vasodilatation. Vasodilatation to S-nitrosothiols was main¬
tained throughout the 20 h perfusion period despite the
slow decomposition of the compounds in the perfusate
reservoir. Our results demonstrate that, despite structural
modifications, RIG200 and d-SNVP retain the character¬
istics of existing S-nitrosothiols in that they do not engen¬
der tolerance (Kowaluk et al., 1987; Kowaluk and Fung,
1990; Bauer and Fung, 1991). Following 20 h S-nitro-
sothiol perfusion, pressure was rapidly restored by washing
out the S-nitrosothiol, confirming the reversibility of the
effect and indicating that the vessel was still viable. RIG200
and d-SNVP have previously been demonstrated to induce
a vasodilatation which persists after washout in endo-
thelium-denuded vessels (Megson et al., 1997, 1999).
Therefore, the rapid restoration of pressure following S-
nitrosothiol washout suggests that the endothelium was
functionally intact after 20 h, consistent with the vasocon¬
strictor effect of l-NAME at the beginning of the experi¬
ment. d-SNVP took significantly longer to wash out than
S-nitrosoglutathione and RIG200, perhaps reflecting its
greater lipophilicity (Megson et al, 1999).
S-Nitrosoglutathione-induced vasodilatation was par¬
tially inhibited by perfusion with ferrohaemoglobin, sug¬
gesting that extracellular decomposition of S-nitrosoglu¬
tathione to release NO contributes to the vasodilatation in
response to this compound. This reflects the sensitivity of
S-nitrosoglutathione to catalyzed decomposition by metal
ions in Krebs solution (Dicks et al., 1996; Gordge et al.,
1996), or by elements of the vascular cell surface (Kowa¬
luk and Fung, 1990; Al-Sa'doni et al., 1997). The vasodila¬
tation produced by RIG200 and d-SNVP was unaffected
by ferrohaemoglobin perfusion, suggesting that ferro¬
haemoglobin does not have access to the site where RIG200
and d-SNVP exert their bioactivity. S-Nitrosothiol-induced
vasodilatation could be completely reversed by addition of
the soluble guanylate cyclase inhibitor, ODQ, suggesting
that in this vascular tissue, unlike in platelets (Gordge et
al., 1998), the action of S-nitrosothiols is entirely mediated
by activation of this enzyme.
Our finding that S-nitrosothiols do not induce tolerance
implies that the underlying cause of nitrate tolerance ex
vivo is upstream of NO release. Desensitization of the
target enzyme, guanylate cyclase (Needleman and John¬
son, 1973; Waldman et al., 1986), or upregulation of
cGMP-phosphodiesterase activity (Axelsson and Anders-
son, 1983) have been suggested as potential mechanisms in
tolerance development. However, our results show that
S-nitrosothiols remain fully active in glyceryltrinitrate-
tolerant vessels through a mechanism entirely mediated by
guanylate cyclase. Our results also question the involve¬
ment of superoxide generation in tolerance development ex
vivo, because S-nitrosothiols retained full activity in glyc-
eryltrinitrate-tolerant vessels. S-Nitrosothiols may release
NO at a site inaccessible to scavenging by superoxide or
possibly stimulate guanylate cyclase directly. However,
elevated superoxide levels would at least be able to inacti¬
vate extracellular NO from S-nitrosoglutathione in tolerant
vessels. The role of superoxide production may, however,
be more prominent in vivo, where neurohormonal mecha¬
nisms including the renin-angiotensin and endothelin sys¬
tems may exacerbate oxidative stress (Munzel and Bas-
senge, 1996).
All the S-nitrosothiols tested were as effective in glyc-
eryltrinitrate-tolerant vessels as in control vessels. This
reinforces our conclusion that events prior to NO release
or S-nitrosothiol formation (Ignarro et al., 1981) limit the
effectiveness of glyceryltrinitrate in tolerance. S-Nitro¬
sothiols decompose spontaneously in solution at varying
rates to generate NO (Williams, 1985) and therefore, may
not be dependent on the same co-factors needed to release
NO from glyceryltrinitrate. In addition, the ability of S-
nitrosothiols to directly transfer NO to reduced tissue
thiols without the release of free NO (Askew et al., 1995)
could lead to activation of guanylate cyclase through nitro-
sation of cysteine residues in the enzyme (Ignarro et al.,
1981). This property could be the underlying reason why
S-nitrosothiols do not induce tolerance.
In summary, we have shown that two novel NO donor
drugs, RIG200 and d-SNVP do not induce tolerance with
20 h of continuous perfusion, in an ex vivo model of
tolerance. In addition, they retain full vasodilator potency
in vessels made tolerant to glyceryltrinitrate, despite its
continued presence. Our results lend weight to the argu¬
ment that RIG200 and d-SNVP may be viable clinical
alternatives to organic nitrates and existing S-nitrosothiols,
because, added to their previously described increased
stability and selectivity for areas of endothelial damage,
they do not appear to engender tolerance. These features
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suggest that RIG200 and d-SNVP could have potential
benefits in the treatment of a number of cardiovascular
diseases including angina, atherosclerosis, cardiac is-
chaemia, heart failure, and other conditions where long-
term and high dose vasodilator therapy is required.
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